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ABSTRACT 
Background:  Invasive pulmonary aspergillosis (IPA) is a common cause of mortality in 
haemato-oncology patients and early diagnosis is vital for improving outcomes.  Since lung 
biopsy in this acute setting is rarely performed due to the associated risks, an empirical 
strategy remains the standard of care in many haematology units, but leads to 
overtreatment with antifungal drugs, which have significant side-effects.  This project has 
developed novel approaches for detecting IPA, allowing early and specific treatment of 
genuine fungal infection. 
Methods:  A combination marker approach involving a new Aspergillus qPCR assay, an 
EORTC/MSG-endorsed GM ELISA and an Aspergillus LFD, was used to establish a robust 
diagnosis of IPA from clinical broncho-alveolar lavage (BAL) fluid samples.  The 
inflammatory cytokine profile associated with IPA biomarker positive BAL fluid was also 
evaluated.  Finally, antigen and qPCR detection were combined in a proximity ligation assay 
(PLA), to demonstrate proof-of-principle for a diagnostic assay for the earliest possible 
detection of fungal infections. 
Results:  A dual testing approach involving a novel MIQE-compliant Aspergillus qPCR assay 
and an Aspergillus LFD showed a sensitivity and specificity of 100% and 94%, respectively in 
BAL fluid, unlike in blood where this approach was not sensitive.  Results confirmed 
previously published concerns over the repeatability of GM in serum, whereas BAL GM 
results appear stable.  Biomarker detection results in exhaled breath condensate did not 
correlate well with results in BAL fluid samples.  Respiratory samples did not identify a 
distinct inflammatory marker profile in IPA.  Finally, antibodies raised against JF5 
mannoprotein were used to develop a PLA test to detect active growth of Aspergillus. 
Conclusions:  The optimised qPCR is a very sensitive and highly specific aid in IPA diagnosis.  
A combination biomarker approach could be incorporated into a diagnostic-driven 
approach to patient management to direct antifungal treatment to patients with evidence 
of invasive fungal disease.   
  
 3 
 
TABLE OF CONTENTS 
 
ABSTRACT .............................................................................................................................. 2 
LIST OF FIGURES .................................................................................................................... 9 
LIST OF ABBREVIATIONS...................................................................................................... 13 
DECLARATION OF ORIGINALITY .......................................................................................... 15 
LIST OF PUBLICATIONS ARISING FROM THIS THESIS .......................................................... 16 
CHAPTER 1 ....................................................................................................................... 19 
INTRODUCTION ................................................................................................................ 19 
1.1 Overview ....................................................................................................................... 20 
1.2 Aspergillus ..................................................................................................................... 21 
1.3 Invasive Aspergillosis..................................................................................................... 23 
1.4 Host immune defences against IA ................................................................................. 24 
1.4.1 First line defences ........................................................................................................ 24 
1.4.2 Cells of the innate immune response ........................................................................... 26 
1.4.3 The adaptive immune response ............................................................................... 28 
1.5 Clinical Diagnosis of IA .................................................................................................. 30 
1.5.1 The haemato-oncology setting .................................................................................... 30 
1.5.2 EORTC/MSG guidelines................................................................................................ 31 
1.5.3 Antifungal patient management ................................................................................. 32 
1.6 Laboratory-based diagnostic options ............................................................................ 33 
1.6.1 Traditional Techniques ................................................................................................ 33 
1.6.2 Imaging ....................................................................................................................... 35 
1.6.3 Serological assays........................................................................................................ 36 
1.6.3.1 Galactomannan ........................................................................................................ 37 
1.6.3.2  (1-3)-β-D-glucan ...................................................................................................... 39 
1.6.4 Real time PCR .............................................................................................................. 43 
1.6.5 Lateral flow device (LFD) ............................................................................................. 45 
1.7 Selection of clinical specimens ...................................................................................... 47 
1.8 Novel body fluid target: Exhaled breath condensate ................................................... 50 
1.8.1 Volatile organic compounds (VOCs) ............................................................................ 52 
1.8.2 Non-volatiles ............................................................................................................... 53 
1.8.3 Pathogen detection ..................................................................................................... 54 
 4 
 
1.9 Clinical use of existing diagnostics – performance analysis.......................................... 56 
1.9.1 Conclusions ................................................................................................................. 58 
1.9.2 Thesis Aims ................................................................................................................. 59 
CHAPTER 2 ....................................................................................................................... 61 
MATERIALS AND METHODS ............................................................................................. 61 
2.1 Patient selection and sample collection ....................................................................... 62 
2.1.1 Barts Health NHS Trust Clinical specimens .................................................................. 62 
2.1.1.1 Ethics Statement ...................................................................................................... 62 
2.1.1.2 Patient Selection ...................................................................................................... 63 
2.1.1.3 Study Interventions .................................................................................................. 64 
2.1.1.4 Sampling ................................................................................................................... 64 
2.1.1.4.1 Bronchoscopy with BAL ......................................................................................... 64 
2.1.1.4.2 Exhaled breath condensate ................................................................................... 65 
2.1.1.4.3 Blood ..................................................................................................................... 66 
2.1.1.4.4 Histological material ............................................................................................. 66 
2.1.1.5 Data from Other Clinical Investigations .................................................................... 67 
2.1.1.6 Data Collection ......................................................................................................... 67 
2.1.1.7 Anti-fungal management ......................................................................................... 67 
2.1.1.8 Radiology Review ..................................................................................................... 67 
2.1.1.9 Diagnosis of Invasive fungal infection ...................................................................... 68 
2.1.2 Innsbruck clinical specimens ................................................................................... 68 
2.2 Isolation of total DNA from clinical specimens and fungal culture .............................. 68 
2.2.1 DNA extraction from histological material .................................................................. 68 
2.2.2 DNA extraction from fungal culture ............................................................................ 71 
2.2.3 DNA extraction from BAL fluid, EBC and whole blood ................................................. 72 
2.3 qPCR assay design tools ................................................................................................ 72 
2.3.1 CLC Sequence Viewer................................................................................................... 72 
2.3.2 Beacon Designer .......................................................................................................... 73 
2.3.3 BLAST .......................................................................................................................... 73 
2.3.4 MFold .......................................................................................................................... 73 
2.4 Aspergillus qPCR assay development ........................................................................... 73 
2.4.1 Assay optimisation using SYBR Green I chemistry ....................................................... 74 
2.4.2 Hydrolysis probe reactions .......................................................................................... 74 
 5 
 
2.4.3 PCR Efficiency/Analytical Sensitivity ............................................................................ 74 
2.4.4 PCR Setup Controls ...................................................................................................... 75 
2.4.5 Carryover Contamination Controls .............................................................................. 75 
2.4.6 Inhibition Testing ......................................................................................................... 76 
2.4.7 Monitoring human DNA content of DNA extracts ....................................................... 76 
2.4.8 Analysis of PCR products ............................................................................................. 77 
2.5 GM assay ....................................................................................................................... 77 
2.5.1 Sample selection for signal loss investigations ............................................................ 78 
2.6 LFD for Aspergillus ......................................................................................................... 78 
2.7 Cytokine profiling .......................................................................................................... 79 
2.7.1 Assay selection ............................................................................................................ 79 
2.7.2 BD CBA kit protocol ..................................................................................................... 79 
2.7.2.1 Cytometer set up...................................................................................................... 80 
2.7.2.2 BD CBA Human Th1/Th2/Th17 kit - Preparation of assay standards ........................ 80 
2.7.2.3 BD CBA Human chemokine kit - Preparation of assay standards ............................. 81 
2.7.2.4 Assay procedure (both kits)...................................................................................... 81 
2.8 Proximity Ligation Assay ............................................................................................... 83 
2.8.1 Assay control demonstration....................................................................................... 84 
2.8.1.1 Preparation of Assay Probe A and Assay Probe B..................................................... 84 
2.8.1.2 Preparation of Assay Probe solution ........................................................................ 85 
2.8.1.3 Preparation of recombinant protein target dilution plate ....................................... 85 
2.8.1.4 Performing the binding reaction .............................................................................. 86 
2.8.2 Aspergillus-specific probe development ...................................................................... 88 
2.8.2.1 Aspergillus-specific antibody production ................................................................. 88 
2.8.2.2 Aspergillus culture filtrate preparation .................................................................... 89 
2.8.2.3 Purified glycoprotein target preparation ................................................................. 89 
2.8.2.4 Preparation of biotinylated antibodies .................................................................... 90 
2.8.2.5 Performing the Forced Proximity Probe Test ........................................................... 92 
2.8.2.6 Aspergillus PLA – original TPA I protocol - method using TaqMan® Protein Assays 
Open Kit ............................................................................................................................... 95 
2.8.2.7 Aspergillus PLA – TPA II KIT ...................................................................................... 97 
2.8.2.8 Antibody affinity purification ................................................................................... 98 
2.9 Statistical Analyses ........................................................................................................ 98 
2.9.1 Significant decline in galactomannan signal during storage of clinical serum ............ 98 
 6 
 
2.9.1.1 Analysis of clinical data ............................................................................................ 98 
2.9.1.2 Assay Repeatability .................................................................................................. 99 
2.9.2 Combination biomarker diagnosis of IA in BAL fluid .................................................... 99 
2.9.2.1 Pairwise agreement ................................................................................................. 99 
2.9.2.2 Diagnostic performance of EORTC/MSG criteria .................................................... 100 
2.9.2.3 Diagnostic performance of the biomarker assay, using EORTC/MSG criteria as the 
gold standard ..................................................................................................................... 100 
2.9.3 Evaluation of lung and serum inflammatory cytokine profile associated with IPA 
biomarker positive BAL fluid............................................................................................... 100 
CHAPTER 3 ..................................................................................................................... 102 
DESIGN AND DEVELOPMENT OF A NEW, ROBUST AND RELIABLE PAN-ASPERGILLUS qPCR 
ASSAY ............................................................................................................................. 102 
3.1 Background .................................................................................................................. 103 
3.2 RESULTS: Critical review of the use of qPCR for the detection of Aspergillus-derived 
nucleic acids....................................................................................................................... 105 
3.2.1 Search strategy ......................................................................................................... 105 
3.2.2 Type of PCR assays .................................................................................................... 109 
3.2.3 Assay specificity......................................................................................................... 111 
3.2.4 Primers characteristics and performance .................................................................. 119 
3.2.5 Type of standards ...................................................................................................... 122 
3.2.6 Assay efficiency and limit of detection (LOD) ............................................................ 123 
3.2.7 Summary ................................................................................................................... 125 
3.3 RESULTS: A MIQE-compliant real-time PCR assay for Aspergillus detection ............. 126 
3.3.1 Assay characterisation .............................................................................................. 126 
3.3.1.1 Primers and amplicon ............................................................................................ 126 
3.3.1.2 Annealing temperature and primer concentration ................................................ 128 
3.3.1.3 Analytical Specificity ............................................................................................... 129 
3.3.2 PCR efficiency/ analytical sensitivity ......................................................................... 131 
3.3.3 Reproducibility .......................................................................................................... 132 
3.3.4 Clinical Evaluation ..................................................................................................... 132 
3.3.4.1 Histological material............................................................................................... 132 
3.3.4.2 Inhibition testing .................................................................................................... 133 
3.4 DISCUSSION ................................................................................................................. 134 
CHAPTER 4 ..................................................................................................................... 140 
 7 
 
DEVELOPMENT OF A COMBINATION BIOMARKER DETECTION APPROACH TO IPA 
DIAGNOSIS ..................................................................................................................... 140 
4.1 BACKGROUND ............................................................................................................. 141 
4.2 RESULTS ....................................................................................................................... 145 
4.2.1 Significant decline in galactomannan signal during storage of clinical serum samples
 ........................................................................................................................................... 145 
4.2.1.1 Scatter Plot ............................................................................................................. 145 
4.2.1.2 Statistically significant reductions in GM signal ..................................................... 147 
4.2.1.3 Assay Repeatability ................................................................................................ 148 
4.2.1.4 Summary ................................................................................................................ 148 
4.2.2 Combination biomarker diagnosis of IA in BAL fluid .................................................. 150 
4.2.2.1 Assay sensitivity ..................................................................................................... 151 
4.2.2.2 Assay specificity ..................................................................................................... 152 
4.2.2.3 Combination testing approach to clinical diagnosis of IPA ..................................... 152 
4.2.2.4 Diagnostic performance of EORTC/MSG criteria .................................................... 155 
4.2.2.5 The use of EORTC/MSG scores as a reference standard to evaluate the performance 
of biomarker assays ........................................................................................................... 156 
4.2.2.6 Biomarker detection in blood ................................................................................ 157 
4.3 DISCUSSION ................................................................................................................. 159 
CHAPTER 5 ..................................................................................................................... 164 
INNOVATIVE APPROACHES TO IPA DIAGNOSIS .............................................................. 164 
5.1 EVALUATION OF EXHALED BREATH CONDENSATE AS A PIONEERING SAMPLE FOR 
NON-INVASIVE DIAGNOSIS OF LUNG PATHOGENS .......................................................... 165 
5.1.1 Background ............................................................................................................... 165 
5.1.2 Results ....................................................................................................................... 166 
5.1.3 DISCUSSION ............................................................................................................... 169 
5.2 EVALUATION OF LOCAL (LUNG) AND SYSTEMIC (SERUM) INFLAMMATORY PROFILE 
ASSOCIATED WITH IPA BIOMARKER POSITIVE BAL FLUID IN IMMUNOCOMPROMISED 
PATIENTS ........................................................................................................................... 171 
5.2.1 Background ............................................................................................................... 171 
5.2.2 Results ....................................................................................................................... 174 
5.2.2.1 Cytokine and chemokine concentration in BAL fluids from ‘gold standard’ proven 
IPA cohort and haemato-oncology Study cohort ............................................................... 174 
5.2.2.2 Cytokine and chemokine concentration in serum samples from the haemato-
oncology Study cohort ....................................................................................................... 178 
 8 
 
5.2.3 Discussion .................................................................................................................. 183 
5.3 PROXIMITY LIGATION ASSAY FOR THE SENSITIVE, SPECIFIC AND EARLY DIAGNOSIS OF 
INVASIVE FUNGAL DISEASE ............................................................................................... 186 
5.3.1 Background ............................................................................................................... 186 
5.3.2 Results ....................................................................................................................... 188 
5.3.2.1 IL-6 expression in a Control Assay .......................................................................... 188 
5.3.2.2 Aspergillus PLA ....................................................................................................... 189 
5.3.2.2.1 Antibody selection .............................................................................................. 189 
5.3.2.2.2 Probe development – Part 1 ............................................................................... 190 
5.3.2.2.3 TaqMan Protein Assay – TPA I protocol – Part 1 ................................................. 192 
5.3.2.2.4 Probe development – Part 2 ............................................................................... 194 
5.3.2.2.5 TaqMan Protein Assay – TPA I protocol – Part 2 ................................................. 195 
5.3.2.2.6 TaqMan Protein Assay – TPA II protocol ............................................................. 196 
5.3.2.2.7 Further probe development ................................................................................ 198 
5.3.2.2.8 TaqMan Protein Assay – TPA II protocol – Part 2 ................................................ 199 
5.3.3 Discussion .................................................................................................................. 199 
CHAPTER 6 ..................................................................................................................... 204 
GENERAL DISCUSSION .................................................................................................... 204 
6.1 Findings ........................................................................................................................ 206 
6.2 Future Directions ......................................................................................................... 209 
6.3 Conclusions .................................................................................................................. 212 
Appendix 1 ......................................................................................................................... 214 
Appendix 2 ......................................................................................................................... 217 
Appendix 3 ......................................................................................................................... 220 
REFERENCES ....................................................................................................................... 222 
 
  
 9 
 
LIST OF FIGURES 
 
Figure 1. A) Spore-forming structures (conidia) of the fungus Aspergillus, B) An 
aspergillum. ................................................................................................................ 21 
Figure 2.  The Aspergillus infection pathway.  A.  Aspergillus conidia are inhaled into 
the lung and reach the alveoli.  B.  In the bronchiole the conidia meet surfactant 
proteins SP-A and SP-D, which trap conidia and promote phagocytosis by 
macrophages. ............................................................................................................. 25 
Figure 3.  Oxidative mechanisms of microbicidal activity initiated by neutrophils to 
destroy invading organisms. ...................................................................................... 27 
Figure 4.  Activation of the TH1, Th2 and Th17 CD4 T-cell responses in the lung ...... 29 
Figure 5.  Antifungal strategies for patients at risk of invasive fungal disease. ........ 33 
Figure 6.  Collection of exhaled breath condensate. .................................................. 66 
Figure 7.  Work flow chart for DNA extraction from histological material. ............... 70 
Figure 8.  Antibody-based detection of Aspergillus antigen. ..................................... 79 
Figure 9.  The steps involved in the TaqMan Protein Assays: Proximity ligation with 
real-time PCR. ............................................................................................................. 83 
Figure 10.  Serial dilution of recombinant protein target in row 1 of the dilution 
plate. .......................................................................................................................... 86 
Figure 11.  Preparation of the binding reaction plate. ............................................... 87 
Figure 12.  TaqMan Protein Assay II work flow.......................................................... 97 
Figure 13.  Sequence alignment of 28S rDNA region for six Aspergillus and four non-
Aspergillus species. ................................................................................................... 110 
Figure 14.  18S ribosomal RNA gene partial sequences aligned in CLC Sequence 
Viewer. ..................................................................................................................... 113 
Figure 15.  18S ribosomal RNA gene partial sequences aligned in CLC Sequence 
Viewer. ..................................................................................................................... 114 
Figure 16.  18S ribosomal RNA gene partial sequences aligned in CLC Sequence 
Viewer. ..................................................................................................................... 115 
Figure 17.  A. fumigatus strain MJ-X6 18S ribosomal RNA gene partial sequence. . 116 
Figure 18.  Homo sapiens BAC clone RP11-237A9 partial sequence........................ 117 
Figure 19.  ITS1 sequences aligned in CLC Sequence Viewer. .................................. 118 
Figure 20.  ITS1 sequences aligned in CLC Sequence Viewer. .................................. 119 
Figure 21.  ITS1 sequences aligned in CLC Sequence Viewer. .................................. 119 
Figure 22.  MFOLD analysis results of analysed papers. .......................................... 121 
Figure 23.  18S ribosomal RNA gene partial sequences aligned in CLC Sequence 
Viewer. ..................................................................................................................... 127 
Figure 24.  MFOLD analysis results of the new assay. ............................................. 128 
Figure 25.  18S assay amplification curve for Aspergillus species. .......................... 130 
 10 
 
Figure 26.  Dissociation (melt) curve analysis of amplification products. ................ 131 
Figure 27.  Eight standard curve plots, generated using A. fumigatus genomic DNA.
 .................................................................................................................................. 132 
Figure 28.  SPUD assay amplification curve for histological samples. ..................... 134 
Figure 29.  Scatter plot with fractional polynomial lines for reduction in GM level.146 
Figure 30.  Scatter plot for repeatability of the threshold control. .......................... 148 
Figure 31.  qPCR assay amplification curve for an EBC from Study sample 2. ......... 168 
Figure 32.  qPCR assay amplification curves for 2 consecutive EBC samples from 
Study sample 4. ........................................................................................................ 169 
Figure 33.  Box plot showing IL-8 concentrations detected in dual test positive (DT+) 
and negative (DT-) BAL fluids. .................................................................................. 177 
Figure 34.  Box plot showing IL-8 concentrations detected in dual test positive (DT+) 
and negative (DT-) BAL fluids, with the exclusion of patients not meeting 
EORTC/MSG host factor inclusion criteria................................................................ 178 
Figure 35.  Bar graph showing circulating serum levels of IL-8, CCL5, MIG (CXCL9), 
CCL2 and IP-10 (CXCL10) in Study sample 5, from 7 days prior to starting antifungal 
treatment to 13 days after starting antifungal treatment. ..................................... 180 
Figure 36.  Bar graph showing circulating serum levels of IL-2, IL-4, IL-6, IL-10, TNF 
and INF-γ in Study sample 5, from 7 days prior to starting antifungal treatment to 
13 days after starting antifungal treatment. ........................................................... 181 
Figure 37.  Bar graph showing circulating serum levels of IL-8, CCL5, MIG (CXCL9), 
CCL2 and IP-10 (CXCL10) in Study sample 10, from 3 days prior to starting antifungal 
treatment to 7 days after starting antifungal treatment. ....................................... 182 
Figure 38.  Bar graph showing circulating serum levels of IL-2, IL-4, IL-6, IL-10, TNF 
and INF-γ in Study sample 10, from 3 days prior to starting antifungal treatment to 
7 days after starting antifungal treatment .............................................................. 183 
Figure 39.  Detection of IL-6 recombinant protein dilutions 0.128-2000pg/mL, by pAb 
probes in a PLA control assay. .................................................................................. 189 
Figure 40.  Structure of the Aspergillus-specific mannoprotein antigen recognised by 
MAb JF5. ................................................................................................................... 190 
Figure 41.  Forced proximity test amplification curve for a) pAb forced proximity 
probe (left trace) and negative control (right trace) and b) MAb forced proximity 
probe (left trace) and negative control (right trace). ............................................... 191 
Figure 42.  Detection of Aspergillus-specific N-linked glycoprotein antigen by TPA I in 
serial 10-fold dilutions of purified glycoprotein antigen (A to D), and antigen-
negative sample (Negative C). ................................................................................. 192 
Figure 43.  Bar graph representation of PLA result for probes A) pAb A/pAb B, B) 
MAb A/pAb B and C) pAb A/MAb B PLA. ................................................................. 193 
Figure 44.  Repeat forced proximity test amplification curve for pAb forced proximity 
probe (left trace) and negative control (right trace). ............................................... 194 
 11 
 
Figure 45.  Forced proximity test amplification curve for pAb forced proximity probe 
(left trace) and negative control (right trace). ......................................................... 195 
Figure 46.  Bar graph representation of PLA result for probes A) pAb A/pAb B, B) 
MAb A/pAb B and C) pAb A/MAb B PLA. ................................................................. 196 
Figure 47.  Bar graph representation of PLA result for probes A) pAb A/MAb B and B) 
MAb A/MAb B. ......................................................................................................... 197 
Figure 48.  Forced proximity test amplification curve for protein A purified A) MAb 
and B) pAb. ............................................................................................................... 198 
Figure 49.  Bar graph representation of PLA result for probes MAb A/MAb B. ....... 199 
  
 12 
 
LIST OF TABLES 
 
Table 1.  Comparisons of real-time PCR studies for detection of multiple Aspergillus species.
 ........................................................................................................................................... 108 
Table 2.  Temperature gradient analysis of the primers with A. fumigatus DNA template. 129 
Table 3.  qPCR results when testing DNA extracts from histological samples. ................... 133 
Table 4.  Results of the Wilcoxon Rank Sum Test. .............................................................. 147 
Table 5.  Testing results and sensitivity of assays in the gold standard proven IPA cohort. 151 
Table 6.  Testing results and specificity of assays in the negative control cohort. .............. 152 
Table 7.  Testing results and suggested clinical interpretation in the Study cohort. ........... 154 
Table 8.  Pairwise agreement of tests in the Study cohort. ................................................ 154 
Table 9.  EORTC/MSG 2008 classification in the Study cohort (N = 25). ............................. 155 
Table 10.  Performance parameters for the EORTC/MSG criteria (with and without GM 
included), in the Study cohort (N=25), using dual LFD/qPCR testing as the gold standard for 
clinical diagnosis of IPA. ..................................................................................................... 156 
Table 11.  Performance parameters for the biomarker assays, individually and in 
combination, in the Study cohort (N = 25). ......................................................................... 157 
Table 12.  Biomarker testing results in blood samples from the Study cohort (N=25). ....... 158 
Table 13.  Testing results for EBC samples and corresponding BAL fluid in the Study cohort 
(N=12). ............................................................................................................................... 168 
Table 14.  Mean cytokine and chemokine concentrations detected in BAL fluid samples from 
the gold standard proven IPA (N=11) and study cohorts (N=20). ....................................... 176 
 
 
 
  
 13 
 
LIST OF ABBREVIATIONS 
 
 
 2PF     2-Pentylfuran 
 Ab     Antibody 
 ABPA     Allergic broncho-pulmonary aspergillosis 
 ALL     Acute lymphoblastic leukaemia 
 AML     Acute myeloid leukaemia 
 APC     Antigen presenting cell 
 ARDS     Adult respiratory distress syndrome 
 BAL     Broncho-alveolar lavage 
 BG     Beta-D-glucan 
 BHQ     Black hole quencher 
 BLAST     Basic Local Alignment Search Tool 
 Bp     Base pairs 
 CBA     Cytokine bead array 
 CF     Cystic fibrosis 
 CFU     Colony forming units 
 CGD     Chronic granulomatous disease 
 COPD     Chronic obstructive pulmonary disease 
 CPA     Chronic pulmonary aspergillosis 
 Cq     Quantification cycle 
 CRP     C-reactive protein 
 CT     Computerised tomography 
 CV     Coefficient of variation 
 CXR     Chest x-ray 
 DMSO     Dimethyl sulfoxide 
 DNA     Deoxyribonucleic acid 
 EAPCRI     European Aspergillus PCR Initiative 
 EBC     Exhaled breath condensate 
 EDTA     Ethylenediaminetetraacetic acid 
 ELF     Epithelial lining fluid 
 ELISA      Enzyme-linked immunosorbent assay 
 EORTC/MSG    European Organization for Research and 
Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the 
National Institute of Allergy and Infectious Diseases Mycoses Study Group 
 FACS     Fluorescence-activated cell sorting 
 GM      Galactomannan 
 GVHD     Graft-versus-host disease 
 HIV     Human immunodeficiency virus 
 HRCT     High resolution computerised tomography 
 HSCT     Haematopoietic stem cell transplantation 
 IA     Invasive aspergillosis 
 IFD     Invasive fungal disease 
 Ig     Immunoglobulin 
 IL     Interleukin 
 14 
 
 INF     Interferon 
 IPA     Invasive pulmonary aspergillosis  
 ITS     Internal transcribed spacer 
 LFD     Lateral flow device 
 LNA     Locked nucleic acid 
 LOD     Limit of detection 
 LOQ     Limit of quantification 
 LT     Long-term 
 MAb     Monoclonal antibody 
 MALDI-TOF    Matrix-assisted laser 
desorption/ionization-time of flight 
 MDS     Myelodysplastic syndrome 
 MFI     Median fluorescence intensity 
 MIQE     Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments 
 MPO     Myeloperoxidase 
 MWCO     Molecular weight cut-off 
 NADPH     Nicotinamide adenine dinucleotide 
phosphate 
 NASBA     Nucleic acid sequence based amplification 
 NCBI     National Center for Biotechnology 
Information 
 NET     Neutrophil extracellular trap 
 NPV     Negative predictive value 
 NTC     No template control 
 OD     Optical density 
 pAb     Polyclonal antibody 
 PA-EIA     Platelia Aspergillus enzyme immuno assay 
 PBS     Phosphate buffered saline 
 PE     Phycoerythrin 
 PLA     Proximity ligation assay 
 PPV     Positive predictive value 
 qPCR     Quantitative polymerase chain reaction 
 RNA     Ribonucleic acid 
 SOT     Solid organ transplant 
 ST     Short-term 
 Th     T helper 
 TNF     Tumour necrosis factor 
 VOC     Volatile organic compound 
  
 15 
 
DECLARATION OF ORIGINALITY 
 
I, Gemma Johnson, confirm that the research included within this thesis is my own work or 
that where it has been carried out in collaboration with, or supported by others, that this is 
duly acknowledged below and my contribution indicated.  Previously published material is 
also acknowledged below. 
I attest that I have exercised reasonable care to ensure that the work is original, and does 
not to the best of my knowledge break any UK law, infringe any third party’s copyright or 
other Intellectual Property Right, or contain any confidential material. 
I accept that the College has the right to use plagiarism detection software to check the 
electronic version of the thesis. 
I confirm that this thesis has not been previously submitted for the award of a degree by 
this or any other university. 
The copyright of this thesis rests with the author and no quotation from it or information 
derived from it may be published without the prior written consent of the author. 
 
 
Gemma Johnson 
 
Date: 30th May 2014 
  
 16 
 
LIST OF PUBLICATIONS ARISING FROM THIS THESIS 
Original research 
 Proximity ligation assay for the sensitive, specific and early diagnosis of invasive 
fungal disease (2013).  Johnson GL, Shannon M, Thornton CR, Agrawal SG, Bustin 
SA.  MYCOSES 56:48-49 (Abstract). 
 Significant decline in galactomannan signal during storage of clinical serum samples 
(2013).  Johnson GL, Sarker S, Hill K, Tsitsikas DA, Morin A, Bustin S, Agrawal SG. Int. 
J. Mol. Sci. 14, 12970-12977. 
 Detection of invasive pulmonary aspergillosis in haematological malignancy 
patients by using lateral-flow technology (2012).  Thornton CR, Johnson G, Agrawal 
S.  J. Vis. Exp. 61:495 e3721 (2012). 
 A MIQE-Compliant Real-Time PCR Assay for Aspergillus Detection (2012).  Johnson 
GL, Bibby DF, Wong S, Agrawal SG, Bustin SA.  PLoS ONE 7(7): e40022.  
 Impact of the revised (2008) EORTC/MSG definitions for Invasive Fungal Disease on 
the rates of diagnosis of Invasive Aspergillosis (2012).  Tsitsikas DA, Morin A, Araf S, 
Murtagh B, Johnson G, Vinnicombe S, Ellis S, Suaris T, Wilks M, Doffman S, Agrawal 
SG.  Med Mycol. 50(5):538-42. 
Reviews 
 Biomarkers for invasive aspergillosis: the challenges continue (2014).  Johnson G, 
Ferrini A, Dolan SK, Nolan T, Agrawal S, Doyle S, and Bustin SA.  Biomarkers in 
Medicine, Vol. 8, No. 3, P 429-451. 
  
 17 
 
ACKNOWLEDGEMENTS 
I would like to express my gratitude to those people who have helped and supported me 
throughout my studies.  Firstly I would like to thank Barts and The London Charity for 
funding my PhD.   
I would like to thank my primary supervisor, Dr Samir Agrawal.  When I first met him I was 
someone who panicked about crossing a crowded room and was physically sick before 
getting up to speak at a conference.  Now I lecture MSc students and thrive on presenting 
my research at conferences.  He believed in me from the start and always challenged me to 
push myself further and beyond my comfort zone.  I cannot thank him enough for the way 
in which he has driven my personal as well as my professional development.  He has been 
my tutor, my critic, my advisor and my friend. 
I would like to thank Professor Stephen Bustin for agreeing to be my second supervisor.  He 
is an amazing teacher, with such enthusiasm and passion for his work, it is impossible to 
not be motivated and inspired.  I have learnt so much from him.  He is always there when I 
need advice, guidance or reassurance…… with a constant supply of Nutella to get me 
through (4.5kg consumed from thesis start to finish)!  I thank Stephen for his guidance, 
support and meticulous attention to detail, which drove me to finally learn the proper use 
of a semicolon.  He is a true friend. 
Thank you to Dr Mark Wilks for employing me straight from university and always being 
there when I needed advice, long after I left his employment.  I am also very grateful to Dr 
Christopher Thornton for his assistance and guidance in all things immunological, Dr Tim 
Farren for teaching me how to use a flow cytometer (and accepting curly fries as a bribe for 
project advice!), Dr Shah-Jalal Sarker for his statistical analyses and advice (in the evenings 
and at weekends!) and Professor Lucinda Hall for her invaluable advice.  I am also deeply 
 18 
 
indebted to Dr Mark Shannon from Life Technologies for teaching me invaluable skills in 
PLA application during the fantastic two weeks that I spent in San Francisco. 
Thank you to David Ball for the constant supply of strong coffee and sweet treats.  Thank 
you to Nicola Thompson for her friendship and for never complaining when I turned our 
coffee breaks into an analysis of my latest experiment.  I would also like to offer my thanks 
to Arianna Ferrini and Francesco Nannini for their hard work and dedication in the 
laboratory and most importantly for their friendship.  When I supervised them in the 
laboratory I never dreamt that I would end up with a wonderful second family in Italy. 
I would like to thank my family for their love and support.  Thank you to my mum and dad 
for always being there when I needed advice, for encouraging me to follow my dream of 
studying at Cambridge University and for driving up to Cambridge every weekend to see 
me when I was home sick and miserable.   
Last but not least I would like to thank my husband and daughter for their unconditional 
love, patience and understanding.  Shaun, you have always encouraged me to push myself 
further, sacrificing your own ambition to support mine.  This dissertation would not have 
been possible without you.  Emily, at only six years old, you have watched me immerse 
myself in my PhD research for half of your life.  You have shown remarkable patience and 
always supported me, telling people that “mummy is always working, but it is ok because 
she makes sick people better”.  You are and will always be my proudest achievement.  
 
 
Gemma Johnson 
 19 
 
  
 
 
 
 
 
 
CHAPTER 1 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20 
 
1.1 Overview 
The incidence and clinical severity of invasive fungal disease (IFD) have increased 
significantly in recent years, posing an increasingly important clinical problem.  This 
challenge has become more acute as the use of cytotoxic treatments in patients with 
common disorders such as asthma, inflammatory bowel disease or rheumatoid arthritis is 
adding to the number of immunocompromised patients beyond the classic groups of 
patients with cancer, HIV-infection or undergoing transplants.  Concomitantly, there has 
been a steady increase in the frequency of opportunistic IFDs in these patients, where they 
are a major cause of morbidity and mortality.  There is substantial controversy concerning 
optimal diagnostic criteria for IFD, which is very difficult to detect at an early stage.  In 
haemato-oncology patients, the most widely studied group, the usual scenario involves 
commencement of empirical treatment in the context of a febrile illness and neutropenia 
unresponsive to broad spectrum antibiotics.  Frequently, antifungal agents are started in 
this setting without definite evidence of an IFD, with associated financial costs, significant 
toxicities and potential drug-drug interactions (1-3).  Consequently, an improvement in 
diagnostic accuracy would lead to early, specific and appropriate treatment of genuine 
fungal infection, minimising the unwarranted application of expensive and potentially 
harmful therapy. 
This chapter  
 introduces the mould Aspergillus, the most common cause of IFDs in the severely 
immunocompromised population 
 describes the range of infections caused by Aspergillus, and then focuses on 
invasive aspergillosis (IA), the clinical problem and the theoretical approaches to its 
diagnosis in the high risk haemato-oncology population 
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 discusses current options and emerging technologies and reviews the practical 
application of these technologies in the context of published findings and 
 provides an overview of the state of the art, and the important questions that still 
remain.  
 
1.2 Aspergillus 
Aspergillus is the name given to a family of common moulds, first described by the Italian 
priest and botanist Pier Antonio Micheli in 1729 (4).  Micheli named the mould after the 
‘Aspergillum’; an instrument used for sprinkling holy water, due to the similarity of its 
appearance under the microscope (Figure 1A and 1B).  
 
Figure 1. A) Spore-forming structures (conidia) of the fungus Aspergillus, B) An aspergillum. 
A) Credit: Microbiology department, Royal London Hospital.  B) Credit: Shaun Johnson, Ad Meliora Art and 
Design, UK. 
 
The genus Aspergillus was originally divided into subgenera and groups (5).  The current 
classification scheme (6), which conforms to the rules of the “International Code of 
Botanical and Mycological Nomenclature”, divides the genus into 7 subgenera and sections 
that consist of related species.  By the current code, different names can be assigned to the 
different asexual and sexual stages of a single species (7).  Until recently, no Aspergillus 
B A 
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species were known to have a sexual cycle, though genes were identified that linked them 
to sexual reproduction (8-11).   However, heterothallic reproductive cycles have recently 
been discovered in three medically important Aspergillus species, namely Aspergillus 
fumigatus, A. parasiticus and A. flavus. 
Aspergillus is a saprotrophic fungus found in nutrient-rich soil or decaying vegetation and 
plays a significant role in carbon and nitrogen cycling by breaking down dead organic 
matter.  However, it is also an opportunistic human pathogen, which can cause allergic and 
infectious diseases, depending on the immune status and pulmonary structure of the host.  
During the asexual cycle, haploid hyphae (mycelia) produce conidiophore vesicles, from 
which a series of mitotic budding events occur.  Chains of haploid spores (conidia) are 
formed and released through a disruption in the environment.  Conidia are dispersed in the 
air and found in both indoor and outdoor environments (12).  Transmission of fungal 
conidia to human host occurs mainly via inhalation and although the average person 
inhales up to 200 conidia each day (13), this will cause most healthy individuals no ill effect.  
The conidia are removed by mucociliary clearance or by epithelial cells and alveolar 
macrophages if they travel as far as the lungs.  Macrophages also initiate a 
proinflammatory response, to recruit neutrophils.  However, when a host is 
immunocompromised, for example, during treatment for cancer, or when undergoing 
transplants, Aspergillus conidia are able to evade macrophage killing, colonise, germinate 
and cause disease. 
Aspergillosis describes a range of diseases caused by Aspergillus species, including both 
invasive and allergic disease.  There are four main types: 
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1. Allergic broncho-pulmonary aspergillosis (ABPA) – a condition where a patient 
develops an allergy to Aspergillus spores, predominantly affecting patients with asthma 
and cystic fibrosis.  
2. Chronic pulmonary aspergillosis (CPA) – a cavitating process in the lungs due to 
invasion of the lung tissue by Aspergilllus, commonly associated with underlying lung 
disease or alcoholism.  
3. Aspergilloma - a mycetoma or fungus ball, which exists in a body cavity such as the 
lung, usually developing in pre-existing lung cavities such as those caused by tuberculosis.  
4. IA – primarily a pulmonary infection, but haematogenous spread can occur to any 
organ, most frequent in individuals with severely weakened immune systems. 
 
1.3 Invasive Aspergillosis  
IA is one of the leading causes of infectious mortality in patients with haematological 
malignancies receiving intensive chemotherapy and haematopoietic stem cell 
transplantation (HSCT) (14, 15), with a mortality rate as high as 90% in the 
immunocompromised population (16).  Incidence of IA ranges from 5% to more than 20% 
in high risk groups and A. fumigatus is the most common species implicated, accounting for 
approximately 90% of all cases of life-threatening infections (17).  However, other strains, 
particularly A. flavus and A. terreus are increasingly shown to be associated with IA (18-20).  
The reported frequencies of A. fumigatus, A. flavus, A. terreus, A.nidulans and A.niger 
isolated in IA range from 30-67%, 14-33%, 3-28%, 1-2.5%and 5-8% respectively (21-23).  A. 
fumigatus has smaller conidia than other Aspergillus species, with an average conidia 
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diameter of 2-3.5µm.  Upon inhalation, this enables it to travel deep into the lower 
respiratory tract of the host and into the lung alveoli.   
 
1.4 Host immune defences against IA  
1.4.1 First line defences 
The main portal of entry for Aspergillus is the airway, in the form of conidia inhalation 
(Figure 2A).  The airway epithelium is the first line of defence of the lungs against invading 
microorganisms and defences include mucus-secreting cells, which trap inhaled conidia and 
ciliated cells, which transport the trapped conidia to the oropharyngeal junction to be 
swallowed.  The cough and sneeze reflexes are added mechanical defences to aid in 
expelling particles.  An additional defence is provided by the airway lining fluid, which 
contains antimicrobial compounds such as lysozyme and defensins.  However, not all 
inhaled Aspergillus conidia will be removed in this way.  Some move to the lung, where 
they must evade the first line immunity presented by Surfactant proteins A and D (SP-A, SP-
D).  These soluble receptors bind Aspergillus conidia, leading to increased phagocytic 
capacity of alveolar macrophages and neutrophils (Figure 2B). 
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Figure 2.  The Aspergillus infection pathway.  A.  Aspergillus conidia are inhaled into the lung and reach the 
alveoli.  B.  In the bronchiole the conidia meet surfactant proteins SP-A and SP-D, which trap conidia and 
promote phagocytosis by macrophages.  
Credit:  Shaun Johnson, Ad Meliora Art and Design, UK. 
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1.4.2 Cells of the innate immune response 
Once spores reach the lungs the host has two important defence needs: 
- to restrict spores germinating into invasive hyphae 
- to limit fungus-induced and inflammation-induced tissue damage 
The binding and internalisation of Aspergillus fumigatus by respiratory epithelial cells has 
been demonstrated (24) and these intra-epithelial conidia may survive and germinate (25).  
This evidence suggests that A. fumigatus may use this internalisation step to evade immune 
cells and as a starting point for dissemination. 
Macrophages used to be considered the first line of defence against spores, with 
neutrophils specifically targeting hyphae (26).  But it has become evident that neutrophils 
have a much more complex role.  For example, they have been shown to kill swollen (but 
not resting) ungerminated Aspergillus conidia after phagocytosis (27).  Neutrophils exhibit 
phagosome proteolytic activity, initiate oxidative mechanisms of microbicidal activity and 
release granule proteins that have crucial roles in the innate immune response to 
Aspergillus infection.  Two enzymes necessary for Aspergillus elimination are 
Myeloperoxidase (MPO), which catalyses the formation of reactive hypochlorites (ClO-) 
from H2O2 and Cl-, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 
which together with superoxide dismutase ensures formation of reactive oxygen species 
such as superoxide and hydroxyl radical (Figure 3).   MPO is stored in neutrophil granules, 
whereas NADPH oxidase is a membrane bound complex and both are activated during a 
respiratory burst (28),   The absence of MPO increases mortality rates in mice infected with 
A. fumigatus and the absence of NADPH oxidase makes mice more susceptible to A. 
fumigatus infection (29).  This helps explain why patients with chronic granulomatous 
disease (CGD) are at such high risk of IA, as the disease is characterised by the absence of 
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NADPH oxidase from neutrophils and macrophages.  Neutrophils, along with epithelial 
cells, also produce lactoferrin, which sequesters iron, inhibiting  Aspergillus growth (30).  
Pentraxin 3 is a secreted pathogen recognition receptor, released from neutrophil granules, 
that has been shown to interact with A. fumigatus.  In the presence of Aspergillus conidia, 
the binding of pentraxin 3 to the spore surface is important for opsonisation.  It has been 
demonstrated that neutrophils take up pentraxin 3 –coated spores more efficiently than 
uncoated spores (31), with neutrophils forming extracellular traps (NET) upon encountering 
germinating spores and hyphae in the lung (32, 33).  Binding of pentraxin-3 to conidia via 
galactomannan, also enhances uptake by alveolar macrophages and dendritic cells (34).     
 
Figure 3.  Oxidative mechanisms of microbicidal activity initiated by neutrophils to destroy invading 
organisms. 
The enzyme NADPH oxidase acts together with superoxide dismutase to form reactive oxygen species such as 
superoxide, which then reacts to form hydrogen peroxide.  The enzyme myeloperoxidase combines the 
hydrogen peroxide with chloride. 
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In response to infection, neutrophils are rapidly recruited to the alveolar spaces and 
cooperate to inactivate conidia.  Together with alveolar macrophages they prevent conidial 
germination in the immunocompetent host.   Hence, prolonged neutropenia is a major risk 
factor for IA.   
1.4.3 The adaptive immune response 
Microbial pathogens are endocytosed by antigen-presenting cells, such as dendritic cells, 
processed and presented preferentially to CD4+ T helper (Th) cells.   Dendritic cells act to 
initiate both innate and adaptive immunity, with control of infection largely dependent on 
Th cell selection and clonal expansion to direct effector cells against germinating 
Aspergillus conidia and growing hyphae (35).  In the murine model, three patterns of Th 
activation have been shown to characterise the adaptive immune response.  CD4+ Th cells 
can develop into Th1, Th2 or Th17 cells (36-38).  The development of Th1 responses is 
influenced by cytokines such as INF-γ, IL-6, TNF-α and IL-12, stimulating macrophage and 
neutrophil activity and healing, in the relative absence of Th2 cytokines such as IL-4 and IL-
10 (39) (Figure 4).  Th2 responses are associated with decreased INF-γ, disease progression 
and poor outcome.  An association has been demonstrated between unimpaired innate 
immune activity, producing high detectable levels of TNF-α and IL-12 in BAL fluid, and 
resistance to IA in a mouse model (40).  In the same study, down-regulation of TNF-α and 
IL-12 production was seen in immunocompromised mice with defective innate immunity 
and resulted in impaired fungal clearance and increased mortality.  Resistance was 
increased in these mice by IL-12 administration.  At a later stage of infection, fungal 
antigen-loaded dendritic cells influence naïve T cells to mature into low- INF-γ-producing 
lymphocytes, via IL-23.  This adaptive immune response counter-regulates IL-12 
production, reducing INF-γ production and impairing host antifungal immunity, resulting in 
high fungal tissue burden (41). 
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Chemokines appear to enhance lymphocyte and macrophage recruitment, with MCP-
1/CCL2 markedly induced in the lungs of neutropenic mice challenged with A. fumigatus 
conidia, playing a vital role in recruitment of immune cells to the lungs in early host 
defence (42).   
More recently, a strong Th17 response has been documented in Aspergillus infection (43), 
with the pro-inflammatory cytokine IL-17A involved in the recruitment, activation and 
migration of neutrophils to the site of inflammation.  In a single exposure model, the A. 
fumigatus-specific CD4 T-cell airway response has been demonstrated to consist of a 
dominant Th1 and a smaller Th17 population (44, 45).  However, the involvement of the 
Th17 pathway in human IA remains unresolved.  A study using human monocyte-derived 
macrophages reported a limited role of IL-17 in Aspergillus infection and low levels of IL-17 
in serum and BAL fluid of haematology patients with IA (46).  Immune response in the 
human haemato-oncology setting is further discussed in Section 5.2. 
 
Figure 4.  Activation of the TH1, Th2 and Th17 CD4 T-cell responses in the lung 
APC = antigen presenting cell. 
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1.5 Clinical Diagnosis of IA 
1.5.1 The haemato-oncology setting 
Early diagnosis of IA is important, as early, appropriate treatment has been shown to be a 
prognostic indicator.  With early diagnosis, treatment may be initiated before the infection 
becomes irreversible (47, 48).  Patients with IA suffer considerable morbidity (49) and often 
the management of the underlying malignancy is compromised, as treatment is delayed or 
cannot be given at all due to the high risk of relapse during subsequent therapy.   IA 
diagnosis remains a challenge as the clinical manifestations are ambiguous.  The most 
frequent clinical manifestation in this setting is invasive pulmonary aspergillosis (IPA) and 
the most frequent scenario is that of a neutropenic patient with non-specific symptoms, 
such as persistent fever, which is unresponsive to broad-spectrum antibiotics.  Patients 
may also present with cough and sputum production, pleuritic chest pain due to vascular 
invasion leading to small pulmonary infarcts, upper respiratory tract symptoms and/or 
evidence of sinusitis.  High-risk patients already have a number of co-morbidities and 
complicated drug treatment regimes.  Current diagnostic tools are described in the 
literature with widely varying sensitivities and specificities (as discussed in section 1.6), 
with many requiring highly skilled operators and facilities that are not routinely available in 
many centres.  To further complicate diagnosis, the diagnostic gold standards of a 
histological demonstration of IFD and/or recovery of the causative agent in culture from a 
normally sterile site are rarely feasible ante-mortem as patients are too unwell to undergo 
invasive procedures. 
Due to this diagnostic uncertainty many patients are unnecessarily treated for presumed 
IA.  This exposes them to associated drug toxicities and has major cost implications, 
particularly when antifungal therapy is usually initiated empirically, based upon fever and 
abnormal findings on chest computerised tomography (CT). 
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1.5.2 EORTC/MSG guidelines 
The European Organisation for Research and Treatment of Cancer and Mycoses Study 
Group introduced the EORTC/MSG guidelines, a set of consensus criteria, in 2002 (50)  and 
published a revised version in 2008 (51).  These were intended for use in clinical and 
epidemiological research and are used as a tool for the classification of IFD in 
immunocompromised patients.  However, the guidelines act as a tool to standardise clinical 
research and were not intended to help with patient management.  These criteria are used 
to classify potential cases according to the likelihood of underlying IFD into possible, 
probable and proven.  In the original 2002 guidelines, ‘proven’ cases require histological 
evidence or isolation of the suspected etiological agent in culture from a normally sterile 
site, namely tissue.  ‘Possible’ and ‘probable’ classifications are based on a combination of 
host, clinical and microbiological criteria, with the clinical criteria sub-divided into ‘major’ 
(i.e. specific radiological changes) and ‘minor’ (mostly clinical symptoms and signs).   
The aim of the 2008 revisions was to improve specificity, partly by removing the sub-
criterion of ‘minor clinical’ and restricting the clinical criteria for fungal lower respiratory 
tract infections to very specific CT scan findings (51).  In addition, the classification of 
‘possible’ now required a combination of host and clinical factors, with microbiological 
factors no longer scoring in the absence of clinical factors.  This is a significant change 
which downgraded the importance of microbiology in defining likelihood of infection.  Our 
own data (at Barts Health NHS Trust) highlighted the impact of this change, with a 75% 
reduction of cases previously classified as ‘probable’ IA, all downgraded to non-classifiable 
(52).  This was due to the combination of host and microbiological factors no longer being 
sufficient factors in the establishment of possible infection.  This change leads to difficulties 
 32 
 
in interpreting previous studies where the 2002 definitions were used to evaluate the 
performance of microbiological tests.  The limitations of the EORTC/MSG criteria in clinical 
studies are discussed further in section 1.9. 
 
1.5.3 Antifungal patient management  
In terms of patient management the most suitable strategy is heavily dependent on the 
prevalence and epidemiology in the clinical setting, and the availability and turn-around 
time of suitable diagnostic tests.  There are three approaches to prophylaxis:  (i) no 
prophylaxis; (ii) mould-inactive prophylaxis (i.e. fluconazole) and (iii) mould-active 
prophylaxis (e.g. itraconazole, voriconazole, posaconazole), as shown in Figure 5 (53).  An 
empiric approach to management remains the standard in many centres.  Using this 
approach, antifungal treatment is commenced when there are clinical signs and symptoms 
of invasive mould disease, but in the absence of identification of a fungal pathogen, whilst 
carrying out investigations to confirm or exclude.  There are varied definitions of ‘signs and 
symptoms of invasive mould disease’, but a recent suggestion by a working group defines it 
as a high risk patient who has persistent or relapsing fever refractory to broad spectrum 
antibiotics, without an identified cause for 72 hours or more (54).  With persistent fever as 
a trigger for this management strategy, it is important to consider that fever may be absent 
if corticosteroids are administered.  Empiric treatment is likely to lead to the treatment of 
patients who do not have IFD, as demonstrated by a retrospective study carried out at St 
Bartholomew’s hospital in London, showing that 44% of high risk haemato-oncology 
patients received antifungal treatment for suspected IFD, whilst the EORTC/MSG revised 
criteria identified less than 5% of this cohort as probable/proven disease. 
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Figure 5.  Antifungal strategies for patients at risk of invasive fungal disease. 
Adapted from Agrawal et al (53). 
 
In a diagnostic driven approach, biomarker detection and imaging techniques are combined 
to direct therapy and aim for a rapid assessment of the likelihood of IFD.  The success of 
such an approach is heavily reliant on the early availability of biomarker assays and imaging 
services, and its efficacy has not yet been established.  This is further complicated by the 
use of a sub-optimal reference standard in the evaluation of assay performance, as 
discussed in sections 1.5.2 and 1.9.  Ultimately, to establish a diagnosis and identify the 
infective organism would be the optimal management strategy. 
 
1.6 Laboratory-based diagnostic options 
 
1.6.1 Traditional Techniques 
 
Histological examination of the infected tissue remains the “gold standard” for diagnosis, 
and is a requirement for a “proven” case, by EORTC/MSG definitions.  However, obtaining 
tissue may be impractical due to the risks associated with the underlying disease.  
 34 
 
Laboratory identification of Aspergillus species has long been based on morphology.  
Phenotype-based diagnostic criteria include the shape, size, colour and ornamentation of 
asexual or sexual structures.  However, such characteristics are unstable and clinical 
isolates are sometimes atypical, with slow sporulation and aberrant conidiophore 
formation.  A Gram’s stain or Grocott’s methenamine silver stain may be carried out to 
identify any fungal elements.   Cells from bronchial washings can be concentrated by 
centrifugation and processed with 10% potassium hydroxide, Parker ink or calcofluor white 
mounts for examination (55).  However, microscopy offers a low sensitivity and fungal 
elements cannot be identified to the species level.  Structures can only be seen if they are 
present in abundance, usually at a later stage of infection (56).  Molecular identification 
based on the sequencing of DNA targets has shown that classification by phenotypic 
characteristics is not always reliable, especially for less common species (57).  DNA 
sequence variation in a number of genes, including the universal ribosomal DNA regions ITS 
and the large ribosomal subunit D1-D2, have been used to arrange fungi into molecular 
phylogeny groups.  This has led to the identification of new fungal species that are 
morphologically similar to A. fumigatus, but are genetically distinct (58).  Such species 
could easily be misidentified by clinical laboratories (59), which can have severe 
consequences as they include human pathogens such as A. lentulus and N. pseudofischeri 
(60, 61), that have been reported to be resistant in vitro to certain antifungal agents (62).  
Therefore, although direct visualisation is simple and rapid approach, identification of 
Aspergillus species by microscopy alone may be misleading.  Confirmation by culture is 
desirable and often essential for definitive identification of the pathogen.   
Culture of Aspergillus from an infected sterile site also provides definitive proof of disease 
and allows species determination and susceptibility testing, at a relatively low cost.  
However, these are rarely obtained in practice, due to inaccessibility of the lesion and the 
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underlying condition of the patient.  Also, culture has the disadvantages of being a slow 
technique (it takes days) and being relatively insensitive (63).  The failure to culture from a 
histopathologically confirmed case of IA may be due to the non-viability of the organism, as 
it is important to remember that antifungal treatment is often started empirically.  Culture 
from a non-sterile site e.g. sputum and broncho-alveolar lavage (BAL) fluid, must be 
interpreted with caution, due to the ubiquitous nature of fungal spores.  However, the 
isolation of Aspergillus species from a sputum or BAL sample is highly predictive of IPA in 
neutropenic patients (64, 65). 
 
1.6.2 Imaging 
As IA in severely immunocompromised people will typically involve the lung, a chest x-ray 
(CXR) may reveal nodules, consolidation, or non-specific infiltrates.  However, CXR often 
shows no abnormalities.  CT scanning of the chest is more sensitive than CXR and is the 
preferred radiological method, as it may detect lung changes in the early stages of infection 
(66, 67) .  Chest CT interpretation is pivotal to assigning a likelihood of IPA using the 
EORTC/MSG guidelines.  Indeed, a key change between the EORTC/MSG 2002 and 2008 
criteria was the elimination of minor clinical criteria and emphasis placed on specific CT 
findings. 
Typical radiological signs of IA include the “halo” sign, which is a pulmonary nodule or mass 
surrounded by a zone of ground glass attenuation (67, 68).  Although the halo sign is not 
specific to fungal infection, pulmonary aspergillosis is the most common cause of the halo 
sign in populations at high risk of fungal infection.  Therefore in the appropriate clinical 
setting it is considered as early evidence of pulmonary aspergillosis (66).  However, the 
presence of the halo sign is short-lived and early scanning is vital (69). 
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The air crescent sign occurs when air fills the space between devitalised tissue and 
surrounding parenchyma and is recognised as a crescent-shaped area of radiolucency 
within a parenchymal consolidation.  The air crescent sign is not specific to Aspergillus 
infection, but is highly suggestive of pulmonary aspergillosis in the appropriate clinical 
setting.  These lesions are considered to be characteristic of later-stage disease, marking 
the recovery phase of the infection (70). 
The specificity of radiological features for IPA diagnosis has been assessed in patients with 
haematologic malignancy.  A retrospective review demonstrated that radiological detection 
of at least 1 lesion with imaging suggestive of aspergillosis had 90% positive predictive 
value for IPA (71). 
Smaller nodules (<1 cm), ground-glass opacities, and consolidation are non-specific 
features and do not necessarily suggest IPA.   However, following the 2008 revisions to the 
EORTC/MSG guidelines, there is increasing evidence to support extending the radiological 
suspicion of IPA to less specific chest CT scan findings when supported by microbiological 
evidence in high-risk haematological patients (72). 
Pulmonary macronodules, the halo sign, and the air-crescent sign have been best studied 
extensively in patients with IPA and haematological malignancy or stem cell transplantation 
(73, 74).  Radiological features are not as well characterised in other settings with IPA (75, 
76). 
 
1.6.3 Serological assays 
A key trait of Aspergillus pathogenicity is angioinvasion.  In the immunocompromised host 
this can lead to dissemination to other organs of the body (77).  Angioinvasion results in the 
appearance of circulating surrogate markers in the blood, which can be tracked using 
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immunological methods.  This has led to development of non-culture based methods using 
monoclonal antibodies (MAbs) to detect antigens that circulate in the body (78).  Blood is 
usually tested, due to the minimally invasive sampling method and the potential to collect 
large volumes on a regular basis.  However, most of the reported antigen detection tests 
have lacked the required sensitivity and specificity in the clinical setting (79).  The 
serological detection of an IA marker has been most extensively investigated using the 
Aspergillus cell wall polysaccharide galactomannan. 
 
1.6.3.1 Galactomannan 
Galactomannan (GM) is a polysaccharide component of the cell wall of Aspergillus and 
Penicillium species (80-82).  GM antigen is released into the blood during hyphal growth.  A 
rat MAb has been targeted to the galactofuranose moieties of GM and used to 
commercially develop two assays; the Pastorex kit (Sanofi Diagnostics Pasteur, Mames-La-
Coquette, France) and the immunoenzymatic sandwich microplate Platelia ELISA (BioRad, 
Mames-La-Coquette, France).  The Pastorex kit is now rarely used, whilst the Platelia ELISA 
is FDA approved and CE marked for both serum and BAL fluid samples, and recommended 
by the EORTC/MSG as one of the mycological criteria for IA diagnosis (51).  The assay uses 
the EB-A2 MAb, directed towards the B(1,5)-linked galactofuranoside side-chain residues of 
the GM molecule, with 4 or more epitopes required for the antibody to bind (83).   
Reported sensitivity and specificity values for the Platelia ELISA have been variable and it is 
clear that this is in part due to the variation in cut-off for assigning a positive result, patient 
population, relative prevalence of IA in the studied population, number of consecutive 
positive results required to confirm positivity and the inclusion of different combinations of 
proven/probable/possible cases in the assessment of assay performance.  Maertens et al 
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(84) reported impressive sensitivity and specificity values of 92.6% and 95.4% respectively, 
when performing twice weekly screening of patients with haematological malignancy.  
Importantly, a cutoff of GM index 1.0 was used, which is higher than the recommended 
serum cutoff of 0.5, which is  widely accepted in Europe and approved by the FDA.  Also, 2 
consecutive positive results were required to confirm positivity, as recommended by the kit 
manufacturer.  These performance figures were taken from an analysis of ‘proven‘ IA cases 
only, by histology.  The authors state that if they included their ’probable‘IA cases (similar 
to EORTC scoring criteria, but predating the criteria), which can be regarded as essentially 
unverified ‘true‘ cases, then assay sensitivity would reduce to 82%. 
Pazos et al (85) reported similar performance in patients with haematological malignancy, 
using a cut-off of 1.5.  Though very limited in sample numbers (5 proven and 3 probable by 
EORTC criteria), they reported sensitivity and specificity of 100% and 97% respectively in 
proven cases and 88% and 98% respectively when considering both ‘proven‘ and ‘probable‘ 
as true cases. 
In a large study by Herbrecht et al (86), again in patients with haematological malignancy, 
the results from serum assays were not as promising, with reported assay sensitivity of only 
65% in proven cases.  However, the threshold of positivity was set at 1.5, which is very high 
for a serum sample and may explain why some of the false negative results occurred.  The 
authors go on to suggest a reduction in the cut-off in their discussion section.  The authors 
also report a negative predictive value of 100% in patients undergoing HSCT.  Results for 
patients with probable IFD (rather than proven) are less encouraging in this trial; with 
reported assay sensitivity of 16%.  Similarly inadequate results have been reported by 
others (87, 88).  Pinel et al report a very low positive predictive value (PPV), though it is 
important to note that reported IA prevalence is also very low.  Maertens et al (84) report 
very high PPV and high prevalance.  This is to be expected, as PPV has been shown to 
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increase with prevalence for both proven and probable cases.  Reported performance is 
better in the haematological malignancy and bone marrow transplant (BMT) populations 
than solid organ transplant (SOT) populations, as reflected in a recent meta-analysis (89), in 
which the sensitivity of serum GM testing for patients with haematological malignancy was 
70%, in BMT recipients was 82% and in SOT recipients was only 22%.   
In addition, there are many reports that challenge the specificity of the GM-ELISA: it 
detects a soluble antigen produced during infection with Geotrichum capitatum, with no 
evidence of aspergillosis (90), reacts with Candida species (91), cross-reacts with other 
opportunistic fungi in some other fungal infections such as histoplasmosis (92) and may 
react with antigens from Cryptococcus neoformans in patients with cryptococcosis (93).  
There have also been consistent and continuous reports of false positive results having 
been obtained from patients receiving β-lactam antibiotics (94-97). There is some evidence 
that this particular problem is caused by manufacturing complications, possibly the 
presence of cross-reacting antigens from Penicillium (98).  Fortunately, the most recent 
evidence suggests that these difficulties have been largely resolved (99) and the clinical 
problem can be minimised if batches are tested before use and/or if samples are collected 
prior to infusion (100).  Further studies into the usefulness and application of GM testing 
may help to reduce the clinical uncertainty.  Application to BAL fluid certainly appears very 
promising as a diagnostic tool, as discussed below. 
 
1.6.3.2  (1-3)-β-D-glucan 
(1-3)-β-D-glucan (BG) is a component of the cell wall of most fungi, with the exceptions of 
Cryptococcus and Zygomycetes (101).   Assays make use of the ability of BG to activate a 
cascading series of serine proteases in the Limulus amoebocyte lysate coagulation cascade.  
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The presence of BG is detected either by a turbidimetric assay or via cleavage of a synthetic 
chromogenic substrate. 
Fungitec-G was the original BG assay, made by Seikagaku Biobusiness (Tokyo, Japan).  
Performance of this assay in the diagnosis of IFD was assessed by Obayashi et al (102).  
Sensitivity and specificity of 90% and 100% respectively, were reported in cases of proven 
fungal and non-fungal infection; demonstrating serum testing as an effective approach to 
IFD diagnosis. 
In another trial, published the same year, the assay performance was assessed in 
immunodeficient mycosis patients with Candidemia, Aspergillosis and Cryptococcosis (103).  
They reported BG levels in healthy volunteers to be <10pg/ml, with significant elevation 
observed patients with Candidemia (>300pg/ml) and IA (>25pg/ml, rising rapidly over 
time).  However, little or no rise was seen in patients with Cryptococcosis (<17pg/ml). 
Performance of the Fungitell assay (formally called Glucatell, Associates of Cape Cod, USA) 
as a diagnostic tool for IFD was evaluated by Odabasi et al (101).  This assay differs from the 
Fungitec-G assay in that it is derived from a different species of horseshoe crab.  
Measurement from healthy volunteers and non-neutropenic patients with Candidemia was 
used to select a cut-off of ≥60pg/ml in the Fungitell assay, as opposed to the cut-off of 
>20pg/ml previously assigned to the Fungitec-G assay (102).  In a test panel of 30 healthy 
volunteers and 30 patients with proven Candidemia, sensitivity and specificity values of 
97% and 93% respectively, were calculated.  In the same report, the authors present results 
from serum BG testing in a trial involving 283 neutropenic adults undergoing 
chemotherapy.  Using a cut-off of 60pg/ml and requiring ≥1 positive serum sample, an NPV 
of 100% was reported when looking at the EORTC proven and probable cases.  Specificity 
was reported as 90% when a single positive result was required, 96% when 2 sequential 
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positive results were required and 99% when 3 were required.  All patients were receiving 
antifungal prophylaxis. 
There is a paucity of data addressing the clinical sensitivity of the BG assay when looking 
specifically for Aspergillus species.  Kami et al (104) reported performance figures from BG 
plasma testing in 16 cases of proven IA (host evidence of tissue invasion and culture 
positive sputum/lung), 14 suspected IA (CT changes and persistent fever/histopathological 
evidence of IA) and 185 cases of no IA.  The Fungitec-G assay was used for once weekly 
plasma screening, with a single positive result required.  Patient-based analysis gave 
sensitivity and specificity of 63% and 76% respectively.  However, it is noted that sensitivity 
was 88% in cases of disseminated IA and only 38% in cases of localised IA (lung only).  This 
suggests that blood screening is not suitable for early diagnosis of IPA.  In sample-based 
analysis, BG assay sensitivity was only 16%, which emphasises the need for repeated blood 
sampling for diagnosis. 
Pazos et al (105) reported performance figures from BG serum testing in 40 neutropenic 
patients.  The Fungitell assay was used for twice weekly serum screening, with a single 
positive result required and a cut-off of 120pg/ml.   When considering true positives to be 
both EORTC/MSG proven and probable cases and true negatives to be those with no 
evidence of IFD, sensitivity and specificity were reported as 87.5% and 89.6% respectively, 
with a false positive rate of 10.3% (3 positive results from 29 cases with no evidence of 
IFD).  When looking at the five proven IA cases only, sensitivity was 100%.  In the three 
probable cases, sensitivity was 66%.  The use of the BG assay as an adjunct in the diagnosis 
and management of IA is suggested by recent data that showed a sensitivity and specificity 
of 63 and 93%, respectively, in patients with acute leukaemia using two consecutive 
samples with a cut-off value of 7pg/ml (106).  The test gave similar results for IA and 
candidiasis, although the time interval between onset of fever and BG result was shorter 
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for IA.  Positive BG test results were obtained before the results of any other conventional 
diagnostic method, including cultures, histopathology or radiological criteria, which may 
make it useful for early evaluation and pre-emptive initiation of appropriate antifungal 
treatment.  A recent meta-analysis of 16 studies concluded that serum BG measurement 
has a good diagnostic accuracy for IFD diagnosed in accordance with the EORTC/MSG 
criteria, with a pooled sensitivity of 76.8% and a specificity of 85.3% (107).  However, there 
was marked statistical heterogeneity among the studies and significant technical 
differences between the studies, extending to the method of measurement, the type of BG 
used as standard, the pre-treatment method and the cut-off levels.  Similar results were 
reported by another meta-analysis that included 17 studies where IA was specifically 
targeted as a subgroup for analysis; here sensitivity and specificity were 77 and 83%, 
respectively, and heterogeneity was equally significant (108).  In addition, the timing and 
frequency of BG testing for patients at risk has not been standardised, and neither have the 
criteria for defining a positive test result.  A study focusing on routine use of BG for 
panfungal screening of IFD in patients with haematological malignancy revealed limited 
usefulness of this test in such a setting, with low sensitivity combined with an extremely 
low positive-predictive value (11.8%) being the major limitations (109).  There are other 
factors that could generate a positive BG result.  False positive BG results have been 
documented in haemodialysis (110) and exposure to glucan-containing gauze such as used 
in major surgery (111), as well as in patients receiving intravenous immunoglobulin (112).  
Therefore, results should always be interpreted in the context of the clinical procedure.  
This is particularly important because BG detection lacks mycological specificity for IA 
diagnosis.  However, it could be used to exclude IA in some scenarios and increase certainty 
of IA when GM is positive (105). 
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1.6.4 Real time PCR 
Real-time quantitative PCR (qPCR) is firmly established as the method of choice for the 
detection of pathogen-derived nucleic acids in routine clinical diagnostics (113). Several 
features make qPCR well suited to the clinical environment: 
 Speed: assay reaction times are typically measured in tens of minutes 
 Convenience: the homogenous assay format obviates the need for post-
amplification processing 
 Simplicity: the assay requires two primers, an optional probe and a single enzyme 
 Sensitivity: single copy targets can be detected, if not quantified 
 Specificity: a well-designed assay is specific for a single target, but mismatch-
tolerant assays are easily designed 
 Robustness: a well-designed assay will yield results across a wide range of reaction 
conditions 
 High throughput: thousands of reactions can be carried out on a single run 
 Quantification: the dynamic range is typically huge (eight to nine orders of 
magnitude) 
 Familiarity: PCR has been around for many years and its advantages and 
disadvantages are well understood 
 Cost: assay reagents are inexpensive; together with the trend towards smaller 
reaction volumes the costs per assay are low. 
 44 
 
There are three main drawbacks to qPCR assays: (i) their sensitivity to environmental 
inhibitors that are concentrated along with pathogens during sample processing can lead to 
false-negative results – this is important in fungal qPCR where large volumes of starting 
material are often tested, increasing the opportunity for concentration of inhibitors, as 
highlighted by the European Aspergillus PCR Initiative (EAPCRI) recommendations to 
extract from at least 3 ml of whole blood and elute DNA into less than 100 µl (114), (ii) 
assays determine only total pathogen number and do not provide information about 
whether a pathogen has the ability to establish an infection or not and (iii) variable assay 
conditions and ill-defined assay designs can generate significant inter-laboratory variation, 
leading to unreliable and often contradictory results obtained from the same samples.  
PCR has been extensively used as an aid in the diagnosis of IA (115).  However, a lack of 
technical standardisation and poor understanding of the kinetics of in vivo fungal DNA 
release has resulted in the development of numerous assays amplifying diverse target 
regions and reporting a wide range of PCR sensitivities and specificities (114).  A recent 
systematic review of Aspergillus PCR methods using whole blood samples (116) highlighted 
the variation in methods across 16 studies that included three extraction and four 
disruption methods, three different starting volumes, three different specimen types, three 
different target genes and four different PCR methods.  Only four qPCR assays were 
included in this review and there was sufficient information to determine PCR efficiency for 
only two – both suboptimal at 91.6% and 86%.  This, together with the inadequate 
reliability of amplification from blood and serum has led to attempts to reach a consensus 
on PCR diagnosis.  This was pioneered by EAPCRI, which aims to standardise Aspergillus 
PCR (114).  The authors have thus far focused on the extraction procedure, which they 
suggest is the limiting step in achieving reliable detection of Aspergillus.  However, closer 
examination of their data obtained by analysing the results from their PCR performance 
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panels reported by various laboratories leads to a different conclusion: the amplification 
results obtained using the range of assays tested are highly variable.  Excluding one assay 
that gives no result at all, the detection threshold in different centres ranges from 0.27 to 
270 copies of target/ml, a considerable 1,000-fold difference that can easily account for the 
difference between a positive and a false-negative result.  This analysis demonstrates that 
there is a maximum difference of 100-fold when the same PCR strategy is carried out in 
different centres, readily explaining the variability commented on by the authors of the 
meta-analyses (117).  The data also confirm that assay performance is greatly influenced by 
the amplification platform used, as previously identified by a UK and Ireland multi-centre 
study of PCR methods for Aspergillus species (118).  Consequently, far from leading to the 
conclusion made by the EAPCRI, the appropriate conclusion is that the PCR assays are 
highly variable, with different PCR efficiencies resulting in significantly different 
sensitivities. 
With such a lack of technical standardisation, it is not surprising that the EORTC/MSG do 
not endorse the routine use of PCR in the diagnosis of IA (50).  There are several additional 
reasons for this, which are discussed in depth in Chapter 2, where the quality of broad 
spectrum Aspergillus qPCR assays published between December 2000 and December 2011 
is reviewed. 
 
1.6.5 Lateral flow device (LFD) 
The use of hybriboma technology recently led to the generation of the Aspergillus-specific 
MAb JF5 and the development of an immuno-chromatographic lateral flow device (LFD) for 
point of care diagnosis of IA (119).  Importantly, this MAb targets an extracellular 
glycoprotein that is only released from the tip of actively growing Aspergillus hyphae and so 
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does not detect quiescent or moribund spores.  Cross-reactivity is seen with some closely 
related Penicillium and Paecilomyces species, but not with clinically relevant Candida 
albicans, Cryptococcus neoformans, Fusarium solani or Rhizopus oryzae IA (119).  The LFD 
has been evaluated in a guinea pig model of IA and became positive earlier than GM and 
BG assays (120).  However, this study did not take place in the presence of antifungal 
therapy, which may reduce assay sensitivity.  The same group addressed the influence of 
antifungal therapy on the performance of the LFD (121) in a more recent report.  They 
found reduced serum sensitivity in animals treated with antifungals.  However, marker 
levels remained elevated in BAL fluid samples from the same animals.  The LFD was tested 
in a small number of BAL and serum samples from patients with haematological 
malignancies (122).  Strong agreement was reported between the LFD, an in-house qPCR 
and GM testing in BAL fluid.   Hoenigl et al evaluated the LFD using 39 BAL specimens for 
IPA diagnosis in 37 haematological malignancy and SOT patients (123).  All 12 EORTC 
probable patients had LFD positive BAL samples.  All 18 patients that did not have evidence 
of IFD (scored ‘No’) had LFD negative BAL samples, giving a sensitivity and NPV of 100%.  
Reported assay specificity was 81%, due to LFD positive BAL samples from 5 patients scored 
as possible.    However, these samples are not necessarily ‘false positive’ LFD results.  It is 
worth noting that in 3 of the 5 samples, GM Index was 0.6-0.7.  Although this falls below 
the cut-off recommended in the literature (124, 125), making the results negative, this 
index value is much higher than the value in LFD negative cases.  All 5 of these patients had 
received antifungal treatment at the time of BAL sampling, which could explain GM 
negative results.  It is also worth noting that A. fumigatus growth was reported in 4 of the 
10 BAL cultures from SOT patients, but only in 1 of 27 BAL cultures from haematological 
malignancy patients.  This culture negativity is typical of the haematological malignancy 
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setting, in which early, empirical systemic antifungal use is common, further highlighting 
the difficulties in diagnosis in this clinical setting.   
The LFD appears to be a very promising new technology in the targeting of surrogate 
biomarkers of IA.  It is a rapid, easy to use device, but is limited by its subjective 
interpretation.  Also, the test has recently undergone optimisation for serum testing, in 
terms of the pre-treatment needed to remove serum proteins that can affect the reliability 
of the result.  The performance of the LFD in serum samples has been evaluated from 
EORTC/MSG proven/probable versus no-IPA cases in a haematological population (126).  
LFD sensitivity and specificity were 81.8% and 84.8% respectively when a single positive 
result was required to assign patient positivity and 59.1% and 98.0% respectively when 2 or 
more positive results were required to assign positivity.  In another study, the performance 
of serum LFD testing was evaluated in patients during and after allogeneic HSCT, with 
comparable specificity values of 86.8% (single positive required) and 97.8% (two or more 
positives required) (127).  Reported sensitivity was much lower, at 40% (single positive 
required) and 20% (two or more positives required).   
The LFD test may prove very useful in combination with detection of another marker, for 
example molecular detection.  It is worth further investigation, to look at the level of 
concordance between different assays. 
 
1.7 Selection of clinical specimens 
Blood sampling allows non-invasive serial monitoring of biomarkers of IA.  Angioinvasion 
makes it possible to detect Aspergillus in the bloodstream, though little is known about the 
exact form of the fungal components present in the blood, when they appear nor their 
persistence or clearance.  The GM assay has been most extensively tested using serum, 
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with variable performance reported, as already discussed in section 1.6.3.1.  Although not 
validated for plasma testing, some studies have evaluated performance in these samples.  
White et al found comparable results when performing serum and plasma testing in the 
haematology population (128).  The authors found that index values tended to be slightly 
higher in plasma than serum from proven/probable/possible cases, but this didn’t reach 
statistical significance.    
Due to the possibility of non-invasive serial sampling for monitoring, blood has been the 
focus of detection of Aspergillus DNA for many studies.  There has been extensive 
discussion as to the nature of positive PCR results in blood specimens.  Viable fungi are 
extremely rare, as evidenced by poor blood culture results (129).  Nonviable Aspergillus 
cells may be present inside phagocytic cells though many patients will be profoundly 
neutropenic.  It is not clear whether free Aspergillus DNA might circulate in blood, but it 
has been shown that in vitro Aspergillus DNA is stable in serum (130).  EAPCRI have 
published protocols for DNA extraction from serum (131) and whole blood (132).  One 
important consideration is that these protocols were developed and validated using blood 
spiked with Aspergillus conidia.  DNA extraction from conidia, combined with the presence 
of a complex, sturdy cell wall, requires extensive and harsh extraction methods that can 
damage DNA and RNA to the extent that amplification becomes unreliable (133).  Arguably, 
such harsh extraction steps are not required in vivo since Aspergillus present in blood is 
highly unlikely to be conidial as Aspergillus rarely sporulates in vivo (134). 
Marker detection in blood, serum and BAL fluid has been investigated in a guinea pig model 
of IA (135).  The authors found BAL fluid to be the most suitable sample for early diagnosis 
of IPA by day 3 (post conidia inhalation) using PCR, GM and BG assays.  Marker levels 
remained elevated throughout the study.  Despite high fungal burden within tissue and BAL 
samples, it was found that serum and whole blood may remain negative with all 3 assays, 
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even at an advanced stage of disease.  This study, however, did not include any antifungal 
treatment, which may interfere with marker detection in the clinical setting.  Another study 
looked at LFD, GM and BG testing in the guinea pig model with antifungal treatment (121).  
The authors found that serum marker levels were significantly reduced in the presence of 
antifungal treatment, whilst all marker levels remained elevated in BAL fluid. 
The BioRad Platelia GM assay has recently been validated for BAL fluid testing.  As with 
serum testing, reported performance is variable due to inconsistency in assay cut-off value, 
inadequate negative controls and lack of standardisation of BAL fluid collection; such as the 
volume of saline instilled.  However, GM testing from BAL fluid has been reported to be 
more sensitive and specific than serum GM testing in immunocompromised patients (125, 
136, 137) with significantly higher index values suggesting much greater fungal load in 
these respiratory samples than in the blood.  A combination of PCR, PCR-ELISA and GM 
testing in the BAL fluid of patients with haematological malignancies was shown to enhance 
routine laboratory diagnosis of IA (138).  This is probably not surprising considering that IA 
is primarily a pulmonary infection. 
Detection of Aspergillus markers from BAL fluid samples represents one of three scenarios: 
(1) current disease, (2) true colonisation, or (3) a marker for future development of invasive 
disease.  Whilst the detection of Aspergillus from respiratory samples does not prove IA, 
the specificity of Aspergillus isolation from the respiratory tract in immunocompromised 
patients – such as those with neutropenia—is very high (64).   
Aspergillus-PCR positive BAL fluids have higher human DNA levels (evaluated by human 
beta-globin gene DNA quantification) than Aspergillus-negative BAL fluids (139).  This may 
reflect increased cellular content and perhaps reflects the presence of phagocytosed 
conidia and hyphae in macrophages and neutrophils.  
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1.8 Novel body fluid target: Exhaled breath condensate 
Use of breath analysis in the aiding of clinical diagnosis is not a new idea.  It has long been 
known that a pungent, fruity smell on a patient’s breath, caused by acetone, is a warning 
sign for diabetes.  Exhaled breath condensate (EBC) was first reported as a human bodily 
fluid in 1980 (140).   
Exhaled breath contains mostly water vapour, but also water-soluble volatile gases and 
aerosolised non-volatile particles, including ions and proteins (141).  There is much 
discussion about the origin of non-volatile markers in EBC; they have a cellular source, but 
is it the airways or the alveoli?  Flow dependence may indicate whether a marker originates 
from the airways or alveoli (142), with the marker concentration dependence on expiratory 
rate suggesting that it is mainly derived from the airway and lack of flow dependence 
suggesting the alveolar region as the source of the marker.  Droplets of epithelial lining 
fluid (ELF), which are the source of non-volatiles in EBC, could be formed in the airways, 
upper respiratory tract or upper gastrointestinal tract.  However, they are most likely to be 
formed in the airways, as this is where air turbulence is greatest. 
The technology to collect and cool exhaled air in a condenser system is now available, with 
several custom collection techniques and commercially available kits reported in the 
literature.  The EcoScreen I (Viasys, USA, Europe) device has a mouth piece and one-way air 
valve, to prevent contamination with saliva.  When the patient breathes into the 
mouthpiece, the valve block separates inspiratory and expiratory air.  This valve block is 
connected to the collecting system, which consists of a condenser and a collection vial.  The 
collecting system is inside a cooling cuff, which is kept cold by a refrigerator.  The water 
vapour in breath condenses and drops into the vial.  The EcoScreen II allows the 
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measurement of respiratory parameters during sample collection.  This system is well 
described in the literature, but is very large and so lacks portability and requires thorough 
cleaning between uses. 
The R-Tube (Respiratory Research, USA) is small, lightweight and portable.  It also has a 
disposable polypropylene collecting system, so cleaning is not required between uses.  The 
exhalation valve serves as a syringe-style plunger to enable the user to pull the fluid from 
inside the condenser wall.  This device does not require a power supply.  An aluminium 
cooling sleeve is placed over the tube; however, since this sleeve will inevitably warm up 
during sample collection, sample collection temperature is neither constant nor known, 
though it could be addressed.  Although the portability and ease-of-use make this device 
suitable for collection in the home, the sample still needs to be brought to the laboratory 
for testing.   
There is evidence to suggest that the choice of collection device influences the type of 
molecules detected.  Rosias et al (143) hypothesised that the adhesive properties of 
different condenser coatings would interfere with the measurement of icosanoids and 
proteins.  They found that the concentration of 8-isoprostane (an icosanoid) detected was 
significantly higher using a silicone coating on the inside of the condenser, compared to 
glass, aluminium, polypropylene or Teflon.  A glass coating also resulted in detection of 
significantly higher concentration than using aluminium, polypropylene or Teflon.  The 
group also found that detected albumin concentration was higher with silicone or glass 
than with the other coatings.  
Liu et al (144) compared glass, siliconised glass, EcoScreen and R-Tube condensers for the 
collection and measure of nitrogen oxides, total protein, mucin and pH in healthy 
volunteers.  Measured nitrogen oxide levels were significantly higher in EcoScreen than in 
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siliconised glass or R-Tube devices.  However, nitrogen oxides can increase from the 
leaching of NO out of plastics (including Teflon).  Indeed, the authors demonstrated NOx 
contribution from the EcoScreen device to aqueous media.  This did not occur with a glass 
device.  Total protein concentration was higher with EcoScreen than glass or R-Tube 
devices.  There was, however, no significant difference in mucin levels or pH between the 
devices.  It is important to note that NOx stability is associated with temperature.  Using the 
R-Tube device, temperature gradually increases during sampling, and a constant 
temperature cannot be maintained.  Therefore, this device may be better suited to the 
monitoring of markers that are not affected by temperature.   
EBC biomarker investigations have been performed in the setting of inflammatory 
conditions and connective tissue disorders, including chronic obstructive pulmonary 
disease (COPD), adult respiratory distress syndrome (ARDS), asthma and pneumonia.  
Studies have revealed changes in patterns in NO, hydrogen peroxide (H2O2), cytokines and 
inflammatory proteins (145). 
 
1.8.1 Volatile organic compounds (VOCs) 
There is much variability in the measurement of breath gas VOCs, due to the inability to 
standardise flow rate and volume of exhalation.  These volatiles are variably in equilibrium 
with gaseous components.  It is important to optimise the sampling procedure where 
possible.  The American Thoracic Society/European Respiratory Society (ATS/ERS) created a 
task force to determine guidelines for the use of EBC.  They highlighted the importance of 
the choice of condensing equipment, the breathing pattern during collection, the 
consumption of food and drink prior to sampling and the use of medication prior to 
sampling, as just a few of the variables that may affect the ability to detect desired target 
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biomarkers in EBC (145).  It is vital that all of these variables are recorded and sampling 
techniques are made as consistent as possible. 
The most studied volatile marker is exhaled NO and this is considered a good marker of 
airway inflammation (146).  The study of lung inflammation currently involves invasive 
methods such as collection of BAL fluid and semi-invasive sputum induction.  Plasma is also 
used for the measuring of inflammatory biomarkers, but these are likely to reflect systemic 
rather than lung inflammation.  EBC collection would certainly be preferable to these 
invasive sampling methods, offering the potential for non-invasive and repeatable 
monitoring of airway biomarkers. 
 
1.8.2 Non-volatiles 
Epithelial lining fluid is massively diluted by water vapour in an EBC sample.  Dilution 
estimates have been made, but the assays used for assessment of dilution are themselves a 
source of variability.  There is currently no gold standard EBC dilution marker, just as is the 
case in BAL sampling.  However, ratios of non-volatile constituents, such as cytokines in the 
Th1 and Th2 profile, can be calculated and then deviation compared with the underlying 
condition.   
There have been attempts within studies to standardise against an additional EBC 
component, such as total protein or urea content.   Urea is not volatile and it is neither 
produced nor destroyed in significant amounts by intact lungs.  It rapidly equilibrates 
across the barriers between blood and air spaces (147).  Therefore, it is likely that the 
concentration of urea in plasma and ELF are similar.  It has been attempted previously to 
use urea to measure the dilution of respiratory fluid in BAL sampling.  However, urea 
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rapidly enters the instilled fluid during the lavage, so this is not a reliable marker.  EBC 
collection, however, does not involve instilled fluid, so this is not a problem. 
Detection of non-volatiles has thus far been at the lower limits of accuracy for most assays.  
When coupled with the unknown degree of variability in sampling and in assay 
performance, there is a definite need for the use of appropriate assay controls, with the 
use of a dilution marker or ratios of different biomarkers measured concurrently. 
It is not always necessary to use a dilution marker or calculate the ratios of biomarkers, for 
example, when the result of the assay serves as an indicator of abnormality.  Detection of 
rhinovirus RNA in a human respiratory sample by reverse transcription-PCR requires simply 
a yes/no answer.  It is not necessary to calculate detection levels/concentrations.  
However, the assay must be reliable, with no false positivity.   
 
1.8.3 Pathogen detection 
The reliable and early detection of pathogens in EBC would constitute a major diagnostic 
breakthrough.  There have been attempts to look for volatiles to identify bacteria in EBC.  
But this is a complex area and the high degree of variability in the composition of human 
breath makes it hard to identify diagnostic biomarkers (148). 
Detection of Pseudomonas aeruginosa has been attempted in cystic fibrosis (CF) patients 
(149), through the detection of 2-aminoacetophenone (2AA) in the breath of patients 
colonised with P. aeruginosa.  However, it was found that environmental factors can 
greatly affect the reliability of the biomarker detection. 
Chambers et al (150) published limited data on the detection of 2-Pentylfuran (2PF); a 
volatile produced by Aspergillus species, as well as Fusarium and Scedosporium.  Using gas 
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chromatography with mass spectrometry (GC/MS) they demonstrated 2PF detection in the 
breath of 16/32 patients at risk of Aspergillus colonisation or infection (due to chronic lung 
disease, asthma, ABPA, CF, COPD or SOT).  Results of the 2PF breath tests were compared 
with recurrent isolation of Aspergillus from sputum or BAL fluid over 2 months, with a 
sensitivity and specificity of 77% and 78%, respectively.   2PF was not detected in breath 
samples from any of the 14 healthy controls.  The group report 2 cases of 2PF detection 
from the breath of severely immunocompromised patients with IA, with 2PF levels 
becoming undetectable following effective treatment for IA.   Similarly, volatiles have been 
identified that are specific to M. tuberculosis and M. bovis. Further testing is needed for 
validation of the monitoring of these volatiles as a marker of disease. 
Genomic DNA has been detected in EBC (151), with detection of the beta actin gene 
fragment reported in 65.7% of EBC samples.  The authors found extracted DNA and neat 
EBC samples equally suited for detection.  In another report (152) the human beta actin 
gene was detected in all DNA extracts from EBC samples collected by EcoScreen.  
Attempts have been made to detect pathogen nucleic acids using qPCR.  However, recent 
literature suggests that detection is at the lower limit of detection.  Costa et al (153) used 
the R-Tube to collect EBC from patients with confirmed respiratory viruses.  They extracted 
DNA from EBC samples, with an internal control (beta globin) added and found no 
correlation between BAL fluid virus levels and EBC detection.    
St George et al (154) used qPCR to look for Influenza virus in EBC samples, in comparison 
with nasopharyngeal swabs.  A single positive EBC was recorded, with very low viral load.  
This sample corresponded to a swab with the highest recorded viral load (lowest Cq), 
suggesting very low sensitivity of EBC sampling.  Vogelberg et al (155) concluded that EBC is 
unsuitable for the detection of DNA from P. aeruginosa, and Burkholderiacepacia in CF 
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patients with sputum positive samples.  The authors state that the qPCR used had a 
demonstrated detection limit of as low as 10fg DNA (in a dilution series of positive control 
DNA), but failed to detect pathogen DNA in EBC samples.   
Fabian et al (156) reported low sensitivity when using qPCR to detect Influenza A or B from 
breath of infected patients.  These reports together suggest that non-volatiles are 
massively diluted in EBC samples and enrichment from EBC is likely to be required to 
achieve a more reliable result. 
With reported detection of nucleic acids in EBC thus far being at the lower limits of 
detection for most assays, together with the unknown degree of variability in sampling and 
the variability in assay performance, there is a definite need for standardisation where 
possible and the use of appropriate assay controls. 
 
1.9 Clinical use of existing diagnostics – performance analysis 
A major obstacle in the performance analysis of any of these tests is the wide variation of 
conditions in which they are used.  It is clear that the wide variation in reported sensitivity 
and specificity values are in part due to the variation in patient population, relative 
prevalence, clinical specimen type tested, method of handling, pre-treating and storing 
clinical specimens, time delay in performing sampling (in relation to antifungal 
administration) and the number of consecutive positive results required to confirm 
positivity.  
Another major factor in the performance analysis of diagnostic tests for IA is the rarity of 
confirmation by a ‘gold standard’.  In the absence of the diagnostic gold standard of a 
histological study and/or recovery of the etiologic agent in culture from a normally sterile 
site, diagnosis is heavily reliant on a strong degree of suspicion.  How then are the 
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performances of new diagnostic tests/combinations of tests to be evaluated in the clinical 
setting?  In reality, the EORTC/MSG criteria are often used as a reference standard, in order 
to evaluate the clinical performance of a test/combination of tests for IA.  It is important to 
consider the errors can occur in classification by a reference standard.  For example, 
important changes in the lungs can be missed due to the delay in obtaining a CT scan (69).  
Changes in a particular biomarker may be caused by the presence of an alternative 
condition in patients (157), or by drug treatment (94), leading to misclassification.  When 
evaluating the performance of the GM assay there is obvious incorporation bias, as the test 
is part of the EORTC/MSG reference standard for assigning a ’probable’ score, but this 
method of evaluation is still used (89).   Review of the literature also highlights the variation 
in the use of the EORTC/MSG guidelines as a reference standard for evaluating assay 
performance.  When evaluating the performance of new diagnostic tests, some studies use 
proven/probable/possible as true positive results and EORTC/MSG non-classifiable as true 
negatives.  Other studies use proven/probable as true positives and EORTC/MSG 
possible/non-classifiable as true negatives.  Whilst this provides a means to evaluate new 
tests and the performance of tests in parallel, it is far from ideal.  Only EORTC/MSG proven 
cases fulfil the criteria for a definitive diagnosis of IA.  Probable and possible cases are 
assigned as estimations of the likelihood of infection and are therefore not a definitive 
diagnosis.  Likewise, an EORTC/MSG non-classifiable case is not a definitive true negative.  
It simply means that it doesn’t fulfil the EORTC/MSG risk criteria for suspicion of an IFD.    
Consequently, a positive molecular biomarker result will be interpreted as a false positive 
result in an EORTC/MSG non-classifiable case, yet we cannot be sure that this is the clinical 
reality.  It is also important to note that the modified 2008 EORTC/MSG criteria elevated 
the importance of specific CT scan findings, with microbiological factors no longer scoring 
in the absence of clinical factors.  However, a negative CT scan of the chest in the presence 
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of positive biomarker results could be due to the timing of the scan itself, as previously 
discussed, and/or due to IA in another organ, such as the brain.  A recent retrospective 
analysis carried out at St Bartholomew’s Hospital in London revealed two ‘proven’ cases of 
IA in which no major clinical criteria were met (52), one of which was only discovered post-
mortem.  This highlights the limitations of the EORTC/MSG criteria as a reference standard 
for evaluating the performance of new tests for IA diagnosis.    
 
1.9.1 Conclusions  
Diagnosis of IA in the haemato-oncology setting presents a very unique combination of 
challenges.  There are co-morbidities to consider, the likely presence of antimicrobials in 
the body that have the potential to affect biomarker detection, the need for minimally 
invasive sampling in very sick individuals or the rarity of definitive diagnosis and the 
absence of clearly-defined ‘outcomes’.  As a result, most patients receive antifungal 
treatment and will either recover from infection or die, without proof of whether they had 
an infection or not, let alone whether it was Aspergillus.   
Whilst the EORTC/MSG criteria form the only reference standard available, they have 
limitations that require consideration.  The development of new diagnostic tools may 
highlight new diagnostic possibilities or stages of disease that have not been previously 
perceived.  This is likely to change the way in which patients are classified with respect to IA 
and influence decisions as to what patients are targeted for antifungal drug treatment. 
It is unlikely that a single test could or would ever be used for the clinical diagnosis of IA in 
the high risk haemato-oncology setting.  It makes sense, in this difficult clinical setting, to 
employ a combination of tests, looking for different markers of Aspergillus, to increase 
diagnostic certainty.  For example, the diagnostic yield from BAL fluid for IPA is potentially 
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optimised with application of a combination of tests; as recently demonstrated in a study 
that reported improved sensitivity with the concomitant application of galactomannan and 
PCR (158).  However, tests that have the potential to change our definition of a disease 
require more than consideration of their accuracy; they also require assessment of the 
clinical consequences of the changes that they bring (159).   
 
1.9.2 Thesis Aims  
The major aim of this study was to use novel approaches to make significant progress in the 
ability to detect IPA, allowing early and specific treatment of genuine fungal infection. 
1.  The first aim of this study was to develop, optimise and validate a robust and reliable 
quantitative pan-Aspergillus qPCR assay.  To do this, a critical review of published 
Aspergillus qPCR assays was performed and assay limitations were highlighted.  This 
information was used, together with strict adherence to published qPCR design and 
reporting guidelines, to design a new qPCR assay. 
2.  The second aim of this study was to develop and validate a combination biomarker 
detection approach in BAL fluid, for the early diagnosis of IPA.  To do this, an existing GM 
enzyme immuno-assay and a newly-developed antibody-based test utilising an LFD were 
compared with the new Aspergillus qPCR assay to evaluate their effectiveness for the 
detection of Aspergillus from the BAL fluid of patients with IPA.  Results were used to 
establish the optimal parameters for achieving a definitive and consistent diagnosis of IPA 
using clinical samples from an ongoing study, in comparison with EORTC/MSG criteria.  
3.  The third aim of this study was to determine whether respiratory samples are useful for 
identifying a distinct inflammatory marker profile in IPA.  To do this, BAL fluid samples from 
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combination biomarker-positive and –negative patients were evaluated by fluorescence-
activated cell sorting (FACS) analysis, to quantify selected immune cytokines.   
4.  The fourth aim of this study was to evaluate the potential of EBC as a pioneering sample 
for non-invasive diagnosis of lung pathogens by providing proof-of-principle for the reliable 
and rapid detection of Aspergillus.  To do this, EBC clinical samples from an ongoing study 
were tested using an LFD/qPCR/GM combination biomarker detection approach and results 
compared to those obtained from respective BAL fluid samples.  
5.  The fifth and final aim of this study was to bring together antigen and real-time qPCR 
detection in a proximity ligation assay (PLA), to demonstrate proof-of-principle for a 
diagnostic assay for the earliest possible detection of fungal infections.  To do this, the JF5 
MAb and a polyclonal serum raised against the same target antigen were combined with 
qPCR to develop a new PLA application for the detection of an Aspergillus-specific N-linked 
glycoprotein antigen that is secreted constitutively at the hyphal apex in actively growing 
organisms. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 Patient selection and sample collection 
2.1.1 Barts Health NHS Trust Clinical specimens 
This study was a retrospective evaluation of biomarker performance for IPA diagnosis, with 
no impact on patient management.  The Study cohort of patients were a subset of those 
recruited in an observational study of IPA diagnosis in the Division of Haemato-Oncology, St 
Bartholomew’s Hospital, based on the availability of BAL fluid samples and full clinical data.  
25 BAL fluid samples from 24 adults at high risk of IFD following intensive chemotherapy or 
allogeneic stem cell transplantation were obtained between August 2005 and February 
2011.  After 72 hours of persistent fever unresponsive to antibiotics, a CT scan of the chest 
was performed and, if abnormal, followed by a bronchoscopy and BAL.  Two physicians 
independently scored each episode using the EORTC/MSG 2008 criteria (51). 
 
2.1.1.1 Ethics Statement 
The work was ethically approved by the East London & the City Local Research Ethics 
Committee 1. Participants were recruited from Barts and the London.  Study title: Early 
diagnosis of invasive Aspergillosis in a high risk group of patients using serum and 
bronchoalveolar lavage fluid real time PCR and galactomannan ELISA.  
REC reference number: 05/Q0603/68. 
Ethics amendment dated 28/10/2009.  
Approval number ReDA : 003933 QM. 
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2.1.1.2 Patient Selection 
This was a single centre, prospective, observational study of haemato-oncology patients at 
high risk of developing IA at Barts Health NHS Trust.  
Inclusion criteria 
 Age greater than 18 
 Able to understand the implications of participation in the Trial and give written 
informed consent 
 Patients with acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) 
and acute lymphoblastic leukaemia (ALL) undergoing intensive chemotherapy 
(predicted neutropenia of <0.5 x 109/L  for > 10 days) and/or receiving high dose 
steroids 
 Patients undergoing allogeneic HSCT 
 Patients requiring high dose steroids for graft versus host disease (GVHD) post 
HSCT 
 Patients with a history of probable or proven invasive aspergillosis and having 
chemotherapy, regardless of their underlying haematological malignancy 
 
Exclusion criteria 
 Inability to give informed consent 
 Patients aged less than 18 
 Pre-existing chest disease  
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2.1.1.3 Study Interventions 
 
Study interventions began prior to the start of chemotherapy/immunosuppression and 
continued until recovery of the neutrophil count to > 1.0 x 109/L. If fungal infection 
occurred, testing continued until discharge.  
Clinicians responsible for daily care of patients included in the trial were not informed of 
the results from the marker detection package. 
Study number and sample date were provided, without patient identifiers such as name or 
hospital number.  Samples were analysed in batches.  
A febrile episode is defined as any of the following: 
 Temperature > 38°C for more than 4 hours 
 Temperature > 38°C on two occasions > 4 hours apart within a 24 hour period 
 Temperature > 38.5°C on one occasion 
 
2.1.1.4 Sampling  
2.1.1.4.1 Bronchoscopy with BAL 
A bronchoscopy was performed in all patients in whom a HRCT chest was found to be 
abnormal, as per recommended clinical practice.  Each patient was assessed immediately 
prior to the procedure.  Fibre-optic bronchoscopy and BAL were performed in the lobe 
most affected radiologically by lesions suggestive of invasive fungal infection.  BAL was 
performed using 3 x 60 ml aliquots of 0.9% normal saline.  Each aliquot was injected and 
aspirated after 5 seconds.  The fluid was examined by Gram stain, silver stain, bacterial and 
fungal cultures and viral PCR.  
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10ml of the fluid obtained was utilised in the study, aliquoted and stored at -80°C, to be 
analysed using the marker detection package.  Inflammatory cytokines were also to be 
measured on this fluid. 
 
2.1.1.4.2 Exhaled breath condensate  
Exhaled breath condensate (EBC) was collected from each patient at entry to the study and 
throughout the course of treatment as indicated, for example by an unexplained fever. 
Collection of EBC was achieved by patients breathing at normal frequency and tidal volume 
for 15 minutes through a mouthpiece and a two-way non-rebreathing valve (Respiratory 
Research, Charlottesville, VA, USA), which also traps saliva (Figure 6).  The expired air was 
passed through a tube and cooled by an aluminium sleeve at –80°C that is completely 
enclosed by thermal insulation.  Samples were aliquoted and stored at -80°C, to be 
assessed by the marker detection package. 
The EBC was performed:  
i) On entry into the study, prior to all treatment 
ii) When the neutrophil count fell to < 0.5 x 109/L or 24 hours after finishing chemotherapy 
(whichever is later) 
iii) At the time of request for HRCT for suspected IFD,  
iv) When the neutrophil count recovered to > 1 x 109/L and, in case of IFI, at the time of 
discharge 
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Figure 6.  Collection of exhaled breath condensate. 
Collection is achieved using a condensation device designed to exclude gross salivary contamination.  Patients 
sitting comfortably breathe at tidal volumes into a mouthpiece attached to a cold condenser for approximately 
15 minutes. 
 
2.1.1.4.3 Blood 
Twice weekly whole blood (collected in BD Vacutainer 4ml plastic whole blood tubes with 
spray-coated K2EDTA) and serum (collected in BD Vacutainer SST 4ml tubes with silica clot 
activator, polymer gel, silicone-coated interior) were collected, to be analysed using the 
marker detection package. Inflammatory cytokines were also to be measured on this fluid.  
Samples were aliquoted and stored at -80°C. 
 
2.1.1.4.4 Histological material 
Histological material from three patients with haematological malignancies was provided 
by the Pathology department at the Royal London Hospital.  These samples consisted of a 
post-mortem lung biopsy (sample A) and an antemortem brain biopsy (sample B), from two 
patients with proven IA and a control post-mortem lung biopsy with no evidence of fungal 
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infection (sample C).  All three samples were provided as shavings, taken from paraffin wax 
embedded tissue blocks. 
 
2.1.1.5 Data from Other Clinical Investigations 
Data from radiological (chest x-ray [CXR], HRCT, CT sinuses/brain) and microbiological 
investigations (cultures) were included in the study. 
 
2.1.1.6 Data Collection 
Simple clinical data were collected for each patient by members of the research team 
blinded to all the results above.  
 
2.1.1.7 Anti-fungal management 
Patients followed the existing antifungal protocol of the Department of Haemato-Oncology 
(see Appendix 1). 
 
2.1.1.8 Radiology Review 
All CXRs, HRCTs and other radiological investigations pertaining to possible fungal infection 
were assessed by an expert radiologist blinded to all laboratory and clinical data.  
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2.1.1.9 Diagnosis of Invasive fungal infection 
Published EORTC/MSG diagnostic criteria for fungal infections were used to ascertain 
likelihood of IFD (see Appendix 2). 
2.1.2 Innsbruck clinical specimens 
BAL samples from the Innsbruck University Hospital (Austria) were obtained during routine 
diagnostic investigations and provided anonymously.  The following cohorts were obtained; 
‘Gold standard’ proven IPA cohort was obtained at routine diagnostic work-up at the 
Innsbruck University Hospital between January 2008 and November 2012 (10 patients with 
11 BAL samples).  Proven cases were defined by positive histology and Aspergillus culture 
from a lung tissue biopsy sample.  
Negative control cohort - 16 BAL samples from 16 adults without any EORTC/MSG risk 
factors for IFD, in whom routine diagnostic procedures were negative for IPA (microscopy, 
culture and local GM testing and Aspergillus PCR). 
 
2.2 Isolation of total DNA from clinical specimens and fungal culture 
2.2.1 DNA extraction from histological material 
Shavings were obtained from the three wax embedded histological blocks [Section 
2.1.1.4.4] using disposable blades.  Extractions were carried out in a Class 2 biosafety 
cabinet, which was cleaned with BioCleanse wipes and DNA Away (VWR, UK) before and 
after use.  Extraction was carried out as follows and summarised in the workflow chart 
(Figure 7).  1 ml xylene (Sigma Aldrich) was added to a tube containing a 5mm2 section of 
paraffin wax embedded tissue.  This was incubated with shaking for 5 minutes at room 
temperature, centrifuged 10,000 x g for 2 minutes, followed by removing and discarding 
 69 
 
the supernatant.  This entire process was repeated, with the shaking incubation time 
increased to 20 minutes.  1ml absolute ethanol (Sigma Aldrich) was added, and the tube 
centrifuged at 10,000 x g for 3 minutes.  The supernatant was discarded, and the ethanol 
step repeated.  Samples were air dried for 10 minutes in a laminar flow hood.  Tissue 
pellets were resuspended in 180µl of ATL buffer and 20µl proteinase K (both from QIAamp 
tissue kit, Qiagen, Germany) by pulse vortexing, incubated at 56°C for 2 hours, and boiled 
(in a 125°C heating block) for 5 minutes.  After cooling to room temperature, the Qiagen 
QIAamp tissue kit column extraction method was followed according to the manufacturer’s 
instructions, eluting into 50 µl buffer AE.  Extracted DNA was quantified using a NanoDrop 
2000 spectrophotometer (Thermo Scientific).  DNA-free water was run as a negative 
extraction control in each batch of extractions to monitor contamination.  DNA extracts 
were stored at -20°C prior to PCR analysis. 
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Figure 7.  Work flow chart for DNA extraction from histological material. 
Add 1ml xylene to histology 
shavings 
Incubate for 5 minutes at 
room temperature with 
shaking 
Centrifuge for 2 minutes at 
10000xg 
Remove and discard 
supernatant 
Add 1ml absolute ethanol 
Centrifuge for 3 minutes at 
10000xg 
Remove and discard 
supernatant 
Air dry pellet for 10 minutes 
in a laminar flow hood 
Resuspend pelletin 180µl ATL 
buffer and 20µ proteinse K 
Incubate at 56°C for 2 hours 
Boil (125°C heating block) 
for 5 minutes 
Follow Qiagen QIAamp tissue 
kit column extraction method, 
eluting into 50µl AE buffer  
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2.2.2 DNA extraction from fungal culture 
The following fungal isolates were selected for use in this study; 
1. A. fumigatus (clinical isolate, confirmed by the Microbiology department at the 
Royal London Hospital, using MALDI-TOF) 
2. A. flavus (NCPF 2008) 
3. A. terreus (NCPF 2729) 
4. A. niger (NCPF 2275) 
5. A. nidulans (NCPF 2181) 
6. Candida albicans (NCPF 3939)  
7. C. dubliniensis (NCPF 3949)  
8. Fusarium solani (CBS 224.34)  
9. Scedosporium prolificans (CBS 100391) 
10. Rhizopus oryzae (CBS 112.09) 
Fungal strains were grown on Sabouraud agar (Oxoid Limited, UK) at 37°C.  Genomic DNA 
was extracted according to the in-house molecular microbiology standard operating 
procedure for extraction from fungal culture (MM-1.3 version 4, 30/9/2007) in the Medical 
Microbiology Laboratory of the Royal London Hospital.  0.3-1g of 0.5 mm diameter glass 
beads (BioSpec products) were added to an apex tube with an O-ring screw cap.  180µL ATL 
buffer and 20µl proteinase K (both from QIAamp DNA extraction kit, Qiagen, Germany) 
were added to the tube.   A 1µl inoculation loop was used to add 2 loopfuls of biomass 
from the culture plate.  The tube was shaken in a mini bead-beater for 30 seconds on the 
‘homogenise’ setting (BioSpec products), before being incubated at 56°C for 2 hours, with 
vortexing every 30 minutes for 10 seconds on a medium setting.  A QIAamp DNA mini kit 
(Qiagen, Germany) was used to complete the extraction, following the manufacturer’s 
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protocol from the step where AL buffer is added.  Elution comprised two 100µl volumes of 
AE, with centrifuging between.  Extracted DNA was quantified using the Implen 
Nanophotometer and diluted in Qiagen kit AE buffer to a concentration of 2ng/µl for PCR 
testing.  A negative extraction control of RNase free water was included with each batch of 
extractions to monitor contamination.  DNA extracts were stored at -20°C prior to PCR 
analysis. 
 
2.2.3 DNA extraction from BAL fluid, EBC and whole blood 
200µl of clinical sample were added to a 2ml sample tube with 10µl proteinase K (both 
from Qiagen EZ1 DNA tissue kit) and mixed by vortex for 10 seconds on a medium setting.  
This was incubated at 56°C for 15 minutes and spun down to remove condensation from 
lid.  Extraction was performed on the EZ1 robot (Qiagen, Germany), using EZ1 DNA tissue 
card programme and tissue kit, eluting into 50µl. DNA-free water was run as a negative 
(fungal free) extraction control in every batch of extractions to monitor for contamination 
during the extraction process.  DNA extracts were stored at -20°C prior to PCR analysis. 
 
2.3 qPCR assay design tools 
2.3.1 CLC Sequence Viewer 
A search of the National Center for Biotechnology Information (NCBI) GenBank sequence 
database (http://www.ncbi.nlm.nih.gov/genbank/) was performed to obtain accession 
numbers for the target organisms.  Sequences were imported into the CLC Sequence 
Viewer (http://www.clcbio.com) and aligned to identify suitable target sequences 
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2.3.2 Beacon Designer 
Primers and a probe with locked nucleic acid (LNA) modifications were designed by Beacon 
Designer, version 7.2 (Premier Biosoft), selecting for a primer annealing temperature of 
55°C and amplicon length of ≤100 base pairs (bp).  LNA probe modification was selected for 
increased thermal stability, providing a more rigid structure for greater sensitivity and 
discrimination of the target amplicon.  The dual-labelled probe was selected to incorporate 
a FAM fluorophore and a black hole quencher (BHQ-1), for detecting and quantifying the 
specific target sequence.  
 
2.3.3 BLAST 
Primer specificity was evaluated in silico using the Basic Local Alignment Search Tool 
(BLAST) (http://blast.ncbi.nlm.nih.gov/) to find regions of local similarity between 
sequences. 
 
2.3.4 MFold 
Target secondary structures and primer/template accessibility were assessed using the 
MFOLD web server (http://mfold.bioinfo.rpi.edu/) using corrections for ionic conditions of 
50 nM Na+ and 3 mM Mg2+, and a folding temperature of 55°C (160). 
 
2.4 Aspergillus qPCR assay development 
All qPCR assays were performed on a Bio-Rad CFX Real-time system (BioRad, Hercules, CA, 
USA) using a 96-well plate format.  
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2.4.1 Assay optimisation using SYBR Green I chemistry 
Using SYBR Green I chemistry, concentrations of forward and reverse primer were 
optimised.  Optimal primer concentrations (50–400nM) were determined by identifying 
conditions resulting in the lowest quantification cycle (Cq) combined with absence of 
primer dimer formation, with each concentration run in four replicate wells.  Reaction 
volumes were set at 10µl. SYBR Green assays contained 1X BioRad iQ SYBR Green 
Supermix, 200nM each primer, and 1µl of DNA extract.  
SYBR Green I chemistry and melt curve analyses were used to determine optimal primer 
annealing temperatures using the CFX’s temperature gradient function (50°C–60°C).  Initial 
thermal cycling conditions were 1 cycle of 95°C for 3 minutes, followed by 40 cycles of 
denaturation at 95°C for 10 seconds and annealing/polymerisation with a temperature 
gradient from 50–60°C for 30 seconds, which allowed selection of the optimal annealing 
temperature. 
 
2.4.2 Hydrolysis probe reactions 
Once optimal conditions were established, hydrolysis probe reactions were run comprising 
1X BioRad iQ Supermix, 200nM of each primer, 100nM probe, and 1µl of DNA.  Thermal 
cycling conditions were 1 cycle of 95°C for 3 minutes, followed by 40 cycles of denaturation 
at 95°C for 10 seconds and annealing/polymerisation at 59°C for 30 seconds. 
 
2.4.3 PCR Efficiency/Analytical Sensitivity 
2ng of genomic DNA, corresponding to 6x104 genome copies of A. fumigatus (clinical 
isolate [Section 2.2.2]) was serially diluted over 6 orders of magnitude in 200ng of 
Aspergillus-free human DNA per dilution.  Using qPCR with hydrolysis probe, standard 
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curves were constructed to calculate PCR efficiency, the linear range of the assay and the 
limits of detection and quantification.  PCR efficiencies were calculated from the slopes of 
eight standard curves that were run in duplicate or triplicate on separate plates, 
incorporating 91 data points.  Quantification was determined on the basis of one A. 
fumigatus genome containing 30fg of DNA, calculated from a genome size of 4.29x106 bp. 
 
2.4.4 PCR Setup Controls 
Multiple negative no template controls (NTCs) were included with every assay and 
amplification of a single NTC well invalidated the entire qPCR run, leading to a repeat run. A 
positive control containing six genome copies of A. fumigatus (clinical isolate) was also 
included with each run, to monitor inter-assay consistency.   Amplification had to be 
reproducible, occurring in all replicate wells, for a sample to be considered ‘PCR positive’. 
 
2.4.5 Carryover Contamination Controls 
All DNA preparations were carried out in a pre-PCR facility that was physically separate 
from the qPCR laboratory. A unidirectional workflow pattern (pre- to qPCR) was enforced, 
with physically separate laboratories utilised for pre- and qPCR analysis.  Reaction set-up 
took place in a laminar-flow biosafety cabinet, following thorough cleaning of the cabinet, 
pipettes and tip boxes with DNA-Away (VWR, UK). Plates were never opened in the qPCR 
facility post-PCR. 
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2.4.6 Inhibition Testing 
The SPUD inhibition assay (161) was used as an exogenous amplification control.  This is a 
control qPCR assay in which a synthetic SPUD amplicon is the only amplifiable target in the 
absence of any added nucleic acid.  This generates a reference Cq value for the SPUD 
amplicon, characteristic of an uninhibited assay.  If DNA from a sample is added, an 
increase in Cq of more than one cycle and a reduction in amplification efficiency indicate 
the presence of PCR inhibitors in the sample.  Each qPCR reaction comprised 1X BioRad iQ 
Supermix, 400nM of SPUD forward and reverse primers, 200nM of FAM-labelled SPUD 
probe quenched with a BHQ, 1µl of SPUD amplicon, and 1 µl of sample extract. Thermal 
cycling conditions were 1 cycle of 95°C for 3 minutes, followed by 40 cycles of 95°C for 10 
seconds, 61°C for 15 seconds and 70°C for 30 seconds. 
 
2.4.7 Monitoring human DNA content of DNA extracts 
A β-globin hydrolysis probe assay was used to monitor the relative human DNA content of 
clinical sample DNA extracts (162).   This assay consisted of the amplification primers β -
globin-354F, 5-GTG CAC CTG ACT CCT GAG GAG A-3, β -globin-455R, 5-CCT TGA TAC CAA 
CCT GCC CAG-3 and a dual-labelled fluorescent TaqMan probe β -globin-402T, 5-(FAM)AAG 
GTG AAC GTG GAT GAA GTT GGT GG(BHQ1)-3.  Each qPCR reaction comprised 1X BioRad iQ 
Supermix, 300nM of both forward and reverse primers, 100nM probe and 1 µl of sample 
extract.  Thermal cycling conditions were 1 cycle of 95°C for 3 minutes, followed by 40 
cycles of 95°C for 10 seconds and 59°C for 30 seconds. 
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2.4.8 Analysis of PCR products 
PCR products were analysed on the Lab901 ScreenTape D1200 (Agilent) microfluidics 
system, which consists of an acrylamide based matrix that has been optimised to separate 
double stranded DNA fragments between 125 and 1200 base pairs.  The ScreenTape D1200 
was used in conjunction with the D1200 Ladder and D1200 loading buffer in the Lab901 
TapeStation®.  
PCR products were also sequenced to confirm amplification of the target sequence.  
Sequencing of PCR products was carried out by the Genome Centre Sanger sequencing 
service, using BigDye 3.1 chemistry with visualisation on the ABI 3730 capillary sequencer.  
 
2.5 GM assay 
GM detection was performed by Platelia Aspergillus enzyme immunoassay (PA-EIA, Bio 
Rad, France).  The GM assay is an immunoenzymatic sandwich microplate assay for the 
detection of Aspergillus galactomannan antigen in serum and BAL fluid.  The assay uses rat 
monoclonal MAb EBA-2, directed against Aspergillus galactomannan.  The MAbs are used 
to coat the wells of the microplate and bind the antigen, and to detect the antigen bound 
to the sensitised plate. 
Techniques were carried out as recommended by the manufacturer. Results were 
expressed as a GM index value – the ratio of the sample optical density (OD) divided by the 
mean OD of the 2 threshold controls.  Serum samples were scored as positive if the GM 
index was ≥0.5.  BAL fluid samples were evaluated using a cut-off of ≥0.8 and/or ≥1.0, for 
performance analysis.  EBC samples were not scored; instead the GM index alone was 
recorded.  This is due to there being no approved cut-off for this sample type. 
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2.5.1 Sample selection for signal loss investigations 
Short-term (ST) storage at +4 °C: Microbiology laboratory records from February 2009 to 
March 2010 were filtered to exclude GM data (i) for non-serum samples and (ii) samples 
repeat-tested after greater than 48hours. A total of 109 serum samples (from 65 different 
patients) and 8 BAL fluid samples were identified. 
Long-term (LT) storage at −80 °C: A total of 54 serum samples (from 35 different patients) 
and 12 BAL fluid samples were collected from July 2005 to September 2007, GM tested and 
sample aliquots were stored at −80 °C.  These samples were repeat tested after 2–4 years 
storage at −80 °C in 2009.  In total, 183 clinical samples were included in this study. 
 
2.6 LFD for Aspergillus 
LFD testing was performed on BAL fluid and serum clinical samples as per manufacturer’s 
recommendations.  Briefly, samples were thawed and mixed thoroughly by vortexing for 10 
seconds on a medium setting and centrifugation for 1 minute at 14,000rpm.  For testing of 
clinical serum samples, serum was diluted 1:1 (v/v) with tissue culture medium and 100µl 
of diluted serum applied directly to the LFD.  For BAL fluid and EBC samples, 100µl of neat 
sample was applied directly to the LFD.  If the Aspergillus antigen is present in the sample, 
the test line appears within 15 minutes of application (Figure 8).  Each LFD device was 
independently checked by two users and assessments were always concordant. 
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Figure 8.  Antibody-based detection of Aspergillus antigen. 
The LFD showing a positive result for Aspergillus detection, indicated by the two bands, one of which serves as a 
positive assay control and the other being specific for the presence of antigen recognised by the monoclonal 
antibody JF5. 
 
2.7 Cytokine profiling 
2.7.1 Assay selection 
The CBA Human Th1/Th2/Th17 Cytokine Kit and Human Chemokine Kit (BD Biosciences, 
USA) were selected, in order to analyse five human chemokines and seven cytokines 
involved in the differentiation of/secreted by each Th1/Th2/Th17 cell type.   
 
2.7.2 BD CBA kit protocol 
The BD CBA system (BD Biosciences, USA) was used on the BD FACS Canto II to quantitate 
multiple analytes in serum, BAL fluid and EBC samples.  The assay uses antibody-coated 
beads, each with its own unique fluorescence intensity, to capture specific antigens and 
form unique populations on a flow cytometer.   The detection reagent is a mixture of 
phycoerythrin (PE) labelled antibody.  This binds the capture bead-bound antigen and 
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provides a fluorescent signal proportional to the amount of bound antigen.  FCAP Array 
version 1.0.1 analysis software identifies each bead population, generates a standard 
curve, and calculates the concentration of unknown samples. 
BD CBA Human Th1/Th2/Th17 kit was used to measure IL-2, IL-4, IL-6, IL-10, IL-17A, 
IFN-γ and TNF in clinical samples. 
BD CBA Human chemokine kit was used to measure IL-8, CCL5 (RANTES), CXCL9 (MIG), CCL2 
(MCP-1) and CXCL10 (IP-10). 
All samples were run in duplicate.   Standard curves for each analyte (cytokine/chemokine) 
were generated using the lyophilised standards provided in the kit.  Mean analyte 
concentrations in clinical samples were determined from the appropriate standard curve. 
 
2.7.2.1 Cytometer set up 
Analyte bead arrays were acquired on a FACS Canto II with standard laser and filter 
configuration (BD Biosciences, UK).  The instrument was calibrated daily using CS&T beads 
(BD Biosciences, UK).  BD FACS Diva clinical software (version 6.1.3) was used for data 
acquisition and analysis to determine the median fluorescence intensity of the bead 
population.  
 
2.7.2.2 BD CBA Human Th1/Th2/Th17 kit - Preparation of assay standards 
Assay standards were prepared as recommended by the manufacturer.  A vial of lyophilised 
standards was opened and the beads transferred to a 15ml conical tube, labelled ‘top 
standard’.  2ml of assay diluent was added to reconstitute the standards, with gentle 
mixing using the pipette.  This was left at room temperature to equilibrate for 15 minutes.  
12 BD Falcon 12 × 75-mm sample acquisition tubes were labelled and arranged in the 
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following order: 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, and 1:256.  300µl of Assay Diluent was 
pipetted into each tube.  300μl was taken from the Top Standard and transferred to the 1:2 
dilution tube, and mixed thoroughly by pipette.  Serial dilutions were made by continuing 
to transfer 300μl from the 1:2 tube to the 1:4 tube and so on to the 1:256 tube.  The 
standard curve for each cytokine covers a concentration range from 20 to 5000pg/ml.  A 
single tube was prepared containing only Assay Diluent to serve as the 0pg/ml negative 
control.  This resulted in 9 standard tubes and 1 negative control. 
 
2.7.2.3 BD CBA Human chemokine kit - Preparation of assay standards 
Assay standards were prepared as recommended by the manufacturer.  A vial of lyophilised 
standards was opened and the beads transferred to a 15ml conical tube, labelled ‘top 
standard’.  4ml of assay diluent was added to reconstitute the standards, with gentle 
mixing using the pipette.  The protocol is as described in section 2.7.2.2.  The standard 
curve for each chemokine covers a concentration range from 10 to 2500pg/ml.   
 
2.7.2.4 Assay procedure (both kits) 
The number of assay tubes for a given experiment was determined (9 standards + 1 
negative control + X unknowns = Y assay tubes).  Each capture bead suspension bottle was 
thoroughly mixed by vortex and Y x 10µl volume of each capture bead was added to a 
single tube labelled ‘mixed Capture Beads’.  This tube was vortexed to thoroughly 
resuspend the contents. 
 
For the BD CBA Human Th1/Th2/Th17 kit and for serum sample testing ONLY: Capture 
Beads were resuspended in Serum Enhancement Buffer by the following procedure.  The 
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mixed capture bead preparation was centrifuged at 200 x g for 5 minutes.  The supernatant 
was aspirated and discarded.  The pellet was resuspended in Serum Enhancement Buffer 
(equal to the volume removed after centrifugation) and mixed by vortex to resuspend.  This 
tube was incubated for 30 minutes at room temperature, protected from light. 
 
Samples and standards were prepared for analysis by vortexing the mixed capture beads 
and 50μl were added to all assay tubes.  50µl of the Standard dilutions were added to the 
labelled control tubes and 50µl of each clinical sample was added to the appropriately 
labelled sample tube.  50µL of PE Detection Reagent was added to all assay tubes.  All 
sample tubes were gently mixed by pipette and incubated for 3 hours at room 
temperature, protected from light.  Following the incubation, 1ml of Wash Buffer was 
added to every assay tube and the tubes were centrifuged at 200 x g for 5 minutes.  
Supernatant was aspirated and discarded from each assay tube.  300µl of Wash Buffer was 
added to each assay tube to resuspend the bead pellet. 
Samples were taken to the flow cytometer to analyse.  The appropriate acquisition 
template was opened and the number of events to be counted was set to 2100 of R1 gated 
events, to ensure that the sample file contained approximately 300 events per Capture 
Bead.  The number of events to be collected was set to ‘all events’, to ensure that no true 
bead events were lost due to incorrect gating. 
The negative control tube was run first, followed by the Standard tubes from highest 
dilution to Top Standard, and the unknown clinical samples. 
The analyte data were analysed using FCAP Array software. 
 
 83 
 
2.8 Proximity Ligation Assay  
The Proximity Ligation Assay (PLA) uses qPCR as a detection method to quantify antibody-
antigen binding.  Here a modified method is described, making use of TaqMan Protein 
Assay reagents (Applied Biosystems, Life Technologies).   
The technology is shown in Figure 9 and described below. 
 
Figure 9.  The steps involved in the TaqMan Protein Assays: Proximity ligation with real-time PCR. 
 
Two antibodies (Ab1 and Ab2), which bind to 2 different epitopes or multiple identical 
epitopes on the same target protein, are conjugated to 2 different oligonucleotides 
through a biotin-streptavidin linkage.  Antibodies can be a single MAb, two different MAbs, 
two polycolonal antisera or a combination of MAb and polyclonal sera.  One of the 
oligonucleotides has a free 3’ end and the other a free 5’ end.  When conjugated, these 
form the two assay probes.  The free ends of the oligonucleotides are brought into 
proximity when both probes bind to their respective epitopes (Figure 9A).  The 3’ and 5’ 
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ends are connected by a ‘linker’ oligonucleotde, that is complementary to the end of the 3’ 
oligo and the start of the 5’ oligo (Figure 9B).  A ligation reaction seals the gap to generate a 
molecule that can be amplified by PCR (Figure 9C).   Amplification is detected by 
fluorescence in real-time (Figure 9D). 
 
2.8.1 Assay control demonstration  
The Applied Biosytems TaqMan Protein Expression kit was run, using ready-biotinylated 
polyclonal antibody (pAb) to human IL-6 and a purified recombinant protein target, 
supplied by Life Technologies.  The control assay was run using the kit designated TaqMan 
Protein Assay II (TPA II) – unpublished and commercially not yet available improvements to 
the original assay, supplied by Life Technologies under a confidentiality agreement.   
 
2.8.1.1 Preparation of Assay Probe A and Assay Probe B 
The 200nM biotinylated antibody was briefly centrifuged to spin the liquid to the bottom of 
the tube (700 x g for 30 seconds), and placed on ice.  The 3’ oligonucleotide was also placed 
on ice.  5µl of the 200nM biotinylated antibody was combined with 5µl of 200nM 3’ 
oligonucleotide in a tube, mixed gently by tapping the tube and briefly centrifuged (700 x g 
for 30 seconds).  This tube was incubated at room temperature for 60 minutes. 
The Assay Probe Storage Buffer was allowed to come to room temperature, before 90μl 
was added to the Ab-oligonucleotide tube and mixed gently by tapping the tube.  The tube 
was incubated at room temperature for 20 minutes.  Assay Probe A could be stored at –
20°C for up to 6 months. 
Assay Probe B was prepared using the same protocol, but with the 5’ oligonucleotide 
instead of the 3’. 
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2.8.1.2 Preparation of Assay Probe solution 
Assay Probe Dilution Buffer and pre-made Assay Probes A and B were placed on ice to 
thaw. 
The reagents were combined as follows; 
 
Components    Volume for 96 reactions (full plate) 
Assay probe dilution buffer  216µl 
Assay probe A (20x)   12µl 
Assay probe B (20x)   12µl 
Total volume    240µl 
This tube was gently mixed by tapping and centrifuged (700 x g for 30 seconds), before 
being placed on ice. 
 
2.8.1.3 Preparation of recombinant protein target dilution plate 
IL-6 recombinant protein target and Serum Dilution Buffer were thawed on ice.  A 96-well 
reaction plate was placed on ice and a dilution series of the protein target was prepared in 
column 1 as follows; 
a. 45μL of serum dilution buffer was pipetted into well A1 and 48µl into wells B1-H1. 
b. 5μL of recombinant protein target (20,000pg/mL) was pipetted into well A1 and pipetted 
up and down several times to mix the sample. 
c. 12μL was transferred from well A1 to B1 and pipetted up and down several times to mix.  
This was continued, transferring 12µL from the previous dilution well to the next dilution 
well, pipetting up and down several times to mix, continued down column 1 of the plate 
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until recombinant protein was added to well G1 (Figure 10).  Well H1 did not contain any 
recombinant protein, only serum dilution buffer (no protein control). 
The plate was sealed with MicroAmp clear adhesive film and briefly centrifuged (700 x g for 
30 seconds) to remove bubbles and placed back on ice. 
 
Figure 10.  Serial dilution of recombinant protein target in row 1 of the dilution plate. 
 
 
2.8.1.4 Performing the binding reaction 
A 96-well plate was placed on ice and 2µl of Assay Probe solution was pipetted into wells 1-
4 of rows A to H.  Recombinant protein dilutions were transferred to the binding reaction 
plate as follows; 
a. 2µl of the diluted recombinant protein was transferred from well A1 of the dilution plate 
to wells A1-4 of the binding plate (Figure 11) 
b. Step a was repeated for rows B through to H of the binding reaction plate 
The binding reaction plate was sealed using a MicroAmp Clear Adhesive Film and briefly 
centrifuged to bring the liquid to the bottom of the wells (700 x g for 30 seconds).  The 
plate was incubated at room temperature for 90 minutes.  The plate was put on ice and the 
ligation reaction set up within 15 minutes. 
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Figure 11.  Preparation of the binding reaction plate. 
 
 
2.8.1.5 Performing the ligation reaction 
DNA Ligase II (250x), TaqMan Protein Expression Fast Master Mix II (2x), nuclease-free 
water and Universal PCR Assay II (20x) were put on ice to defrost.  Tubes were gently 
flicked to mix and briefly centrifuged (700 x g for 30 seconds).  A MicroAmp Optical 96-well 
Reaction Plate was also put on ice. 
The ligation mix was prepared as follows and inverted to mix; 
Ligation/PCR solution  Volume for 1 reaction 
Fast Master Mix II (2x)   10µl 
DNA Ligase II (250x)    0.076µl 
Universal PCR Assay II (20x)   1µl 
Nuclease-Free Water    4.92µl 
Total Volume    16µl 
 
16µl of this master mix was pipetted into columns 1-4 of the Reaction Plate.  The plate was 
sealed with a MicroAmp Optical Adhesive Cover and briefly centrifuged (700 x g for 30 
seconds).  The reaction plate was loaded into a StepOne real-time system (Life 
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Technologies).   Thermal cycling conditions were 1 hold at 25°C for 15 minutes (ligation 
step), 1 hold at 95°C for 2 minutes (ligase inactivation), followed by 40 cycles of 
denaturation at 95°C for 1 second and annealing/polymerisation at 60°C for 20 seconds. 
Data from the TaqMan protein expression experiment was analysed using a threshold 
setting of 0.2 with automatic baseline.  The Cq data was exported for comparative analysis. 
 
2.8.2 Aspergillus-specific probe development 
2.8.2.1 Aspergillus-specific antibody production 
Monoclonal antibody (Ab) JF5 was prepared by Dr Christopher Thornton (University of 
Exeter), as previously described (119).  Mouse MAb JF5 was raised against an extracellular 
glycoprotein secreted by actively growing Aspergillus hyphae, with mice challenged with 
lyophilised mycelium of A. fumigatus AF293.   The JF5 hybridoma cell line was produced.  Ig 
subclass and target epitope characterisation revealed the MAb belonged to the IgG3 class 
and binds a protein epitope that does not contain carbohydrate moieties.  Dr Thornton also 
provided antiserum (pAb) raised in rabbits against purified A. fumigatus mannoprotein 
antigen (119) suspended in phosphate buffered saline (PBS). Three New Zealand white 
male rabbits were each given four sub-cutaneous injections at 2-week intervals. Each 
injection contained a total of 1.0mg of antigen plus 25µg of Quil A adjuvant (Superfos a/s, 
Denmark) with each injection. Test bleeds were performed prior to immunisation and 7 
days after the third injection. The final bleed was made 1 week after the fourth injection.  
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2.8.2.2 Aspergillus culture filtrate preparation 
A crude culture filtrate (CF) of A. fumigatus AF293 was provided by Dr Thornton.  This CF 
acted as a positive control samples for Aspergillus PLA development, as it contained the 
target glycoprotein.  This CF was prepared by Dr Thornton as follows; 
Three replicate sterile tissue culture flasks (Greiner Bio-One) containing 15ml tissue culture 
medium (TCM; RPMI-1640 medium containing 10% (v/v) fetal calf serum, 10mM L-
glutamine and penicillin-streptomycin) were inoculated with 103 washed spores per ml 
TCM and incubated at 37°C with shaking (50 rpm). Washed spore suspensions were 
prepared from malt extract agar cultures.  After 48 hours growth, the contents of flasks 
were centrifuged at 4,000 rpm for 10 minutes and the cell-free culture fluids stored at -
20°C prior to assay by PLA. 
 
2.8.2.3 Purified glycoprotein target preparation 
Purified glycoprotein target was prepared by Dr Thornton as previously described (119).  
Antigen was purified from PBS extracts of lyophilised mycelium by affinity chromatography 
with a Protein A IgG Plus Orientation kit (Pierce Biotechnology, Rockford, IL) containing 
immobilised MAb JF5.  Ascitic fluid was prepared from JF5 hybridoma cells in female 
BALB/c mice (Eurogentec, Belgium).  The mice were injected with 106 hybridoma cells 
washed in PBS.  After 3 weeks approximately 5ml of ascitic fluid was recovered from each 
mouse and stored at -20°C prior to use.  For preparation of the affinity column, 15µl of 
ascitic fluid was mixed with 2ml of binding buffer and the solution was applied to the 
protein A-agarose matrix.  Crude PBS antigen extract was incubated with the immobilised 
antibody and bound antigen was eluted with 0.1M glycine-HCl (pH 2.8) buffer.  
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2.8.2.4 Preparation of biotinylated antibodies 
This step required the following reagents; 
a. Monoclonal antibody JF5 (1–2μg/μl) 
b. Polyclonal serum (1–2μg/μl) 
c. Life Technologies Probe/buffer kit 
d. Life Technologies Core reagents base kit/mastermix 
e. APEX Biotin-XX Ab labelling kit (Invitrogen) or EZ-Link Sulfo-NHS-LC-Biotin, No-Weigh 
Format Biotinylation kit (Thermo Scientific) 
f. Thermo Slide-A-Lyzer MINI Dialysis Unit, 7K MWCO 
 
Biotinylation was performed using two commercial kits, for comparison. 
Biotinylation of the selected Abs was performed using the APEX Biotin-XX Ab labelling kit 
(Invitrogen), as follows:  
The APEX antibody labelling tip was gently tapped on a hard surface to settle all resin at the 
bottom of the tip.  Both caps were removed from the labelling tip and the tip was placed 
into a microcentrifuge tube.  The resin was hydrated by applying 100μl of wash buffer 
(Component C) to the resin in the tip.  10μl of antibody solution was applied to the top of 
the resin.  The antibody solution was gently pushed onto the resin using the elution syringe 
(Component H).  Any drops that eluted from the tip were discarded as waste. 
To the vial of reactive dye (Component A), the following were added; 
a. 2μl Dimethyl sulfoxide (DMSO, Component D); pipetted up and down to dissolve 
b. 18μl Labelling buffer (Component E); pipetted up and down to dissolve 
 
10μl of this was added to the top of the resin, and the solution was gently pushed through.  
Any dye that eluted from the tip was discarded as waste.  The tip was incubated at room 
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temperature for 2 hours.  The APEX antibody labelling tip was washed twice with 50μl of 
wash buffer (Component C) by applying 50μl to the top of the resin, pushing through the 
tip into the microcentrifuge tube.  10μl of neutralisation buffer (Component F) was added 
to a clean microcentrifuge tube and the APEX antibody labelling tip was transferred to this 
tube.  40μl of elution buffer (Component G) was applied to the top of the resin. This was 
pushed through the tip to elute the labelled antibody into the microcentrifuge tube 
containing neutralisation buffer.  The 50µl of eluted solution was mixed to ensure 
neutralisation and the tube placed on ice. 
The biotin-labelled Ab solution was extensively dialysed in cold PBS (pH 7.4) using the 
Thermo Slide-A-Lyzer MINI Dialysis Unit. 
 
Biotinylation of the selected Abs was performed using the EZ-Link Sulfo-NHS-LC-Biotin, No-
Weigh Format Biotinylation kit (Thermo Scientific), as follows:   
a. A vial of Sulfo-NHS-LC-Biotin was removed from the freezer and brought to room 
temperature. 
b. The antibody was prepared in PBS (dialysed in cold PBS (pH 7.4) using the Thermo Slide-
A-Lyzer MINI Dialysis Unit). 
c. A 10mM solution of the biotin reagent was prepared by adding 180μl of water to the 
1mg microtube. 
d. The appropriate volume of 10mM biotin reagent solution was added to the antibody 
solution. 
e. The tube was incubated on ice for two hours 
f. With antibody labelling completed, excess biotin was removed by extensive dialysis in 
cold PBS (pH 7.4) using the Thermo Slide-A-Lyzer MINI Dialysis Unit. 
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2.8.2.5 Performing the Forced Proximity Probe Test 
The Forced Proximity Probe Test is performed to determine whether or not the 
biotinylated antibody can bind to the oligonucleotide.  The average Cq value is calculated 
for each biotinylated antibody and negative control.  The ΔCq value is calculated for each 
biotinylated antibody: AvgCq(negative control) – AvgCq(Forced Proximity Probe).  ΔCq≥8.5 
is required for the antibody to pass the Forced Proximity Probe Test.  This confirms that the 
biotinylated antibody is suitable for use in TaqMan Protein Assays experiments. 
The biotinylated antibody will fail this test if there is an excess free biotin in the preparation 
or if the biotinylation step has been unsuccessful. 
The biotinylated antibody was first diluted to 200nM (30μg/mL) using Antibody Dilution 
Buffer as the diluent. This dilution was briefly centrifuged to spin the liquid to the bottom 
of the tube (700 x g for 30 seconds) and placed on ice.  The oligonucleotide mix was 
prepared in a clean tube by combining 5µl of 200nM 3’ oligonucleotide with 5µl of 200nM 
5’oligonucleotide.  The tube was gently mixed by tapping and briefly centrifuged (700 x g 
for 30 seconds) and placed on ice.   
Two tubes were labelled: Forced Proximity Probe and Negative Control.  Working on ice, 
the following mixes were made in the appropriate tube; 
 
Component   Forced Proximity Probe Tube Negative Control Tube 
200nM Prox-Oligo mix   2µl    2µl 
200nM biotinylated Ab   2µl    ---- 
Ab dilution buffer   ----    2µl 
Total Volume    4µl    4µl 
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The tubes were mixed gently by tapping and centrifuged (700 x g for 30 seconds).  The 
tubes were incubated at room temperature for 60 minutes.  396μl of Assay Probe Dilution 
Buffer was added to each tube and the tubes were incubated at room temperature for 30 
minutes, before being placed on ice. 
DNA Ligase (500x), Ligase Dilution Buffer (1x) and Ligation Reaction Buffer (20x) were 
thawed on ice. The DNA Ligase was diluted with Ligase Dilution Buffer as follows; 
a. The DNA ligase tube and Ligase Dilution Buffer were gently flicked to mix and briefly 
centrifuged (700 x g for 30 seconds)  
b. 2µl DNA Ligase (500x) was combined with 198µl Ligase Dilution Buffer in a new tube, 
gently flicked to mix and put on ice. 
 
The ligation solution was prepared as follows and inverted to mix; 
Ligation solution   Volume     
Ligation Reaction Buffer (20x)  50µl     
Deionised water   908µl     
Diluted ligase    2µl     
Total      960µl     
 
A MicroAmp Optical 96-well Reaction Plate was put on ice.  4µl of the Forced Proximity 
Probe mix was added to wells A1-4.  4µl of the Negative Control mix was added to wells A5-
8.  96μL of the ligation solution was pipetted into each of the 8 reaction wells and pipetted 
up and down once to mix.  The plate was sealed with a MicroAmp Clear Adhesive Film, and 
briefly centrifuged (700 x g for 30 seconds).  Using a thermal cycler with a heated cover, the 
sealed plate was incubated at 37 °C for 10 minutes.  The plate was returned to ice. 
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TaqMan Protein Expression Fast Master Mix (2x), Universal PCR Assay (20x) were put on ice 
to defrost.  Both tubes were gently flicked to mix and briefly centrifuged (700 x g for 30 
seconds).  A MicroAmp Optical 96-well Reaction Plate was also put on ice. 
The PCR reaction mix was prepared in a tube as follows,  briefly mixed by tapping the tube 
and centrifuged (700 x g for 30 seconds); 
 
Real-time PCR mastermix  Volume    
Fast Master Mix (2x)   100µl     
Universal PCR Assay (20x)  10µl     
Total     110µl     
 
11µl of this master mix was pipetted into wells A1-12 of the new Optical 96-well Reaction 
Plate.  9µl of ligation product was pipetted from the original reaction plate into the 
corresponding wells of the Optical 96-well Reaction Plate. The wells were pipetted up and 
down once to mix.  The plate was sealed with a MicroAmp Optical Adhesive Cover and 
briefly centrifuged (700xg for 30 seconds).   
The PCR plate was loaded into a Bio-Rad CFX Real-time system (BioRad, Hercules, CA, USA).   
Thermal cycling conditions were 1 hold at 95°C for 20 seconds, followed by 40 cycles of 
denaturation at 95°C for 3 seconds and annealing/polymerisation at 60°C for 30 seconds. 
Data from the TaqMan protein expression experiment was analysed using a threshold 
setting of 0.2 with automatic baseline.  ΔCq≥8.5 was required for the antibody to pass the 
Forced Proximity Probe Test.   
 
Once biotinylated Abs had passed the Forced Proximity Probe Test they could be used to 
prepare PLA probes.  Assay Probes were prepared as described in section 2.8.1.1. 
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2.8.2.6 Aspergillus PLA – original TPA I protocol - method using TaqMan® Protein 
Assays Open Kit 
Preparation of Assay Probe Solution was performed as described in section 2.8.1.2. 
Binding reaction - A 96-well plate was placed on ice and 2µl of Assay Probe solution was 
pipetted into the appropriate number of reaction wells.  2μl of Aspergillus culture filtrate 
(dilutions made in 1xPBS as appropriate) was added to appropriate wells in the binding 
plate.  The binding reaction plate was sealed using a MicroAmp Clear Adhesive Film and 
briefly centrifuged to bring the liquid to the bottom of the wells.  The plate was incubated 
at 37°C for 60 minutes inside a thermal cycler with a heated cover.  The plate was put on 
ice and the ligation reaction set up within 15 minutes. 
Ligation reaction - DNA Ligase (500x), Ligase Dilution Buffer and Ligation Reaction Buffer 
(20x) were placed on ice to defrost.  The DNA Ligase was diluted with Ligase Dilution Buffer 
as follows; 
a. The DNA ligase tube was gently flicked to mix and briefly centrifuged (700 x g for 30 
seconds) 
b. The Ligase Dilution Buffer was briefly mixed by vortex and briefly centrifuged (700 x g for 
30 seconds) 
c. 2µl DNA Ligase (500x) was combined with 998µl Ligase Dilution Buffer in a new tube, 
gently flicked to mix and put on ice. 
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The ligation solution was prepared as follows and inverted to mix; 
Ligation solution  Volume for 1 reaction   
Ligation Reaction Buffer (20x)  5µl  
Deionised water   90.9µl  
Diluted ligase    0.1µl  
Total      96µl  
 
96μL of the ligation solution was pipetted into each binding reaction well, on ice.  Each well 
was pipetted up and down once to mix.  The plate was re-sealed with a MicroAmp Clear 
Adhesive Film, and briefly centrifuged (700 x g for 30 seconds).  Using a thermal cycler with 
a heated cover, the sealed plate was incubated at 37 °C for 10 minutes.  The plate was 
returned to ice. 
Real-time PCR reaction - TaqMan Protein Expression Fast Master Mix (2x) and Universal 
PCR Assay (20x) were put on ice to defrost.  Both tubes were gently flicked to mix and 
briefly centrifuged (700 x g for 30 seconds).  A MicroAmp Optical 96-well Reaction Plate 
was also put on ice. 
 
The PCR reaction mix was prepared in a tube as follows,  briefly mixed and centrifuged (700 
x g for 30 seconds); 
 
Real-time PCR mastermix Volume for 1 reaction 
Fast Master Mix (2x)   10µl  
Universal PCR Assay (20x)  1µl  
Total     11µl  
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11µl of this master mix was pipetted into the appropriate number of wells in the new 
Optical 96-well Reaction Plate.  9µl of ligation product was pipetted from the original 
reaction plate into the corresponding wells of the Optical 96-well Reaction Plate. The wells 
were pipetted up and down once to mix.  The plate was sealed with a MicroAmp Optical 
Adhesive Cover and briefly centrifuged.  The PCR plate was loaded into a Bio-Rad CFX Real-
time system (BioRad, Hercules, CA, USA).   Thermal cycling conditions were 1 cycle of 95°C 
for 20 seconds, followed by 40 cycles of denaturation at 95°C for 3 seconds and 
annealing/polymerisation at 60°C for 30 seconds. 
Data from the TaqMan protein expression experiment was analysed using a threshold 
setting of 0.2 with automatic baseline.  The Cq data was exported for comparative analysis. 
 
2.8.2.7 Aspergillus PLA – TPA II KIT  
Using a simplified work flow and modified reagents, Life Technologies provided the 
following PLA protocol, as shown in Figure 12. 
 
Figure 12.  TaqMan Protein Assay II work flow. 
R = fluorescent reporter.  NFQ = non-fluorescent quencher.   
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Preparation of Assay Probe Solution was performed as described in section 2.8.1.2. 
The binding reaction was performed as described in section 2.8.1.4, with 2μl of the Assay 
Probe solution and 2µl of Aspergillus culture filtrate dilutions added to each well. 
The ligation reaction was performed as described in section 2.8.1.5, with addition to 
appropriate wells.  Real-time PCR was performed as described in section 2.8.1.5, but on a 
Bio-Rad CFX Real-time system (BioRad, Hercules, CA, USA). 
 
2.8.2.8 Antibody affinity purification 
The Thermo Scientific NAb Protein A Plus spin kit was used for rapid affinity purification of 
the Aspergillus IgG antibodies.  Protein A is a bacterial protein that binds with high 
specificity to mammalian IgG and is generally preferred for affinity purification of rabbit, 
pig, dog and cat IgG.  Protein A purification was performed as recommended by the 
manufacturer.  
 
2.9 Statistical Analyses 
2.9.1 Significant decline in galactomannan signal during storage of clinical serum 
samples 
2.9.1.1 Analysis of clinical data 
Data from serum testing were presented on a scatter plot, with fractional polynomial 
regression lines for each storage type.  As the relationship between the two test results 
was found not to be linear, fractional polynomial regression was the best choice to capture 
the exact relationship between them.  Due to routine twice-weekly screening of high-risk 
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patients, more than one sample was collected for most of the patients.  As first and second 
test values are likely to be correlated, due to sampling from the same patient, the Wilcoxon 
Signed Rank Sum Test was used to test the GM signal loss both in the ST as well as LT serum 
samples based on the first sample taken from each patient.  Probability values <0.05 were 
defined as significant based on a 2-tailed test.  All calculations were carried out by Dr Shah-
Jalal Sarker, using the statistical software package Intercooled STATA 10.1 (Stat Corp, 
College Station, TX, USA, 2008). 
 
2.9.1.2 Assay Repeatability 
In order to determine the intra- and inter-assay variability, the OD value of the threshold 
control, loaded in duplicate, was recorded for 40 randomly selected assay runs.  The mean 
OD was calculated, together with range.  Inter-assay repeatability of the threshold control 
was calculated by using the Jones and Payne (163) coefficient of variation (CV) for duplicate 
measures. 
 
2.9.2 Combination biomarker diagnosis of IA in BAL fluid 
2.9.2.1 Pairwise agreement 
Cohen's kappa coefficient (including 95% confidence intervals) was calculated to measure 
the agreement between any two biomarkers (LFD/qPCR/GM).  Kappa values were 
interpreted using the method of Landis and Koch (164), with  values greater than 0.8 
representing almost perfect agreement.   
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2.9.2.2 Diagnostic performance of EORTC/MSG criteria 
The EORTC/MSG criteria (51) were evaluated against the clinical biomarker diagnosis of 
IPA, both with and without GM results included – excluding GM data removes 
incorporation bias, as GM is itself a criterion in the EORTC/MSG scoring.  The sensitivity, 
specificity, positive predictive values (PPV) and negative predictive values (NPV) of 
EORTC/MSG scoring were determined using i) proven/probable/possible as positive results 
and EORTC/MSG none as negatives and ii) proven/probable as positives and EORTC/MSG 
possible/none as negatives. 
 
2.9.2.3 Diagnostic performance of the biomarker assay, using EORTC/MSG criteria 
as the gold standard 
Diagnostic performance of the individual and combination biomarker assays was evaluated 
in the Study cohort.  Combined assay results were treated as a single entity (positive or 
negative) and discrepant results excluded from analysis.  Sensitivity, specificity, PPV and 
NPV were determined using the EORTC/MSG (excluding GM) proven/probable IA as true 
positives and those with possible/none as true negatives, with 95% confidence intervals.   
 
2.9.3 Evaluation of lung and serum inflammatory cytokine profile associated with 
IPA biomarker positive BAL fluid 
FCS 2.0 data files were exported from the BD CBA assay for analysis using FCAP Array 
software.  This software reads the FCS 2.0 data files from an experiment, locates clusters 
(with assigned analytes) and determines the median fluorescence intensity (MFI) of the 
detector antibody for each analyte. The software fits a standard curve to the data from the 
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concentration standards. The 5-parameter logistic fitting equation was used to fit the data, 
as recommended by BD.  The standard curve for each analyte was used to calculate 
concentration values in each Study sample. 
Cytokine and chemokine distributions between defined populations were compared using 
the non-parametric Mann Whitney test, with 2 tailed P values and 95% confidence intervals 
calculated (GraphPad Prism 5).   
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CHAPTER 3 
 
DESIGN AND DEVELOPMENT OF A NEW, ROBUST AND 
RELIABLE PAN-ASPERGILLUS qPCR ASSAY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 103 
 
3.1 Background 
qPCR is the most widely used molecular technology for diagnostic applications designed to 
detect and quantify pathogens (113). 
Its accessibility, characteristic sensitivity, specificity, and wide linear dynamic range make 
qPCR well suited to use within the clinical environment. 
However, there are several drawbacks to qPCR assays:  
(i) need to extract DNA which can result in contamination of sample and false 
positive results 
(ii) sensitivity to environmental inhibitors, which can cause false-negative results  
(iii) inability to provide information about whether a detected pathogen has the 
ability to establish an infection or not and  
(iv) inadequately designed and controlled qPCR assays can generate significant 
inter-laboratory variation, leading to unreliable and often contradictory results 
obtained from the same samples  
As a consequence, although qPCR is widely used, the peer-reviewed literature contains 
numerous publications reporting inconsistent data from poorly designed assays, resulting 
in unreliable conclusions and diagnoses (133, 165).  
PCR has been widely used in attempts to establish a diagnosis of IA.  DNA samples 
commonly analysed are extracted from various fractions of blood (serum, plasma, whole 
blood), BAL fluid specimens as well as tissue, including paraffin-embedded sections. 
However, a lack of technical standardisation and relatively poor understanding of the 
kinetics of in vivo fungal DNA release continues to hamper the broad applicability of this 
technique.  Hence qPCR has not yet been included in the EORTC/MSG mycological criteria 
for defining IA (51). 
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Two recent reviews have examined the quality of PCR-based studies in the diagnosis of IA 
(116, 166).  Khot and Fredricks (166) examined the quality of PCR-based studies in fungal 
diagnostics using 42 variables from the Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments (MIQE) guidelines to analyse the impact of 
analytical variables on diagnostic performance.  The focus of their review was the 
diagnostic performance of the assays.  Therefore, the majority of MIQE variables used in 
the analysis focused on aspects of study design, patient population selection, sampling, 
criteria for assigning likelihood of IFD and evaluation of assay diagnostic performance.  The 
focus of the review was not on the quality of the PCR assays themselves, with only 13 of 
the 42 selected analytical variables specifically addressing the PCR assay design, control and 
validation.  The review does however highlight that a significant number of studies fail to 
use or report the use of negative extraction controls to monitor contamination during the 
nucleic acid extraction stage.  Also, only just over half of the studies evaluated using the 
MIQE guidelines reported the use of some form of inhibition or amplification control, even 
though it is well known that PCR inhibitors can reduce product yield and even result in 
complete failure of the PCR.  Mengoli et al (116) report a systematic review and meta-
analysis on the use of PCR tests for the diagnosis of IA, focusing on the practical application 
of PCR assays and their diagnostic performance.  They highlight the variation in methods 
across 16 studies, including PCR targets and chemistry, concluding that formal validation of 
this technology for the diagnosis on IA in specific patient populations will require the design 
of a standard for Aspergillus PCR.  Attempts to reach a consensus on PCR diagnosis have 
been coordinated by EAPCRI, who have thus far focused on the extraction procedure (114).  
However, closer examination of their data reveals the high variability of PCR assays, with 
different PCR efficiencies resulting in significantly different sensitivities [Section 1.6.4]. 
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Taken together, these reports emphasise the need to examine the quality of published 
assays.  A development that may improve the reliability of PCR-based assays for the 
diagnosis of IA was the publication of the MIQE guidelines (167).  These provide a blueprint 
for good assay design and aim to restructure qPCR methods into a more consistent format 
that will encourage detailed auditing of experimental detail, data analysis and reporting 
principles (168).  MIQE has become acknowledged as the defining event in the maturing of 
qPCR technology and its implementation is essential if qPCR is to remain the benchmark 
technology for molecular diagnosis (133).   
This chapter first describes a critical literature review of Aspergillus qPCR assays, focusing 
on the analysis of the parameters that define good assay design and examining the quality 
of broad spectrum Aspergillus qPCR assays published between December 2000 and 
December 2011.  Next, a series of design steps and experiments is described in the 
development, optimisation and validation of the first MIQE-compliant pan-Aspergillus qPCR 
assay. 
 
3.2 RESULTS: Critical review of the use of qPCR for the detection of Aspergillus-
derived nucleic acids 
3.2.1 Search strategy 
The review excludes case studies, reviews and non-English language papers and limits itself 
to an analysis of the first publication of any particular assay.  Assays that target A. 
fumigatus only were also excluded.  Whilst A. fumigatus accounts for approximately 90% of 
all cases of life-threatening IA (17), there has been an increase in the frequency of other 
Aspergillus species associated with IA, with reported frequencies of A. flavus, A. terreus, A. 
nidulans and A. niger of 14-33%, 3-28%, 1-2.5% and 5-8%, respectively (21-23).  This is of 
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relevance to the design of a reliable diagnostic assay for IA, which must be sufficiently 
specific to detect all clinically-relevant Aspergillus species whilst not amplifying other, 
closely related non-Aspergillus targets, such as Candida spp.   
Nested PCR assays were also excluded.  Nested PCR assays have been used to enhance 
analytical sensitivity (169).  However, it is arguable whether analytical sensitivity increases 
assay sensitivity (170), whereas its reduced specificity has been documented (171, 172).  
Also, the use of nested-PCR assays is considered too prone to false-positive results and 
unlikely to attain widespread acceptance outside specialist molecular centres (131). 
In addition, alternative nucleic acid-based tests such as fluorescence in situ hybridization 
and isothermal amplification techniques such as nucleic acid sequence-based amplification 
(NASBA) were excluded.  Although there are a few reports describing the use of NASBA, an 
isothermal technique for the amplification of RNA (173-176), the theoretical advantage of 
higher sensitivity and reduced likelihood of carry-over contamination must be balanced by 
the complexity of this technology.  The review presented in this chapter focuses on real-
time qPCR, the most commonly used nucleic acid-based test. 
A PubMed search was performed for articles published over a period of 12 years between 
December 2000 and December 2011 using the search criteria ‘aspergillosis [Title/Abstract] 
OR aspergillus [Title/Abstract] AND PCR [Title/Abstract] AND diagnosis [Title/Abstract]’.  
The search resulted in 223 publications, which were reduced to ten after applying the 
exclusions discussed above, (Table 1). 
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Study 
Author Type of PCR assay Target 
Targeted Aspergillus 
species 
Amplicon size (bp) 
Secondary 
structures at primer 
binding location? 
Type of 
Standards 
Efficiency
a
 Limit of detection 
1 Khot, 
2008(177) 
Hydrolysis probe 18S rDNA Aspergillus spp 114
 
No Genomic DNA No 
information 
1fg (single target gene copy) 
2 Schabereiter-
Gurtner, 
2007(178) 
SYBR Green with bi-
probes for Aspergillus 
species-specific melt 
point analysis 
ITS2 A. fumigatus, A. flavus, A. 
nidulans, A. niger, A. 
terreus 
242-251 Yes Conidia 
spiked in 
blood and 
genomic DNA 
No 
information 
0.45-0.9 CFU/PCR reaction 
3 Musher, 
2004(158) 
Molecular beacon 18S rDNA Aspergillus spp 219 No Genomic DNA No 
information 
No information (lowest 
standard 1pg) 
4 Sanguinetti, 
2003(179) 
Hydrolysis probe 18S rDNA Aspergillus spp  124 Yes Recombinant 
DNA 
118%b 10 target gene copies 
5 Costa, 
2002(180) 
Hybridisation probes Mit A. fumigatus and A. flavus 91 Yes Genomic DNA 77.1% 3fg genomic DNA (less than a 
single genome copy) 
6 Kami, 
2001(181) 
Hydrolysis probe 18S rDNA Aspergillus spp 156c No Recombinant 
DNA 
91.6%a 10 target gene copies 
7 Faber, 
2008(182)  
Hybridisation probes for 
Aspergillus species-
specific melt point 
analysis 
18S rDNA A. fumigatus, A. flavus, A. 
niger and A. terreus 
504c  No Conidia 
spiked in 
blood 
No 
information 
A. fumigatus 5 CFU/ml, 
others 1-5 CFU/ml 
8 White, 
2006(183) 
Hydrolysis probe 28S rDNA Aspergillus spp 184 Yes Recombinant 
DNA  
86%b 5 gene copies/ 
10CFU/mL 
9 Springer, a) Hybridization probes ITS1 a) 3 groups; i) A. 
fumigatus, A. versicolor, A. 
153 Yes Conidia 
spiked in 
No 20 CFU/ml 
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Table 1.  Comparisons of real-time PCR studies for detection of multiple Aspergillus species.   
a 
Efficiency, if not quoted in the original paper, is derived from the formula: PCR efficiency = 10 
-1/slope
 -1 (where slope refers to the slope of the standard curve given in the study.  However, 
this is frequently not provided by the authors) 
b 
Information on efficiency or slope of standard curve not available in the paper, the efficiency of the assay is estimated from standard curve or amplification curve shown in the paper. Refer 
to Appendix 3 for an example of calculation in detail. 
c
 Information on size of the amplicon were not given in the paper, the size were deduced by mapping the primers on an A. fumigatus 18S ribosomal RNA gene sequence.  Abbreviations: rDNA: 
ribosomal DNA; Mit: mitochondrion; ITS: internal transcribed spacer; spp: species; CFU: Colony forming units.
2011(184) for melt point analysis 
b)Hydrolysis probe 
nidulans, ii) A. terreus, A. 
niger, iii) A. flavus 
b) Aspergillus spp 
blood information 
10 Walsh, 
2011(185) 
a) Hydrolysis probe and 
primers targeting 
specific Aspergillus 
species 
b) Hydrolysis probe 
a) ITS1 
b) 18S 
rDNA 
a) A. fumigatus, A. flavus, 
A. niger, A. terreus 
b) Aspergillus spp. 
a) A. fumigatus 
136bp, A. flavus 
89bp, A. niger 79bp, 
A. terreus 70bp 
b) 153 
a) Yes 
b) No 
Recombinant 
DNA  
a) A. 
fumigatus 
99.6%, A. 
terreus 93.5% 
b) 95.8% 
5 target gene copies 
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3.2.2 Type of PCR assays 
The ten publications emphasise the variation in strategies used for the detection of 
Aspergillus species. There are two broad approaches: 
 A simple and common approach is the use of broad-range PCR in which a universal 
set of primers and a probe are designed from consensus regions in the genome of 
Aspergillus species (Figure 13).  The main advantage of using genus-specific sets of 
primers and probe is that all Aspergillus species including rare ones would be 
detected in a single reaction. However, identification of specific species would not 
be possible. Examples of this approach are the assays reported in studies 1-4,6-
8,10b) 
 An alternative approach is to use different sets of primers targeting specific 
Aspergillus species.  Examples are study 5, where multiplex PCR identifies two 
Aspergillus species (A. fumigatus and A. flavus) along with some Candida species.  It 
is important to note that multiplex PCR assays are more difficult to design, as it is 
vital to avoid complementarity between all primers.  Also, competition for reagents 
can reduce assay efficiency, especially if one of the targets is present at much lower 
levels than the others.  In study 9a, different primer and probe sets were designed 
to target four Aspergillus species, run as individual assays.  This would be an 
expensive method.  A slightly different method is to combine broad range primers 
with species-specific probes (studies 2, 7 and 9).  Using species-specific probes can 
be clinically useful, as knowing the exact species may be important for clinical 
management (e.g. A. terreus strains are known to be more drug resistant to 
amphotericin B deoxycholate).  The rather serious disadvantage is that infection 
with other Aspergillus species will be missed.   
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Figure 13.  Sequence alignment of 28S rDNA region for six Aspergillus and four non-Aspergillus species. 
Example primer and probe target regions for Aspergillus species specific amplification are highlighted by the 
purple boxes 
 
Additional variation includes the use of different types of chemistries and different targets.  
 The different chemistries that have been used to detect Aspergillus, include 
hydrolysis probes (studies 1,4,6, 8, 9b,10a, 10b ), hybridisation probes (studies 5, 7 
and 9a), molecular beacons (study 3) and SYBR Green (study 2), even though this 
approach, which relies on a non-specific double stranded DNA-binding dye, lacks 
the specificity essential for use in clinical diagnostic assays (186).  Hence that study 
increased the specificity of the SYBR green assay with biprobes (sequence specific 
hybridisation probes) labeled with fluorophore Cy5.  Confirmation of the identity of 
the amplified product was achieved by subsequent melting temperature 
determination of the biprobe dissociating from the target sequence. However, 
quantification of the target was not possible.  
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  There are four major targets for qPCR-based assays: the 18S and 28S rRNA genes, 
the internal transcribed spacer (ITS) and mitochondrial DNA. Studies 1, 3, 4, 6, 7, 
10b target the 18S rDNA (or nuclear small subunit) ribosomal gene.  Study 8 targets 
the 28S rDNA ribosomal gene.  These regions are highly conserved among 
Aspergillus species, making them ideal targets for a broad range assay.  Also, the 
ribosomal gene is present in multiple copies within the genome, which increases 
the sensitivity of the assay (187, 188).  However, although constant in the same 
strain, the ribosomal gene copy numbers are variable among different A. fumigatus 
strains, and range from 38-91 in the eight strains analysed (189).  This will 
complicate attempts to quantify fungal load with PCR assays targeting ribosomal 
gene regions, and may make it more difficult to compare fungal load between 
patients.  It will also affect the apparent LOD.  The ITS regions, targeted in studies 
2, 9 and 10a, are more heterogeneous (190, 191) and are therefore suitable targets 
for species-specific primers and probes. Study 5 targeted a mitochondrial gene, 
which is another multiple copy gene target (192).  
 
3.2.3 Assay specificity 
Studies differ considerably in terms of the methods and extent to which analytical 
specificity is determined, as there are no standard techniques or criteria.  Although 
primer targets are generally identified by aligning sequences retrieved from public 
databases, this in silico approach is insufficient for establishing the analytical specificity 
of a PCR assay.  Ideally, amplicons should be sequenced and that sequence should be 
used to verify that the intended target has been amplified.  Furthermore, it is good 
practice to challenge the assay with organisms that have a high likelihood of cross-
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reacting with the target; in the case of Aspergillus spp, genera that are close 
phylogenetic relations—eg, Penicillium and Paecilomyces spp are especially important to 
consider.  A further consideration is that sequences are being continuously deposited in 
public databases; a unique sequence at the time of primer design may subsequently 
align with a sequence from an unrelated species or genus deposited at a later date.  Also, 
some of the deposited sequences or sequence assignments may simply be incorrect.  
After designing oligonucleotide primers, a Primer BLAST search 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) should be performed to determine 
the specificity.  A Primer-BLAST search was performed for the primer pairs used in each 
study.  Unsurprisingly, since there is 100% sequence identity across the 18S subunits of 
Aspergillus and Penicillium, the primers of studies 1, 2, 3, 4, 6, 7 and 10b amplify 
Penicillium and Paecilomyces species.  Of these, only studies 2 and 7 ensure Aspergillus 
specificity of detection, through biprobe melt analysis.  The probes in studies 1, 3, 6 and 
10b do not provide the necessary specificity to exclude Penicillium and Paecilomyces 
species.  An example is shown in Figure 14, in which 18S ribosomal RNA gene partial 
sequences from two Penicillium strains and an A. terreus strain are aligned, with the 
primer and probe binding sites highlighted.  This shows 100% homology across the three 
sequences, indicating that the Penicillium strains will also be amplified and detected in 
this assay.  
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Figure 14.  18S ribosomal RNA gene partial sequences aligned in CLC Sequence Viewer. 
Primer and probe binding sites for study 1(177) highlighted. 
 
The primers of studies 3, 6, 7 and 10b also amplify Candida species, generating an 
amplicon of approximately the same size as the target Aspergillus species, however the 
probe probably adds the necessary specificity to exclude Candida detection, due to base 
mismatches within the sequence.  An example is shown in Figure 15, in which 18S 
ribosomal RNA gene partial sequences from two Candida strains and an Aspergillus 
terreus strain are aligned, with the primer and probe binding sites highlighted.  This 
shows 100% homology across the forward and reverse primer binding sites for three 
sequences, indicating that the assay primers would bind to and amplify Candida species.  
However, there are 4 single base pair mismatches between the Candida sequences and 
the assay probe, so the probe will probably add the necessary specificity to exclude 
Candida species from detection.  This would need to be confirmed empirically.  However, 
if the primers amplify more than one target, PCR efficiency could suffer and the assay’s 
sensitivity could be reduced.   
 
  
114 
 
 
Figure 15.  18S ribosomal RNA gene partial sequences aligned in CLC Sequence Viewer. 
Primer and probe binding sites for study 3 (158) highlighted. 
 
The primers from study 8 have only a single base mismatch with Candida at the 5’ end of 
each primer and therefore the assay is also likely to amplify Candida species, however, 
the probe adds the necessary specificity to exclude Candida detection, although again 
this must be confirmed empirically.  Study 3 targets Aspergillus species, but the 
sequence alignment analysis presented in Figure 16 shows that there are several 
mismatches to A. nidulans and A. niger in the molecular beacon. Therefore the assay 
may not detect these species efficiently.   
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Figure 16.  18S ribosomal RNA gene partial sequences aligned in CLC Sequence Viewer. 
Primer and probe binding sites for study 3 (158) highlighted. 
 
Study 4 also targets Aspergillus species, but primer analysis shows there is 1 mismatch to 
A. flavus at the 3’ end of the reverse primer and 2 mismatches to A. nidulans in the 
reverse primer, therefore the assay may also not amplify these species efficiently.  
Crucially, sequence analysis reveals that the probe in study 4 does not bind between the 
forward and reverse primer binding sites (Figure 17).  The probe does not bind the 124bp 
target amplicon at all, hence from a technical point of view it is therefore not possible for 
that assay to detect any amplicons.  A correction of the probe sequence was published 
online in July 2005, two years after the publication of the original article. However, the 
publication of the original article in a peer-reviewed journal, with incorrect probe 
sequence, highlights the importance of the rigorous auditing and reporting of 
experimental detail that the MIQE guidelines promote. 
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Figure 17.  A. fumigatus strain MJ-X6 18S ribosomal RNA gene partial sequence. 
Primer and probe binding sites for study 4 (179) highlighted. 
 
Study 8 also targets Aspergillus species, but primer analysis shows there is 1 mismatch to 
A. nidulans in the reverse primer and 2 mismatches in the probe, therefore the assay 
may not amplify and detect these species efficiently.   The authors of study 5 state that 
their assay targets A. fumigatus and A. flavus mitochondrial DNA.  However, analysis of 
the primer pair reveals that they do not amplify A. flavus at all.   
Study 6 is one of two assays deemed to be optimal by the United Kingdom Fungal PCR 
Consensus Group (118).  However, the reverse primer from study 6 anneals to human 
DNA and the forward primer anneals with a single base mismatch at the 3’ end, 
therefore the assay may amplify human DNA, generating a 163bp product (Figure 18).  
Although the probe adds the necessary specificity to exclude detection of human DNA, 
this would be expected to reduce the sensitivity of the assay.  This was indeed 
acknowledged by the United Kingdom Fungal PCR Consensus Group (118), who reported 
that the detection threshold of this assay was significantly reduced when using blood 
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extracts, and speculated that this was possibly as a result of amplification of human DNA.  
They also sequenced the amplicons and revealed the high sequence similarity with the 
human 18S rRNA gene.  This cross homology with human DNA makes the assay sub-
optimal. 
 
 
Figure 18.  Homo sapiens BAC clone RP11-237A9 partial sequence. 
Primer binding sites for study 6 (181) highlighted.  A single base mismatch in the forward primer is 
highlighted in yellow. 
 
Study 9 targets Aspergillus species using broad range primers and adds species specificity 
by using hybridization probes for melt point analysis, to detect i) A. fumigatus, A. 
versicolor, A. nidulans, ii) A. terreus, A. niger, iii) A. flavus.  However, primer-BLAST 
analysis shows that the primers are in fact A. fumigatus-specific and do not amplify any 
other Aspergillus species. 
Study 10a uses hydrolysis probes and primers targeting A. fumigatus, A. flavus, A. niger 
and A. terreus specifically in individual assays.  However, inspection reveals that the 
primers and probe of the ‘A. fumigatus-specific assay’ will also bind A. lentulus, with only 
a single mismatch in the reverse primer (Figure 19).  Therefore, this may be amplified 
and detected.  This would need to be tested empirically.  The ‘A. flavus-specific assay’ 
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will also amplify and detect A. oryzae, as the primers and probe bind with 100% 
homology (Figure 20).  The ‘A. niger-specific assay’ will also amplify and detect A. 
tubingensis (Figure 21).  A. tubingensis belongs to the Aspergillus section Nigri, which 
includes species that morphologically resemble Aspergillus niger.  However, sequencing 
identifies it as a separate species in its own right.  Study 10 highlights the difficulty in 
species-specific assay design, with sequencing identifying new, genetically distinct 
species that are often morphologically indistinguishable from their relatives.  
 
Figure 19.  ITS1 sequences aligned in CLC Sequence Viewer. 
Primer and probe binding sites for the ‘A. fumigatus-specific assay’ in study 11(185) highlighted.  A single base 
mismatch in the reverse primer is highlighted. 
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Figure 20.  ITS1 sequences aligned in CLC Sequence Viewer. 
Primer and probe binding sites for the ‘A. flavus-specific assay’ in study 11(185) highlighted. 
 
 
Figure 21.  ITS1 sequences aligned in CLC Sequence Viewer. 
Primer and probe binding sites for the ‘A. niger-specific assay’ in study 11(185) highlighted. 
 
3.2.4 Primers characteristics and performance 
Efficiency of a PCR reaction determines analytical sensitivity and reliability in quantification 
of the assay.  A good PCR assays should have an efficiency of 90% or more, with 
optimisation making an efficiency of close to 100% fairly easy to achieve for most assays.  
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Efficiency of a PCR assay depends on a number of factors.  The most important factors are 
size of amplicon and absence of primer and amplicon secondary structures (193).  
Shorter amplicons generally result in a more efficient PCR, with amplicon sizes of below 
100-150bp optimal and 60-70bp amplicons increasingly common.  A comparison of 
amplicon size was made between the reviewed studies.  If the size of the amplicon or the 
exact location on the targeted sequence was not given in the paper, it was deduced from 
mapping the primers set on an A. fumigatus 18S ribosomal RNA gene sequence.  8 of the 10 
studies reported results from an assay with an amplicon size over 150bp.  A frequently used 
strategy in Aspergillus qPCR assay design is to adopt previously designed primers from 
conventional PCR assays, as used in study 7.  This approach leads to suboptimal qPCR as the 
amplicons are relatively large (greater than 500bp in assay 7), since the primary means of 
detection by “legacy” PCR is to separate amplicons by gel electrophoresis according to their 
size.  
Another reason for avoiding the use of “legacy” primers is that they have not been 
designed to avoid areas of target secondary structure.  Target accessibility to primer 
annealing is an important parameter that is best be checked in silico as efficient qPCR 
assays require primers annealing to areas of minimal secondary structure.  Useful analysis 
tools for determination of secondary structures of RNA or DNA molecules are found on the 
MFOLD web server (http://mfold.bioinfo.rpi.edu/).  MFOLD was used to determine the 
likelihood of primer binding at sites of secondary structure (160).  Folding of the amplicons 
from studies 2, 4, 5, 8, 9 and 10a (A. flavus, A. fumigatus and A. terreus) shows that primer 
binding is likely to occur at sites of secondary structure, as shown in Figure 22.  
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Figure 22.  MFOLD analysis results of analysed papers. 
Results display amplicons with primer binding sites at locations of secondary structure.  Primer binding 
locations shown (green). A. Study 2; B. Study 4; C. Study 5; D. Study 8; E. Study 9; F. Study 10a (A. flavus); G. 
Study 10a (A. fumigatus); H. Study 10a (A. terreus).  
 
Study 5 quotes a PCR efficiency of 77%, despite amplifying a short region of DNA (91bp); 
however, structure analysis of the assay reveals a large stem structure at the 3’-end of the 
amplicon.  This secondary structure incorporates 15 bases of the 22 base reverse primer 
binding site.  Formation of this secondary structure could reduce the ability of the primer to 
bind its target sequence, resulting in decreased product yield or a failed reaction.  It is likely 
that inefficient primer annealing at the site of secondary structure is reflected in the low 
PCR efficiency reported by this assay. 
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3.2.5 Type of standards 
Assay efficiency can be calculated from the slope of the standard curve using the following 
equation: 
 
PCR efficiency = 10 -1/slope -1 
 
The preparation of reliable standards is essential for qPCR, when the standard curve is used 
as a method for absolute quantification in unknown samples.  Accurate pipetting is 
essential for performing a dilution series and aliquots should be stored in low volume to 
minimize freeze-thawing and ensure the stability of the standards.  Genomic DNA and 
plasmids containing cloned target sequences are commonly used as standards in qPCR.  
Studies 4, 6, 8 and 10 use recombinant DNA, with dilutions of the purified plasmid target 
gene.  Extreme caution should be exercised when handling plasmid sequences, as they are 
present in a very high concentration and therefore pose a high risk for PCR contamination.  
Studies 1, 3 and 5 use genomic DNA, extracted from pure Aspergillus culture.  
Concentration of the target gene is calculated by identifying the genome size of the 
organism of interest, identifying the mass of DNA per genome using the equation: 
m = (n) (1.096e-21g/bp)        where n = plasmid size (bp), m = mass, e-21 = x10-21 
 
Then dividing the mass of the genome by the copy number of the gene of interest per 
haploid genome, calculating the mass of genomic DNA containing the copy numbers of 
interest. 
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A limitation of the use of genomic DNA or plasmid DNA in standard curve preparations is 
that they only reflect the analytical sensitivity of the qPCR itself.  As the DNA and plasmid 
dilutions are added directly to the PCR reaction, they do not control for issues of extraction 
efficiency or the effect of potential inhibitors in the clinical samples.   
Studies 7 and 9 use standards prepared by spiking known amount of Aspergillus conidia 
into human blood.  DNA is extracted prior to running the qPCR assay.  This method will 
assess the analytical sensitivity of the DNA isolation method in combination with the qPCR 
assay.  It will reflect the analytical sensitivity of the DNA isolation method in releasing 
Aspergillus DNA from fungal cells.  Hence, it is difficult to compare the performance of 
assays that use different type of standard, unless they are using identical DNA isolation 
protocols.  Study 2 uses both genomic DNA dilutions to assess qPCR assay sensitivity and 
conidia spiking dilutions in blood to assess extraction efficiency.                  
 
3.2.6 Assay efficiency and limit of detection (LOD) 
It is often impossible to ascertain the reliability of published data, as (i) NTC data are 
frequently omitted, (ii) detailed information about LOD is lacking or obscured to allow for 
so-called ‘background amplification’ and (iii) PCR efficiencies are not reported.  Despite 
being an essential piece of information about the performance of the assay, only studies 5, 
6, 8 and 10 had included their assay efficiency or the slope of the standard curve in their 
article.  An attempt was made to estimate the efficiency of Study 4, using the amplification 
plot (see Appendix 3). 
Study 4 had an estimated efficiency of 118%, which is theoretically impossible, rising to 
130% if the neat sample is excluded. This may be due to non-specific amplification (e.g. 
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primer dimers or secondary products), poor pipetting or both.  The broad range Aspergillus 
assays from studies 6 and 10 reported acceptable efficiencies of 91.6% and 95.8% 
respectively.   
Study 1 had the lowest reported LOD of 1 target gene copy.  However, this is reported at Cq 
41, which is very late and would suggest sub-optimal amplification efficiency.  Studies 2, 7, 
8 and 9 determined the LOD with conidia spiked in blood.  The LOD ranged from 5-20 
colony forming units (CFU) per ml of blood, which was equivalent to 0.5-6 CFU per PCR 
reaction. 
An efficient and reliable probe-based qPCR assay does not detect amplification in NTC 
wells.  Hence, the LOD is determined by the highest dilution of a standard curve that results 
in reliable amplification.  This can be as low as one copy of DNA, in which case Poisson’s law 
of small numbers predicts that six out of ten amplification replicates should be positive.  
The theoretical threshold should not be reported if it is greater than the results can actually 
demonstrate.  NTCs are essential to monitor contamination during the extraction stage.  
Amplification detected in these wells is either due to primer-dimers or contamination with 
target DNA.  Alternatively, the increase in fluorescence that is seen in the reaction may not 
be due to actual amplification; instead it may reflect degradation of the probe.  Despite 
NTC data being an essential piece of information about the performance of the assay, only 
5 of the 10 reviewed studies mention the use of NTCs.  Of these, only two studies actually 
report the results of the NTC reactions.  Study 7 reports that there was no amplification in 
the NTC wells.  Study 1 reports that all NTC reactions were negative.  However, in the 
context of their paper, this does not mean that there was no amplification in the NTC wells.  
This study ran their qPCR assay for 45 cycles and assigned a positive cut-off of Cq 41, which 
they calculated to be the LOD of the assay and approximately equivalent to a single copy of 
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the target 18S rRNA gene.  The authors did not claim that the NTCs did not amplify, merely 
that they crossed threshold at Cq>41.  Ideally, signal amplification should not be observed 
at all in the NTC wells.  If the NTCs do cross the threshold, their Cqs should be at least five 
cycles from the Cqs of a ‘positive’ sample (194).  Any amplification in an NTC well will 
complicate interpretation of results, particularly when fungal load in a clinical sample is low 
and detection occurs at the limits of sensitivity of the assay. 
 
3.2.7 Summary 
qPCR has become the most widely used molecular technology for diagnostic applications 
designed to detect and quantify pathogens.  Key reasons include its accessibility, sensitivity, 
specificity, and wide linear dynamic range.  One potential application is its use for the 
detection of IA, caused by Aspergillus fungi.  Although the high mortality rate associated 
with IA and complications in surviving patients make early diagnosis and treatment 
essential for adequate therapeutic management, its definitive diagnosis is hampered by the 
limited reliability of current diagnostic tools.  
A wide variety of methods, targeting different DNA regions, have been reported, each with 
its own merits.  In the setting of IA, it is vital to maximise assay efficiency for single target 
copy detection, with sufficient controls to monitor for contamination.  It is apparent from 
the reviewed studies that assays are falling short of their potential sensitivity and specificity 
due to inadequate design and controls.  Furthermore, it has become increasingly clear that 
PCR-based assays in general are compromised by their variable performance as well as lack 
of transparency in reporting experimental details.  These variables hinder the 
interpretation of diagnostic performance and so impede the widespread acceptance of 
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qPCR-based technology in clinical diagnostics.  These variables are addressed by the MIQE 
guidelines (195, 196). 
Together with optimization and ideally standardisation of sample collection and nucleic 
acid extraction methods, improved qPCR assay design and reporting are critical parameters 
to address, if endorsement by the EORTC/MSG is to be achieved for the diagnosis of IA. 
 
3.3 RESULTS: A MIQE-compliant real-time PCR assay for Aspergillus detection 
3.3.1 Assay characterisation 
3.3.1.1 Primers and amplicon 
Accession numbers were obtained for the target organisms A. fumigatus (Accession no FJ 
840490), A. flavus (Accession no: D63696), A. terreus (Accession no. DQ173743) and A. 
niger (Accession no. GQ338836), and aligned to identify suitable target sequences [Section 
2.3.1].  Primers and a probe with LNA modifications were designed by Beacon Designer, 
version 7.2 [Section 2.3.2].  Selected primer and probe sequences and binding sites are 
shown in Figure 23.  In silico analysis of primer binding sites was performed using Primer-
BLAST [Section 2.3.3].  Unsurprisingly, since there is 100% sequence identity across the 18S 
subunits of Aspergillus and Penicillium, the primers of the new assay amplify Paecilomyces 
and Penicillium species, including the clinically significant Talaromyces marneffei.  The 
assay probe does not provide sufficient specificity to exclude these species.  There is no 
significant similarity with other clinically relevant fungal pathogens and no similarity to the 
human genome. 
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The primers generate a 76bp amplicon.  Target secondary structures and primer/template 
accessibility were assessed using the MFOLD web server [Section 2.3.4].  Folding of the 
amplicon shows that the forward primer binding site is predicted to be free of secondary 
structure, as shown in Figure 24.  The program predicts secondary structure in the form of 
a stem loop at the 3’ end of the reverse primer binding site.  However, ΔG is -1.06, 
suggesting that formation of this double stranded state is unlikely to occur.  
 
Figure 23.  18S ribosomal RNA gene partial sequences aligned in CLC Sequence Viewer. 
Primer and probe binding sites for the new assay design highlighted. 
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Figure 24.  MFOLD analysis results of the new assay. 
Results display amplicon with primer binding sites shown (green).  Primer and probe sequences are shown.  
Upper case letters of probe sequence indicate position of LNA-incorporated oligonucleotides. 
 
3.3.1.2 Annealing temperature and primer concentration  
Optimal primer annealing temperature and primer concentration was investigated [Section 
2.4.1] using A. fumigatus DNA template [Section 2.2.2] and established a wide optimum 
primer annealing temperature range of 55-61.4°C (Table 2).  The annealing temperature 
was set at 59°C for subsequent reactions.  Optimal primer concentration was calculated to 
be 200nM of each primer.  
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Annealing temperature (℃) Cq values (cycles) 
65 29.5 
64.5 27.2 
63.3 25.1 
61.4 24.2 
59 24.1 
57 24.2 
55.7 24.5 
55 24.2 
Table 2.  Temperature gradient analysis of the primers with A. fumigatus DNA template. 
Analysis performed using SYBR Green. 
 
3.3.1.3 Analytical Specificity 
DNA was extracted from clinically relevant fungal isolates [Section 2.2.2] and qPCR 
performed under optimised conditions for hydrolysis probe reactions [Section 2.4.2], to 
evaluate the analytical specificity of the qPCR assay.  The assay detects A. fumigatus, A. 
flavus. A. niger, A. terreus and A. nidulans DNA (Figure 25); it does not detect C. albicans, C. 
dubliniensis, S. prolificans, F. solani and R. oryzae DNA.  No amplification was seen with 
human DNA (study blood samples [Section 2.1.1.4.3], DNA extracted [Section 2.2.3], tested 
negative by Aspergillus qPCR [Section 2.4.2] and positive by human β-globin qPCR]) or in 
any NTC well [Section 2.4.4].  
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Assay specificity was validated using SYBR Green I chemistry and melt curve analysis 
[Section 2.4.1] of A. fumigatus genomic DNA, indicating a melting temperature of 77°C for 
the target amplicon (Figure 26).  PCR products were analysed [Section 2.4.8], suggesting 
amplification of the appropriate target sequence.  
 
 
Figure 25.  18S assay amplification curve for Aspergillus species. 
A. flavus (green trace), A. terreus (red trace), A. nidulans (purple trace), A. fumigatus (blue trace) and A. niger 
(black trace).  A. flavus and A. terreus were assayed at similar concentration (2x10
5
 genomes load). In order to 
make the amplification plots more visible, A. nidulans and A. fumigatus were run at 6x10
4
 and A. niger at 
1.5x10
4
 genomes loaded. 
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Figure 26.  Dissociation (melt) curve analysis of amplification products. 
A. fumigatus genomic DNA dilutions of 2 ng (6x10
4
genomes), 200 pg (6x10
3
 genomes) and 20 pg (6x10
2
 
genomes).  Melting temperature of 77°C. 
 
3.3.2 PCR efficiency/ analytical sensitivity 
A. fumigatus DNA was extracted from a clinical isolate [Section 2.2.2] and qPCR performed 
under optimized conditions for hydrolysis probe reactions [Section 2.4.2], to calculate PCR 
efficiency, the linear range of the assay and the limits of detection and quantification 
[Section 2.4.3].  PCR efficiency range was 95-107% (Figure 27).  Dilutions spanned six orders 
of magnitude from 2ng (6x104 genomes) to 20fg (0.6 genomes).  0.6 genomes give rise to 
an appropriate amplification product in every assay. 
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Figure 27.  Eight standard curve plots, generated using A. fumigatus genomic DNA. 
 
3.3.3 Reproducibility 
Reproducibility was high across all six orders of magnitude, with an inter-run standard 
deviation that ranged from 0.37 at an average Cq of 20.66 (for 6x104 genomes load) to 0.97 
at an average Cq of 37.77 (for 0.6 genome load).  Limits of quantification and detection 
were calculated as 6 and 0.6 A. fumigatus genomes, respectively.   
 
3.3.4 Clinical Evaluation 
3.3.4.1 Histological material 
Histological material was obtained from three patients with haematological malignancies 
[Section 2.1.1.4.4].  Total DNA was extracted from these samples [Section 2.2.1] and used 
to evaluate the Aspergillus qPCR assay [Section 2.4.2], with all extracts loaded in duplicate 
wells (Table 3).  A post-mortem lung biopsy (sample A) and an ante-mortem brain biopsy 
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(sample B), from two patients with proven IA, amplified with mean Cqs of 24.6 and 31.5, 
respectively.  Referring to the standard curve, this equates to 35 and two A. fumigatus 
genome equivalents/ng DNA extract, respectively.  A control post-mortem lung biopsy with 
no evidence of fungal infection (sample C), did not amplify.   
 
Tissue 
sample 
Diagnosis Mean Cq DNA load of 
extract (ng/µl) 
A. fumigatus genome 
equivalents/ng DNA 
extract 
A Proven IA 24.6 83 35.5 
B Proven IA 31.5 13 1.8 
C No fungal infection Negative 172 0 
Table 3.  qPCR results when testing DNA extracts from histological samples. 
A (post-mortem lung biopsy), B (ante-mortem brain biopsy) and C (post-mortem lung biopsy).  Genome 
equivalent of PCR result calculated from A. fumigatus standard curve plot. 
 
3.3.4.2 Inhibition testing  
Each of the DNA extracts from histological material was included in a SPUD assay [Section 
2.4.6] and results indicated that no inhibition was present in these samples (Figure 28). 
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Figure 28.  SPUD assay amplification curve for histological samples. 
Samples A, B and C (blue traces).  Reference Cq value for the SPUD amplicon, characteristic of an uninhibited 
assay (red trace).  
 
3.4 DISCUSSION 
This chapter describes 3 key findings; 
 the lack of rigorous standards of practice has resulted in widespread publication of 
poor qPCR data, resulting in inappropriate conclusions  
 In the context of reliable detection of pathogens in general, and Aspergillus in 
particular, the major limitation of qPCR is the lack of standardisation at every stage of 
the molecular process from sample type and processing to interpretation of results 
 when optimised, qPCR is an extremely sensitive and highly specific tool to aid in IA 
diagnosis 
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PCR is widely used as a diagnostic tool in clinical laboratories and is particularly effective for 
detecting and identifying infectious agents for which routine culture and microscopy 
methods are inadequate.  Aspergillus-specific qPCR assays have been proposed as 
alternatives to conventional diagnostic procedures for IA, where early diagnosis and 
treatment are critical (114, 177, 197).  However, the EORTC/MSG do not endorse the 
routine use of PCR in the defining of IA (50).  There are several reasons for this: (i) disparate 
chemistries that include the use of SYBR Green (198), although it lacks the required 
specificity for use in clinical diagnostic assays (186), hydrolysis probes (179, 181, 199), 
hybridisation probes (180) and molecular beacons (175, 200); (ii) variability of targets (28S, 
18S and ITS2) (114, 181, 201); (iii) sample-specific instrument-dependent variability (116, 
118), including contamination-prone nested PCR methods aimed at enhancing analytical 
sensitivity (169, 180).   
Aspergillus qPCR assay design has also been hampered by the use of primers designed for 
conventional PCR assays (180, 182, 201).  This can lead to suboptimal qPCR as the 
amplicons are relatively large and no structural analyses of primers or primer binding sites 
have been carried out.  These parameters have a strong influence on PCR efficiency and 
determine analytical sensitivity and reliability of quantification (193).  Hence it is not 
surprising to note that one report quotes a PCR efficiency of 77% (180), despite amplifying 
a short region of DNA (91bp).  Structure analysis (160) of the amplicon revealed a large 
stem structure at its 3’-end.  In a setting that requires low copy number detection, it is vital 
to have contamination assessment at the DNA extraction stage.  Negative extraction 
controls (no DNA template present) are extracted alongside clinical samples, to detect any 
cross contamination or environmental contamination.  A significant number of studies fail 
to use or report the use of negative extraction controls to monitor contamination during 
the extraction stage and, even if they do, they are usually water-only, as opposed to 
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controls that have similar properties to the clinical sample but without target nucleic acid 
(166).  Ideally, biological (sample) replicates should also be included, especially when the 
qPCR results suggest very low levels of fungal DNA.  Even though it is well known that PCR 
inhibitors can reduce product yield and even result in complete failure of the PCR, only just 
over half of the studies evaluated by Khot et al (166) reported the use of some form of an 
inhibition control, also referred to as an amplification control.  
With any assay targeting Aspergillus, the risk of procedural contamination is high, and false-
positive results may arise due to the ubiquitous nature of fungi in the environment, as well 
as product carryover from positive samples or from cross-contamination by PCR products 
from earlier experiments (166).  Therefore, rigorous procedures were instituted for the 
monitoring of contamination during sample handling, DNA extraction and PCR set up 
[Sections 2.2, 2.4.4 and 2.4.5].  Reagents were tested for contamination on a regular basis 
and a separate biosafety cabinet was used for the reaction setup.  Multiple negative 
controls were included, i.e. samples that are as similar to the test samples as possible but 
exclude the target.  The SPUD assay (161) was used, as inhibition assessment is mandatory 
for all clinical diagnostic qPCR assays.  The inclusion of such rigorous experimental controls 
has enabled the avoidance of procedural false positivity and false negativity. 
This chapter describes the development of an assay that is not just rapid, sensitive and 
specific, but that rigorously complies with the MIQE guidelines, both in design and in its 
reporting.  The resulting assay satisfies all of these criteria essential for a clinically useful 
molecular assay: 
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A. Speed: Following extraction of DNA, results from the qPCR assay are available within 60 
min. The development of fast PCR reagents, together with the use of smaller reaction 
volumes and novel thermocyclers has the potential to reduce this to below 5 minutes. 
Indeed, the fastest PCR currently completes 30 cycles in 17 seconds (Carl Wittwer, pers. 
commun.) 
 
B. Sensitivity: analytical sensitivity is a critical parameter of any diagnostic qPCR assay 
since the fungal load in the blood of patients with IA is believed to be very low (30-
100fg/µl or less) (180, 199, 202, 203).  Analytical sensitivity refers to the smallest 
number of nucleic acid molecules that can be detected and distinguished from a zero 
result.  This is best done using a standard curve, which defines the range of the assay 
and hence the upper and lower target concentration that can be reported. The new 
assay design presented in this chapter targets an amplicon devoid of secondary 
structure, has been extensively optimised, is linear over at least six logs of template 
concentration and has an efficiency close to 100%. Its limit of quantification is 6 
Aspergillus fumigatus genomes, whereas its limit of detection is 0.6 genome copies. 
Since a single A. fumigatus genome contains between 38 and 91 target rDNA sequence 
copies (189), this suggests the new assay can detect as few as 23 target copies (189).  
 
C. Specificity: analytical specificity is determined by identifying the percentage of samples 
without the target sequence that generate a positive result.  If a well-designed assay is 
used, in the absence of contamination, this will be zero.  In a qPCR experiment all 
detectable products, be they specific or non-specific, contribute to the final 
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amplification plot and hence any qualitative or quantitative result.  Post reaction melt 
analysis using SYBR Green I dye confirmed the specificity of the assay, since it resulted 
in a single peak and sequencing of the amplicons confirmed the amplification of 
Aspergillus target sequences.  The assay designed in this chapter is a pan-Aspergillus 
assay since A. fumigatus is implicated in only up to two thirds of cases of IA.  
Importantly, the assay does not amplify human DNA or fungal DNA extracts from 
Candida, Fusarium, Scedosporium or Rhizopus species, well-characterised pathogens of 
immunocompromised (and immunocompetent) patients. Unsurprisingly, since there is 
100% sequence identity across the 18S subunits of Aspergillus and Penicillium, 
Penicillium DNA is also amplified.   
 
D. Cost: Excluding the expense of a thermocycler, the cost of running this Aspergillus-
specific assay including the use of spin column DNA extraction, qPCR reagent and 
plastics cost is less than USD 500 per 96 reactions.  In comparison, the Platelia 
Aspergillus galactomannan antigen test (Bio-Rad Laboratories), which is included in the 
EORTC/MSG criteria for the likelihood of IFD (50) has a list price of approximately USD 
770 for 96 reactions. 
 
The new qPCR assay was evaluated on histological material from two cases of proven IA 
with A. fumigatus (see Table 3).  
All relevant parameters have been reported, clearly demonstrating the huge potential 
qPCR has as a tool for the early diagnosis of IA.  However, reliable diagnosis of IA depends 
on at least two factors in addition to the quality of the qPCR.  The first is sample quality: 
  
139 
 
sample collection, preparation and transport as well as nucleic acid extraction methods are 
critical parameters in test performance and must be optimised and, ideally, standardised.  
In principle, extraction of fungal nucleic acids, especially if present in a cell-free state, from 
BAL fluid, blood and serum is relatively straightforward; however, it is easy to co-purify 
inhibitors of the PCR that will generate inconsistent and unreliable results.  Hence dilution 
curves are recommended for every sample to highlight contamination. Secondly, regular 
calibration of the real-time instrument is crucial for obtaining consistent and accurate 
results.  Quantification cycle (Cq) values are neither absolute nor invariant, but vary 
between assays carried out on different days with different reagents, different users or on 
different instruments.  This is because the Cq depends on the instrument’s threshold 
setting, which in turn depends on background fluorescence, which varies with different 
probes, chemistries, instruments and assay protocols.  Finally it is important to emphasise 
that a definitive identification of Aspergillus in clinical samples relies on histology, as this is 
the only direct evidence for invasion of the tissue (50, 51).  Therefore, an assessment of the 
clinical utility of any molecular assay, for detection of Aspergillus, is challenging (204) and 
will require prospective studies. 
 
 
  
  
140 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
DEVELOPMENT OF A COMBINATION BIOMARKER DETECTION 
APPROACH TO IPA DIAGNOSIS 
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4.1 BACKGROUND 
Invasive fungal disease (IFD) is a significant risk to haematology patients, due to their 
underlying disease and its treatment, which lead to periods of prolonged 
immunosuppression (205).  IA is the most common cause of mortality due to infectious 
disease in patients with haematological malignancy (206, 207) and early diagnosis and 
treatment are vital for improving outcomes (208).  However, early diagnosis is hampered 
by the limitations of current biomarker assays, together with a lack of consensus on the 
best sampling site for early detection; both in terms of practicability and the sensitivity of 
detection.    For these reasons, together with the high morbidity and mortality associated 
with delayed diagnosis, an empiric treatment strategy has become the standard of care in 
many haematology units, in the setting of persistent, unexplained fever despite antibiotic 
therapy (209).  This approach exposes many patients who do not have IFD to antifungal 
drugs,  with the associated drug toxicities, a potential impact on their subsequent 
management once labelled as having had an IFD; while healthcare systems are exposed to 
spiralling drug costs (210). 
These considerations have prompted attempts to optimise and standardise the use of 
existing assays (50, 51, 89, 114, 117) and develop new antigen-based technologies (119) to 
serve as additional tools for rapid and early diagnosis of IA.   
Aspergillus detection has been most extensively investigated in blood; a preferred sample 
due to minimally invasive sampling and potential for serial monitoring.  Detection of 
circulating serum GM has generated variable results, with a recent meta-analysis of 27 
studies concluding that GM is moderately useful for surveillance of patients with IA (89).  
However, significant heterogeneity was observed between studies, which depended largely 
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on the patient population and the type of reference standard used.  Sensitivity and 
specificity of 71% and 89% were reported when considering only proven cases as ‘true 
positive’ for IA.  Positive predictive value (PPV) was calculated for a range of prevalence 
estimations, with the highest PPV calculated as a disappointing 62%, at a prevalence 
estimation of 20%.  With IA prevalence in the setting of patients with haematological 
malignancy ranging from 1-15% (211), this assay is best for ruling out disease, rather than 
making a positive diagnosis.  Two further reviews (212, 213) confirmed the reported 
heterogeneity between studies, with a wide range of reported assay sensitivities.  Reasons 
for this included the effects of antifungal prophylaxis and variations in testing protocol, 
including frequency of testing, the cut off used to assign positivity and the number of 
positive sera results required to define IA.  A further reason is the lack of reproducibility 
from repeat testing of the same serum sample, including long term storage (214), but also 
short term storage of under 7 days (215, 216).  These reports raise doubts about the 
interpretation of data from stored samples, as well as real-time testing for patient 
management using GM.  However, a recent report claims the long term stability of GM in 
serum and BAL fluid samples stored at -20°C (217). 
Attempts to improve diagnostic sensitivity have led to investigation of respiratory samples, 
as Aspergillus infections are primarily air-borne pulmonary infections, with secondary 
haematogenous dissemination.  BAL fluid from an established guinea pig model gave a GM 
positive result 2 days sooner than serum (218).  GM levels remained elevated in another 
guinea pig model of IA, in the presence of antifungal therapy, whilst assay sensitivity in 
serum was reduced (121).  These findings are consistent with reports of reduced GM assay 
sensitivity in patients receiving antifungal therapy (219).  A recent meta-analysis of 30 
studies evaluating BAL GM for IA diagnosis reported a pooled sensitivity and specificity of 
87% and 89% using a cut off of 0.5 (220).   Increasing the cut off to 1.0 gave a higher 
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specificity of 95%, whilst maintaining a superior sensitivity to serum testing.  However, the 
included studies varied widely in the chosen cut off value, definition of a ‘true positive’ 
(Proven/probable VS proven only), likelihood scoring (EORTC 2002 VS 2008 criteria, with or 
without modifications) and the underlying disease of the study population.  This resulted in 
significant variation in reported sensitivity (from 33-100%) and specificity (from 50-100%). 
The Aspergillus-specific mAb JF5 has been used in an immunochromatographic LFD for 
point of care diagnosis of IA (119).  Diagnostic utility of the LFD was demonstrated in a 
guinea pig model of infection, showing superior sensitivity and specificity when compared 
to serum GM (120).  Limited clinical evaluation of the LFD in serum has given variable 
results, with sensitivity reported as 82% in a haematological malignancy population (126) 
and 40% in an HSCT population (127).  An evaluation of the LFD in 39 BAL fluids from a 
mixed haematology and SOT population reported sensitivity and NPV of 100%, and 
specificity of 81% (123). 
Real time PCR has been extensively used in the development of IA detection assays.  
However, there are no externally validated methods for PCR-based diagnosis and the lack 
of standardisation of protocols has been highlighted and extensively discussed in Chapter 
3.  
Evaluation of these assays in combination has revealed improved sensitivity and PPV, 
without significant loss of specificity (126, 138, 221, 222).  The EORTC/MSG published 
definitions for IFD to facilitate clinical studies and research (50, 51); however, these 
definitions were not designed for clinical management.  Due to the difficulty in establishing 
the gold standard diagnosis of proven IPA, the EORTC/MSG criteria have been used 
extensively to evaluate the performance of diagnostic methods (123, 126, 127, 220, 223).  
Publications have highlighted the poor diagnostic performance of the original EORTC/MSG 
  
144 
 
definitions when compared to autopsy examination (224, 225), as well as the revised 
definitions (52, 226).  This raises doubts as to the use of the EORTC/MSG criteria, an 
imperfect reference standard, to assess new diagnostic approaches. 
Whilst there is considerable heterogeneity in the reported diagnostic performance of 
individual assays , there is a general consensus that i) BAL fluid is a suitable sample for early 
IA diagnosis  due to its superior sensitivity to serum testing, ii) a combination of biomarker 
assays provides an optimal testing strategy.   
This chapter first describes a series of experiments that were performed to clarify the 
effects of sample storage on the repeatability of GM levels using the Platelia Aspergillus 
enzyme immunoassay (PA-EIA, Bio Rad, Marnes-la-Coquette, France).  Next, a series of 
experiments is described that assessed the feasibility of a combination biomarker testing 
approach in BAL fluid from CT-guided bronchoscopy, to diagnose IPA.  The best biomarker 
combination was then selected as a proposed diagnostic-driven testing approach to patient 
management, to direct antifungal treatment to patients with evidence of invasive fungal 
disease and used to evaluate the diagnostic performance of the EORTC/MSG criteria, using 
BAL fluid from patients with haematological malignancy.  In order to highlight the 
inappropriate use of the EORTC/MSG criteria to evaluate the performance of diagnostic 
methods, the performance of the biomarker assays, individually and in combination, was 
evaluated using the EORTC/MSG criteria as the reference standard.  Finally, the diagnostic 
performance of the biomarker assays was evaluated in corresponding blood samples. 
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4.2 RESULTS  
4.2.1 Significant decline in galactomannan signal during storage of clinical serum 
samples 
Serum and BAL fluid samples were collected from patients in the Division of Haemato-
Oncology at St Bartholomew’s Hospital undergoing serum GM monitoring in a screening 
strategy throughout their episode of intensive chemotherapy [Section 2.1.1].  Samples 
were selected as described in Section 2.5.1 to form the Long-term (LT) storage and Short-
term (ST) storage test groups.  GM detection was performed by PA-EIA [Section 2.5].  
 
4.2.1.1 Scatter Plot 
Data from serum testing were presented on a scatter plot and analysed as described in 
section 2.9.1.1.  Figure 29 shows that there was a clear loss of GM signal in both the ST and 
LT serum, with the signal loss more apparent in the plot including only the first sample 
taken from each patient (Figure 29A) than in the plot including all serum data (Figure 29B). 
Repeated samples from the same patient may mask the loss of signal in both ST and LT 
stored sera.  Loss of GM signal was higher in LT than ST stored samples.  BAL fluid samples 
did not show GM signal loss following either in ST or LT storage (Figure 29C).  Importantly, 
the removal of the two outlier values from Figures 29A and 29C does not change the shape 
of the relationships significantly. 
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Figure 29.  Scatter plot with fractional polynomial lines for reduction in GM level. 
Diagonal solid lines indicate the line of equality. (A) GM serum level excluding repeat sera from patients with 
multiple samples; (B) GM serum level including multiple samples from the same patient; (C) GM BAL level (no 
repetition) during short-term and long-term storage. 
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4.2.1.2 Statistically significant reductions in GM signal 
Serum samples (without repetition): The Wilcoxon Signed Rank Sum Test [Section 2.9.1.1] 
applied to the first sample from each patient, showed statistically significant reductions in 
GM signals both in the ST storage (n = 65, median GM1 index: 0.65, median GM2 index: 
0.19; p < 0.001) and in the LT storage (n = 35, median GM1 index: 0.56, median GM2 index: 
0.10; p < 0.001), as shown in Table 4.  In total, 44/65 (68%) ST and 31/35 (89%) LT serum 
samples showed a reduction in GM signal upon repeat testing.  
In the ST serum group, 65.2% of samples that were initially GM positive became GM 
negative on repeat testing; with an average GM signal reduction of 50.2% in samples that 
were initially GM positive. In the LT serum storage group, 67.9% of GM positive samples 
became GM negative on repeat testing; with an average GM signal reduction of 49.3%.  
To ascertain the stage at which GM signal loss occurred, repeat testing in a subset of GM 
positive samples (n = 14) was performed following ST storage from the original serum 
sample or using the EDTA pre-treated sample.  All EDTA pre-treated samples remained 
positive.  In contrast 9/14 (64%) of repeats from the original serum sample became 
negative. 
 
 
Sample 
size 
Samples with GM 
reduction 
Median GM1 
index 
Median GM2 
index 
p-
value  
Short-Term 
Serum 
65 44 0.65 0.19 <0.001 
Long-Term 
Serum 
35 31 0.56 0.10 <0.001 
Table 4.  Results of the Wilcoxon Rank Sum Test. 
Analysis was applied to both ST and LT stored serum populations.  GM1 = first GM assay run.  GM2 = repeat GM 
assay run. 
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4.2.1.3 Assay Repeatability  
The OD value of the threshold control, loaded in duplicate, was recorded for 40 randomly 
selected assay runs (Figure 30) and used to determine the intra- and inter-assay variability 
[Section 2.9.1.2].  The duplicate values of the OD were repeatable as most of them are 
close to the line of equality and all measurements were within the recommended limits 
(OD 0.3–0.8).  The mean OD of the 40 threshold control measurements was 0.49, with 
range 0.33–0.69.  The coefficient of variation for duplicate measures was 7.09, which 
confirms repeatability.  
 
Figure 30.  Scatter plot for repeatability of the threshold control. 
Controls provided with the PA-EIA kit were loaded in duplicate wells (GM Index 1 and GM Index 2) over 40 
randomly selected assay runs. Diagonal solid line indicates the line of equality. 
 
 4.2.1.4 Summary 
The international EORTC/MSG mycological criteria for defining IA include serum and BAL 
fluid GM results as key diagnostic criteria (51). These are routinely obtained using the PA-
EIA, which provides non-invasive, quantitative Aspergillus-specific detection for serum GM. 
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Recent reports have raised concerns with regard to the repeatability of GM levels.  The 
results presented in this chapter confirm these doubts and broaden these findings by 
establishing a lack of repeatability of serum GM testing of the same sample.  A clinically 
significant reduction in GM reactivity was recorded, with two thirds of GM positive sera 
becoming negative following ST or LT storage.  This phenomenon was not seen with repeat 
GM testing of BAL fluid following ST or LT storage.  We have published our rate of IFD in 
haemato-oncology at Barts Health, using the EORTC/MSG criteria of probable/proven IFD, 
which are usually regarded as representing true cases, as only 8/589 episodes (1.4%) by 
2008 and 20/589 (3.5%) by 2002 criteria (52).  It has been previously reported (227) that 
the decrease in GM values after retesting was much more pronounced in those samples 
with initially false positive GM results.  Clearly, in the results presented in this chapter, the 
phenomenon of GM signal loss cannot be correlated to the EORTC/MSG criteria of IFD 
given the much higher frequency GM signal loss in both ST and LT data sets. 
The OD value of the threshold control is critical in the calculation of the GM index value of 
clinical samples.  Repeatability of the OD of the threshold control was confirmed by the CV 
for duplicate measures.  These data indicate that technical issues per se cannot explain the 
observed GM signal loss in clinical samples.  Furthermore, extensive review of the technical 
performance of the assay by different operators was undertaken, in conjunction with Bio-
Rad, including monitoring of heating block temperature and plate washer performance.  No 
concerns were identified.  Although environmental contamination is a risk during testing, 
the presented data are not consistent with contamination, which would lead to random 
increases or decreases with repeat testing.  In contrast, the data show a consistent pattern 
of signal loss, with the first reading being higher than the repeat.  In addition, sporadic 
repeat testing of GM negative serum samples never gave a positive result. 
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The repeatability of the OD of the threshold control suggests that the observed GM signal 
loss was specific to clinical serum samples.  Interestingly, following ST storage of sera, the 
GM signal loss was not seen if the repeat was performed using EDTA pre-treated samples 
from the first step of the testing protocol, all of which remained positive.  Although the 
mechanisms of GM decline in clinical serum samples are unclear, they appear to occur in 
the original serum sample prior to the EDTA pre-treatment stage.  The data do not permit 
specification of an acceptable storage time without major signal loss, but it can be 
concluded that serum signal loss is associated with storage, and that it is therefore 
important to minimise the time from phlebotomy to the EDTA stage of processing.  Further 
work needs to be done to determine whether short term storage without major signal loss 
is possible.  
 
4.2.2 Combination biomarker diagnosis of IA in BAL fluid 
This study was a retrospective evaluation of biomarker performance for IPA diagnosis, with 
no impact on patient management.  The Study cohort of patients were a subset of those 
recruited in an observational study of IPA diagnosis in the Division of Haemato-Oncology, St 
Bartholomew’s Hospital [Section 2.1.1], based on the availability of BAL samples and full 
clinical data.  25 BAL fluid samples from 24 adults at high risk of IFD following intensive 
chemotherapy or allogeneic stem cell transplantation were included in this study.   
The performance of three biomarker assays were evaluated; the Aspergillus LFD [Section 
2.6], GM assay [Section 2.5] and the new MIQE-compliant Aspergillus qPCR [Chapter 3, 
section 3.3].  Total DNA was extracted for qPCR analysis, as described in section 2.2.3. 
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Assay sensitivity was ascertained using BAL samples from a  ‘gold standard’ proven IPA 
cohort of 11 BAL fluids from 10 patients, obtained at routine diagnostic work-up at the 
Innsbruck University Hospital between January 2008 and November 2012 [Section 2.1.2].  
Specificity was calculated from BAL samples from a negative control cohort from the same 
institution - 16 BAL samples from 16 adults without any EORTC/MSG risk factors for IFD, in 
whom routine diagnostic procedures were negative for IPA (microscopy, culture and local 
GM testing and Aspergillus PCR). 
 
4.2.2.1 Assay sensitivity 
Results of qPCR, LFD and GM testing in the gold standard proven IPA cohort are shown in 
Table 5.  The sensitivity of the qPCR assay and the LFD were both 100%.  The sensitivity of 
the GM assay was 81.8% (GM Index ≥0.8) or 72.7% (GM Index >1.0).  There was 100% 
agreement between the qPCR and LFD assays.  The calculation of agreement with the GM 
assay is not possible as all samples are positive based on LFD and qPCR.  
Sample LFD result GM result (0.8) GM result (1.0) qPCR result  
Proven 1 Positive Positive Positive Positive 
Proven 2 Positive Positive Positive Positive 
Proven 3 Positive Positive Positive Positive 
Proven 4 Positive Positive Positive Positive 
Proven 5 Positive Positive Positive Positive 
Proven 6 Positive Negative Negative Positive 
Proven 7* Positive Positive Positive Positive 
Proven 8* Positive Negative Negative Positive 
Proven 9 Positive Positive Positive Positive 
Proven 10 Positive Positive Positive Positive 
Proven 11 Positive Positive Negative Positive 
Assay 
Sensitivity 100% 81.82% 72.73% 100% 
Table 5.  Testing results and sensitivity of assays in the gold standard proven IPA cohort. 
 (N=11). *samples from the same patient. 
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4.2.2.2 Assay specificity 
Results of qPCR, LFD and GM testing in the negative control cohort are shown in Table 6.  
The specificity of all 3 assays was 93.75%.  The pair-wise agreements of three assays were 
100%.    
 
Sample LFD result 
GM result 
(0.8) 
GM result 
(1.0) 
qPCR 
result  
Negative 1 Negative Negative Negative Negative 
Negative 2 Negative Negative Negative Negative 
Negative 3 Positive Positive Positive Positive 
Negative 4 Negative Negative Negative Negative 
Negative 5 Negative Negative Negative Negative 
Negative 6 Negative Negative Negative Negative 
Negative 7 Negative Negative Negative Negative 
Negative 8 Negative Negative Negative Negative 
Negative 9 Negative Negative Negative Negative 
Negative 10 Negative Negative Negative Negative 
Negative 11 Negative Negative Negative Negative 
Negative 12 Negative Negative Negative Negative 
Negative 13 Negative Negative Negative Negative 
Negative 14 Negative Negative Negative Negative 
Negative 15 Negative Negative Negative Negative 
Negative 16 Negative Negative Negative Negative 
Assay 
Specificity 93.75% 93.75% 93.75% 93.75% 
Table 6.  Testing results and specificity of assays in the negative control cohort. 
 (N=16). 
 
4.2.2.3 Combination testing approach to clinical diagnosis of IPA 
Results of qPCR, LFD and GM testing in the Study cohort are shown in Table 7. Microscopy, 
including calcofluor staining, and mycological culture of all BAL fluids were negative for 
evidence of Aspergillus.  However, 5/25 samples were positive for all three biomarkers, 
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while 15/25 were negative with all three assays.  Based on the high sensitivity and 
specificity of triple testing in the gold standard proven IPA and negative control cohorts, 
the following test interpretation and clinical action are suggested (see Table 7): a positive 
result for all 3 tests indicates IPA and antifungal treatment is advised;   if all 3 tests are 
negative, IPA is excluded and antifungal treatment should be withheld in a stable patient.  
However, a negative result does not rule out non-Aspergillus IFD and further investigation 
is required if IFD is still suspected.   
Pairwise comparison of tests [Section 2.9.2.1] showed that the highest level of agreement 
was between qPCR and LFD, with a Kappa value of 0.88 (almost perfect agreement, see 
Table 8).  All other pairs of biomarkers, regardless of the GM threshold used for positivity 
(≥0.8 or >1.0), showed significantly less agreement.  Based on this result, it is suggested 
that agreement between LFD and qPCR tests determines the clinical interpretation in the 
face of a discrepant GM result.  This is reflected in the results of Study samples 7-10, in 
which an LFD negative/qPCR negative/GM positive result is interpreted as negative for IPA 
and withholding of antifungals is advised.  Disagreement between LFD and qPCR tests was 
seen in Study sample 6 only and interpreted clinically as inconclusive and further clinical 
investigation would be advised. 
24 of the 25 Study BAL samples were collected after commencing antifungal therapy.  
Median time from antifungal start to bronchoscopy was 5.5 days in combination test 
negative samples (range 1-69 days) and 6 days in combination test positive samples (range 
4-8 days). 
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Sample LFD result GM 
result 
(0.8) 
GM 
result 
(1.0) 
qPCR 
result  
Test 
interpretation 
Suggested action 
1 Positive Positive Positive Positive Positive Treat for IPA 
2 Positive Positive Positive Positive Positive Treat for IPA 
3 Positive Positive Positive Positive Positive Treat for IPA 
4 Positive Positive Negative Positive Positive Treat for IPA 
5 Positive Positive Negative Positive Positive Treat for IPA 
6 Positive Negative Negative Negative Inconclusive Repeat tests/further clinical 
investigation required 
7 Negative Positive Positive Negative Negative Withhold/stop antifungal treatment* 
8 Negative Positive Positive Negative Negative Withhold/stop antifungal treatment* 
9 Negative Positive Positive Negative Negative Withhold/stop antifungal treatment* 
10 Negative Positive Negative Negative Negative Withhold/stop antifungal treatment* 
11 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
12 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
13 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
14 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
15 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
16 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
17 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
18 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
19 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
20 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
21 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
22 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
23 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
24 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
25 Negative Negative Negative Negative Negative Withhold/stop antifungal treatment* 
Table 7.  Testing results and suggested clinical interpretation in the Study cohort. 
(N=25). 
*unless a non-Aspergillus IFD is still suspected. 
 
Test Cohen's Kappa (95% CI) 
LFD+qPCR 0.88 (0.66-1.0) 
LFD+GM (0.8) 0.53 (0.18-0.88) 
LFD+GM (1.0) 0.34 (-0.08-0.76) 
qPCR+GM (0.8) 0.62 (0.30-0.93) 
qPCR+GM (1.0) 0.42 (-0.004-0.84) 
Table 8.  Pairwise agreement of tests in the Study cohort. 
 (N=25). 
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4.2.2.4 Diagnostic performance of EORTC/MSG criteria   
The EORTC/MSG criteria were evaluated against the LFD+qPCR clinical biomarker diagnosis 
of IPA as described in section 2.9.2.2.  The EORTC/MSG 2008 scores, with and without GM, 
in the Study cohort are shown in Table 9, along with the results of the dual LFD/qPCR 
combination as the best biomarker pairing.  Performance parameters for the EORTC/MSG 
scoring criteria (with and without GM) were evaluated against the dual LFD/qPCR approach 
as the proposed standard, to direct antifungal treatment to patients with evidence of IPA 
(Table 10).  The low sensitivity values suggest that the EORTC/MSG definitions are 
inappropriate for IPA diagnosis. 
Sample Dual LFD/qPCR interpretation EORTC/MSG 2008 EORTC/MSG 2008 (excluding GM) 
1 Positive None None 
2 Positive None None 
3 Positive None None 
4 Positive Probable Possible 
5 Positive Probable Probable 
6 Inconclusive None None 
7 Negative None None 
8 Negative None None 
9 Negative None None 
10 Negative Probable Probable 
11 Negative None None 
12 Negative None None 
13 Negative None None 
14 Negative None None 
15 Negative None None 
16 Negative None None 
17 Negative None None 
18 Negative None None 
19 Negative None None 
20 Negative Possible Possible 
21 Negative Possible Possible 
22 Negative Possible Possible 
23 Negative Possible Possible 
24 Negative Possible Possible 
25 Negative Probable Probable 
Table 9.  EORTC/MSG 2008 classification in the Study cohort (N = 25). 
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Test % Sensitivity 
(95% CI) 
% Specificity 
(95% CI) 
PPV (95% CI) NPV (95% CI) 
EORTC  
(Probable vs 
Possible/None) 
40.00  
(6.49-84.60) 
89.47 
 (66.82-98.39) 
50.00  
(8.30-91.70) 
85.00  
(62.08-96.62) 
EORTC excluding GM 
(Probable vs 
Possible/None) 
20.00  
(3.30-71.19) 
89.47  
(66.82-98.39) 
33.33  
(5.47-88.45) 
80.95  
(58.08-94.44) 
EORTC 
(Probable/Possible vs 
None) 
40.00  
(6.49-84.60) 
63.16 
(38.38-83.65) 
22.22  
(3.47-59.94) 
80.00  
(51.91-95.43) 
EORTC excluding GM 
(Probable/Possible vs 
None) 
40.00  
(6.49-84.60) 
63.16  
(38.38-83.65) 
22.22  
(3.47-59.94) 
80.00  
(51.91-95.43) 
Table 10.  Performance parameters for the EORTC/MSG criteria (with and without GM included), in the Study 
cohort (N=25), using dual LFD/qPCR testing as the gold standard for clinical diagnosis of IPA. 
 
4.2.2.5 The use of EORTC/MSG scores as a reference standard to evaluate the 
performance of biomarker assays 
Diagnostic performance of the individual and combination biomarker assays was evaluated 
in the Study cohort, using the EORTC/MSG (excluding GM) criteria as the gold standard 
[Section 2.9.2.3].  Results are shown in Table 11.  The small sample size together with the 
disagreement between the assay results and the EORTC/MSG definitions are reflected in 
the low assay sensitivity results.  These poor performance statistics are in stark contrast to 
the high sensitivity and specificity obtained in the gold standard and negative control 
cohorts [Sections 4.2.2.1 and 4.2.2.2], suggesting that the EORTC/MSG definitions are 
inappropriate for the clinical diagnosis of IPA.   
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Assay N Samples 
exclude
d 
% Sensitivity  
(95% CI) 
% Specificity  
(95% CI) 
% PPV (95% CI) % NPV (95% CI) 
LFD+PCR+GM 
(0.8) 
25 5 50.00 (8.17-91.83) 77.78 (52.36-
93.45) 
20 (3.3-71.19) 93.33 (67.98-
98.89) 
LFD+PCR+GM 
(1.0) 
25 6 * 82.35 (56.55-
95.99) 
* 87.5 (61.62-98.08) 
LFD+PCR 25 1 33.33 (5.47-88.45) 80.95 (58.08-
94.44) 
20 (3.3-71.19) 89.47 (66.82-
98.39) 
LFD+GM (0.8) 25 5 50.00 (8.17-91.83) 77.78 (52.36-
93.45) 
20 (3.3-71.19) 93.33 (67.98-
98.89) 
LFD+GM (1.0) 25 6 * 82.35 (56.55-
95.99) 
* 87.5 (61.62-98.08) 
PCR+GM (0.8) 25 4 50.00 (8.17-91.83) 78.95 (54.43-
93.82) 
20 (3.3-71.19) 93.75 (69.69-
98.96) 
PCR+GM (1.0) 25 5 * 83.33 (58.56-
96.23) 
* 88.24 (63.52-
98.20) 
GM (0.8) 25 0 66.67 (11.55-
94.53) 
68.18 (45.13-
86.08) 
22.22 (3.47-59.94) 93.75 (69.69-
98.96) 
GM (1.0) 25 0 * 72.73 (49.78-
89.20) 
* 84.21 (60.40-
96.43) 
LFD 25 0 33.33 (5.47-88.45) 77.27 (54.62-
92.09) 
16.67 (2.76-63.90) 89.47 (66.82-
98.39) 
PCR 25 0 33.33 (5.47-88.45) 81.82 (59.70-
94.70) 
20 (3.3-71.19) 90 (68.26-98.47) 
Table 11.  Performance parameters for the biomarker assays, individually and in combination, in the Study 
cohort (N = 25). 
Analysis performed using EORTC/MSG 2008 criteria (excluding GM) as the gold standard for clinical diagnosis of 
IPA.  GM cut-off is shown in brackets.  *Calculation was not possible due to the absence of any ‘true positives’ 
from the data set. 
 
4.2.2.6 Biomarker detection in blood 
Study patients underwent twice weekly blood sampling [Section 2.1.1.4.3] during the 
course of study participation.  Retrospective testing of LFD and GM was performed on 
serum samples and qPCR on DNA extracts from EDTA blood samples.  Results are shown in 
Table 12.  In the 5 cases with combination biomarker positive BAL fluid, 4 had consistently 
negative serum GM results during the period of neutropenia (samples 1 and 3-5). Only one 
case (sample 2) was serum GM positive and also had one blood qPCR positive result – 
interestingly, the BAL qPCR indicated this patient had the highest respiratory fungal load in 
Study cohort.  Study case 4 had two consecutive LFD positives in serum, but GM and qPCR 
were negative.  Study case 3 had one qPCR positive result, but LFD and GM testing were 
negative.  In the other 20 Study cohort episodes that were not combination biomarker 
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positive in BAL fluid, 115 blood/serum samples were analysed and all were negative by LFD, 
GM and qPCR. 
  BAL fluid Blood 
Sample 
Test 
interpretation LFD  GM (0.5) PCR  
1 Positive Negative <0.5 NA 
2 Positive NA 2.2 Positive 
3 Positive Negative <0.5 Positive 
4 Positive Positive <0.5 Negative 
5 Positive Negative <0.5 NA 
6 Inconclusive Negative <0.5 NA 
7 Negative Negative NA NA 
8 Negative Negative <0.5 NA 
9 Negative NA NA NA 
10 Negative Negative <0.5 Negative 
11 Negative Negative <0.5 Negative 
12 Negative Negative <0.5 Negative 
13 Negative Negative <0.5 Negative 
14 Negative Negative <0.5 Negative 
15 Negative Negative <0.5 Negative 
16 Negative Negative <0.5 Negative 
17 Negative Negative <0.5 Negative 
18 Negative Negative <0.5 Negative 
19 Negative Negative <0.5 Negative 
20 Negative Negative <0.5 Negative 
21 Negative Negative <0.5 Negative 
22 Negative Negative <0.5 Negative 
23 Negative Negative <0.5 Negative 
24 Negative Negative <0.5 NA 
25 Negative Negative <0.5 NA 
Table 12.  Biomarker testing results in blood samples from the Study cohort (N=25). 
NA = no sample available for testing     
< 0.5 indicates that all samples from serial testing were negative  
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4.3 DISCUSSION 
IPA is the most common manifestation of IFD in haemato-oncology patients (15) and its 
diagnosis and treatment remain a challenge.   
The poor repeatability of serum sample GM testing presented in this chapter suggest that: 
(i) caution should be exercised when testing serum samples after a period of storage, 
including samples stored at −80 °C; (ii) the interpretation of GM negative results obtained 
after delays in processing may be problematic; (iii) careful coordination is required 
between the laboratory and clinical teams to minimise the time from sampling to testing; 
(iv) a better understanding of GM kinetics is necessary to address the impact of sample 
processing and storage times on detectable GM concentrations. Furthermore, given a wide 
range of sensitivity and specificity data plus multiple causes of false-positive results for the 
PA-EIA reported in the literature, a prudent approach to clinical utilisation of GM testing 
would be to combine the PA-EIA with other markers of Aspergillus in a diagnostic algorithm 
(53). 
This chapter demonstrates that a triple biomarker approach - LFD, GM and qPCR – in BAL 
fluid has a very high sensitivity and specificity for IPA.  In the Study cohort of haemato-
oncology patients at high-risk of IFD, the LFD and qPCR combination showed almost perfect 
agreement (Cohen’s kappa 0.88), which is then proposed as a diagnostic-driven testing 
approach to patient management, to direct antifungal treatment to patients with evidence 
of IPA, in the absence of direct examination or culture of pulmonary tissue. Having defined 
the sensitivity of triple biomarker testing in the proven IPA cohort, it was possible to show 
the low sensitivity of the EORTC/MSG criteria using the biomarker approach as the 
reference standard in the Study cohort, i.e., in patients in whom a definitive, proven 
diagnosis has not been made. This data, and other reports (52, 224-226), highlight that the 
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EORTC/MSG criteria, developed for clinical research, should be used with caution both 
when evaluating new diagnostic approaches for IFD and when used in clinical algorithms 
defining management on “probable/possible” classification.  To highlight this, the 
diagnostic performance of the individual and combination biomarker assays was also 
evaluated in the Study cohort, using the EORTC/MSG (excluding GM) criteria as the 
reference standard.  Results suggested individual biomarker assay performance to be very 
poor (33-66% sensitivity) in this small sample population.  Of the five Study episodes that 
tested GM, LFD and PCR positive in BAL, three of these episodes were classified as having 
no risk factors for IA (none) by EORTC-scoring, and would therefore be regarded as ‘false 
positive’ test results.  Given the documented limitations of the EORTC criteria, it could be 
argued that these cases are in fact true positives and that the sensitivity of these assays is 
much greater than suggested in comparison to the EORTC-scored, which is an imperfect 
reference standard.   
In clinical practice, two factors may significantly impact on our proposed biomarker 
approach for IPA diagnosis in BAL fluid: the use of mould-active drugs (as prophylaxis or 
treatment) and the availability of rapid bronchoscopy.  There are very limited and 
conflicting reports about the effect of antifungal therapy on the performance of assays in 
BAL fluid.  Antifungal therapy has been reported to both decrease (228) and increase (158) 
the diagnostic performance of qPCR in BAL fluid from high risk patients.  In a guinea pig 
model of IPA, levels of LFD and GM remained elevated in the BAL fluid of animals treated 
with antifungals, whereas serum sensitivity was reduced (121).  In the Study cohort 
presented in this chapter, the median interval between starting mould-active antifungal 
treatment and bronchoscopy was 5.5 days in the dual LFD/qPCR negative cases and 6 days 
in the positive cases.  Therefore, neither the use of anti-fungal drugs nor the delay in 
bronchoscopy is likely to explain the biomarker negative results.  Furthermore, the five 
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triple biomarker positive BAL fluids were obtained after four to eight days of mould-active 
antifungal therapy, which highlights the utility of biomarker testing in this setting, whereas 
microscopy and culture of BAL fluid were uninformative. 
Another key clinical issue is whether the proposed biomarker approach could be used in 
the blood and avoid the need for bronchoscopy.  In the Study cohort, blood was sampled 
twice weekly and retrospective testing of LFD, GM and qPCR was performed.  Overall, the 
data indicate the insensitivity of combination biomarker detection in blood compared to 
respiratory sampling.  Furthermore, concerns over the repeatability of GM in serum (215, 
216)  have been confirmed in this chapter, whilst also demonstrating that BAL GM results 
appear stable (229). 
A positive BAL GM result would support the use of antifungal drugs.  The GM assay showed 
72.7% sensitivity in the proven IPA cohort when a cut-off index of 1.0 was used, as deemed 
‘optimal’ by a recent meta-analysis of GM-BAL studies (220), but 81.8% using a lower cut-
off of 0.8.  The latter value may be more relevant to our clinical practice, where mould-
active antifungal therapy was started in the Study cohort patients prior to bronchoscopy.  
Furthermore, the combination biomarker approach revealed 4 BAL samples in the Study 
cohort with GM positivity that was discrepant with dual LFD/qPCR negativity. The near 
perfect agreement between LFD and qPCR would suggest that these cases should be 
interpreted as having false positive GM results and no evidence of IPA.  Disagreement 
between the LFD and qPCR tests was seen in a single Study cohort sample (GM was 
negative).  As the two tests performed identically in the gold standard proven IPA and 
negative control cohorts with 100% agreement, in cases of discrepancy the results should 
be interpreted as invalid and repeat testing and further clinical investigation 
recommended. 
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The EORTC/MSG criteria (50, 51) are often used as a diagnostic reference standard because 
of the rarity of proven IPA cases.  However, misclassification by these criteria can occur for 
many reasons: lung lesions may be missed due to delays in CT scanning (69); biomarker 
changes may be caused by an alternative condition to IPA (157) or by drug treatment (94).  
Furthermore, when evaluating the performance of the GM assay there is incorporation 
bias, as the test is part of the EORTC/MSG criteria for assigning a ’probable’ score, but this 
method of evaluation is still used (89).  In this chapter, the EORTC/MSG 2008 criteria were 
used (51), with and without GM results included, to assign likelihood of IFD in the Study 
cohort and the results were evaluated against the dual LFD/qPCR combination as a 
reference standard for clinical diagnosis of IPA.  Depending on whether an EORTC/MSG 
‘possible’ score was deemed a negative or positive result, sensitivity of the EORTC/MSG 
criteria was between 20-40%.  The performance of the EORTC/MSG criteria has also been 
evaluated in autopsy studies : 8 of 22 (225) and 78 of 314 (224) cases of autopsy-proven 
IFD were diagnosed as proven or probable by EORTC/MSG 2002 criteria; sensitivities of 
36% and 25%, respectively; while the EORTC/MSG 2008 modifications identified 6 of 40 
cases of autopsy-proven IFD - a sensitivity of 15%.  These sensitivity values for EORTC/MSG 
criteria in proven autopsy cases are comparable to the data presented in this chapter, using 
dual LFD/qPCR testing as the reference standard and further support this combination 
testing approach.  However, it is important to note that in the study by Chamilos et al (224) 
there is very limited information provided about the tests performed and results used in 
EORTC/MSG scoring.  It is not clear whether any imaging was performed, or antigen testing, 
such as GM ELISA.  This could have a significant impact on an analysis of the diagnostic 
performance of the EORTC/MSG classification system.  In the study by Subira et al it is 
stated that no antigen testing was performed (225).  Also, although imaging was available, 
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less than half of the patients in this study actually had CT scans performed.  Again, this 
absence of test results limits the utility of the EORTC/MSG classification in this study.     
The study presented in this chapter has a number of limitations.  Selection of adult patients 
at high risk of developing IPA, who have had a bronchoscopy, leads to a high pre-test 
probability of IFD.  The timing of the bronchoscopy in relation to the course of IFD may also 
introduce bias, as collection can occur at various stages of disease.  However, the Study 
cohort patients followed a standardised protocol [Section 2.1] and in clinical practice such 
bias could be minimised by using integrated care pathways (53).  BAL sampling is also not 
standardised, raising issues about the interpretation of biomarker thresholds and 
quantification.  
In conclusion, the data presented in this chapter suggest that a dual LFD/qPCR testing 
approach in BAL fluid could be a new diagnostic-driven testing approach to patient 
management, to direct antifungal treatment to patients with evidence of IPA in the 
absence of direct examination or culture of pulmonary tissue.  This proposed combination 
test would require validation.  Importantly, biomarkers remain informative even if 
antifungals are commenced before bronchoscopy.  A systematic approach to bronchoscopy 
combined with dual LFD/qPCR testing could make a significant difference to IFD 
management.  We envisage LFD testing as a near-patient assay in the bronchoscopy suite, 
allowing an immediate decision on antifungal drug usage, with qPCR results within 24 hours 
for a definitive diagnosis.  
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CHAPTER 5 
 
INNOVATIVE APPROACHES TO IPA DIAGNOSIS 
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5.1 EVALUATION OF EXHALED BREATH CONDENSATE AS A PIONEERING SAMPLE 
FOR NON-INVASIVE DIAGNOSIS OF LUNG PATHOGENS  
5.1.1 Background 
The analysis of exhaled breath condensate (EBC) provides a non-invasive method for 
identifying biomarkers associated with lung pathology, making it especially useful for 
longitudinal assessments of patients.  Although its use was first reported in 1980 (140), a 
number of technical limitations have limited its value for clinical applications.   EBC is 
believed to reflect the composition of the airway lining fluid and alveoli and has been 
shown to contain bioaerosols (bacteria, fungi and viruses) derived from the respiratory 
tract (230).  The reopening of closed bronchioles and alveoli creates turbulence in the 
airways, which results in non-volatile compounds being aerosolised (231).  There is still 
dispute as to whether EBC contains aerosol particles derived mainly from the respiratory 
lining fluid of the lower airways (232), or from the central airways (233), and despite the 
commercial development of devices for EBC collection, it is still impossible to standardise 
flow rate and the volume of exhalation.  Despite this unknown degree of sampling 
variability and uncertainly as to the origin of EBC content, this biological sample may prove 
useful in the study of inflammatory pulmonary disorders.  In theory, the proximity of the 
sample to the initial site of infection, together with the relative ease of sample collection in 
comparison to BAL fluid (non-invasive and minimal discomfort, with the potential to even 
sample from ventilated patients) makes EBC an attractive option for diagnosing respiratory 
infections such as IPA.  
In practice, the small number of studies that have investigated the potential of EBC 
sampling for nucleic acid detection of respiratory pathogens have recorded discouraging 
results, describing a lack of sensitivity (154-156) and poor correlation with BAL fluid (153), 
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nasopharyngeal swabs (154) and sputum (155).  There have been a limited number of 
attempts to detect specifically non-nucleic acid-based markers of IPA.  One encouraging 
report recorded 2-pentyl-furan detected in the breath of two IPA patients, but not 
following treatment or in healthy controls (234, 235).  Two conference papers have 
reported GM positive results in EBC from patients at high risk of IPA, with corresponding 
GM positive serum (236, 237); however, neither was followed up with a full publication. 
Despite the generally discouraging results and negative conclusions published regarding 
the usefulness of EBC, the development of the combination biomarker testing approach 
described in Chapter 4 makes it worthwhile investigating this clinical sample in the 
diagnosis of IPA. 
This section (Section 5.1) describes a series of experiments evaluating the potential of EBC 
as a pioneering sample for non-invasive diagnosis of IPA.  First, the feasibility of 
qPCR/LFD/GM testing for Aspergillus biomarker detection is assessed in EBC samples from 
a Study cohort of haemato-oncology patients at high-risk of IFD.  These results are 
correlated with Aspergillus qPCR/LFD/GM testing results in corresponding BAL fluid from 
CT-guided bronchoscopy. 
 
5.1.2 Results 
This study was a retrospective evaluation of biomarker performance for IPA diagnosis, with 
no impact on patient management.  The Study cohort of patients were a subset of those 
recruited in an observational study of IPA diagnosis in the Division of Haemato-Oncology, St 
Bartholomew’s Hospital [Section 2.1.1], based on the availability of BAL samples, EBC 
  
167 
 
samples and full clinical data.  37 EBC samples from 12 adults at high risk of IFD following 
intensive chemotherapy or allogeneic stem cell transplantation were included in this study.   
The performance of three biomarker assays were evaluated: (i) the Aspergillus LFD [Section 
2.6], (ii) GM assay [Section 2.5] and (iii) the new MIQE-compliant Aspergillus qPCR [Chapter 
3, section 3.3].  Total DNA was extracted for qPCR analysis, as described in section 2.2.3.  
EBC testing results were compared to biomarker testing results obtained in corresponding 
BAL fluid samples [Chapter 4, section 4.2.2.3].  Results are shown in Table 13. 
All EBC samples gave an instant ‘weak positive’ test line within minutes of being added to 
the LFD.   EBC from 11 of the 12 episodes were consistently GM index <0.5.  Only EBC 
sample 14 had a positive GM result, with GM index 1.3.  However, the corresponding qPCR 
result was negative, and the BAL fluid from this patient was negative by all 3 biomarker 
assays.   
EBC from 2 episodes tested PCR positive for Aspergillus DNA.  A single EBC from sample 2 
amplified with Cq39 (Figure 31) and corresponding BAL fluid tested positive by all 3 assays.  
Two consecutive EBC samples from sample 4 amplified with Cqs of 36-39 (Figure 32) and 
corresponding BAL fluid tested positive by all three assays.  Positive PCR results were 
consistent across triplicate wells and also when the assay was repeated.  Twenty-five 
percent of wells in every assay were NTCs and no amplification products were detected in 
these wells.  There was insufficient sample to perform a repeat extraction.  All EBC extracts 
were tested in the β-globin hydrolysis probe assay to monitor the relative human DNA 
content [Section 2.4.7].  All extracts were negative for human DNA. 
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  BAL fluid EBC  
Sample LFD result GM Index qPCR result  LFD result GM Index qPCR result  
2 Positive 6.4 Positive Positive missing Cq 39 
4 Positive 0.8 Positive Positive missing Cq 36-39 
8 Negative 1.8 Negative Positive <0.5 negative 
10 Negative 0.8 Negative Positive <0.5 negative 
11 Negative 0.4 Negative Positive <0.5 negative 
13 Negative 0.2 Negative Positive <0.5 negative 
14 Negative 0.2 Negative Positive 1.3 negative 
15 Negative 0.3 Negative Positive <0.5 negative 
16 Negative 0.2 Negative Positive <0.5 negative 
20 Negative 0.1 Negative Positive <0.5 negative 
22 Negative 0.3 Negative Positive <0.5 negative 
23 Negative 0.4 Negative Positive <0.5 negative 
Table 13.  Testing results for EBC samples and corresponding BAL fluid in the Study cohort (N=12). 
 
 
Figure 31.  qPCR assay amplification curve for an EBC from Study sample 2. 
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Figure 32.  qPCR assay amplification curves for 2 consecutive EBC samples from Study sample 4. 
 
5.1.3 DISCUSSION 
Although amplification was very late (at the limits of detection), three EBC samples were 
PCR positive for Aspergillus DNA.  Amplification at such a high Cq must be interpreted with 
caution.  However, the results were consistent across triplicate wells and also when the 
assay was repeated.  With consistent amplification between Cq 36 and 39, and no 
amplification of the negative control wells, these EBC samples are very likely to be positive 
for Aspergillus DNA, albeit in very low copy number.  This allows no conclusions to be 
drawn with regards to the clinical relevance of such extremely low target copy numbers.  
However, this is this first report of the detection of Aspergillus DNA from EBC samples.  In 
addition, the PCR results for EBC samples were in full agreement with results from BAL 
fluid.  The two patients that had PCR positive EBC samples also had corresponding PCR 
positive BAL fluid samples.  Furthermore, these BAL samples were positive by GM and LFD 
assays, inferring that these two patients should be treated for IPA (see Chapter 4).  The 
other 10 patients were PCR negative in both EBC and BAL samples.  GM and LFD testing of 
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EBC did not appear to be useful in this limited data set.  Interestingly, all EBC samples were 
negative for human DNA, using a β-globin qPCR assay.  Previous studies reported human 
DNA in 65% (151) and 100% (152) of tested EBC samples.  However, a different EBC 
sampling device was used in these cases.  Therefore, the results presented in this thesis 
section may reflect the limitations of the sampling technique itself. 
This study is limited by the small population size, together with the limited EBC sample 
volume available for testing.  This prevented repeat DNA extraction from the original 
sample, confirmation testing with an alternative assay and also prevented any investigation 
into the optimisation of EBC sample handling, such as a step to concentrate the sample 
prior to testing.   EBC is a highly dilute, low protein sample.  Therefore, biomarkers will be 
highly diluted and attempts to detect them will push assays to their lower limits of 
accuracy.  Whilst the results of this study demonstrate detection of Aspergillus DNA from 
EBC, the amplification threshold of detection in these samples was not reached until 36-39 
cycles.  In Study sample 2 the EBC sample amplified at Cq 39, whilst the corresponding BAL 
fluid sample amplified at Cq 27.8, a 4,000-fold difference.  This suggests that enrichment 
from EBC is required to get a more reliable result.  There are several ways in which this can 
be accomplished, most readily by enriching for Aspergillus nucleic acids using magnetic 
beads coated with Aspergillus specific probes.  These could be added to EBC and allow 
several thousand-fold enrichment (e.g. from 50ml to 5l). 
Despite the limitations of this study, the results provide encouraging data regarding the 
possible use of EBC samples in an early detection method for IPA. 
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5.2 EVALUATION OF LOCAL (LUNG) AND SYSTEMIC (SERUM) INFLAMMATORY 
PROFILE ASSOCIATED WITH IPA BIOMARKER POSITIVE BAL FLUID IN 
IMMUNOCOMPROMISED PATIENTS 
5.2.1 Background 
IPA is the most common cause of mortality due to mould disease in haemato-oncology 
patients (206, 207).  Their underlying disease and its treatment lead to periods of 
prolonged immunosuppression (205), leaving them lacking sufficient innate immune 
effector cells (neutrophils and macrophages) to protect the lungs from spores.  The lung is 
regularly challenged by microbial pathogens and the local immune response must be rapid 
and efficient, to prevent potentially lethal infections. Neutrophils and macrophages are 
crucial in the early defence steps against Aspergillus infection [Section 1.4.2].  Phagocytes 
residing in the lungs at the time of infection will attack the fungi, whilst additional effector 
cells are recruited to the site of infection by inflammatory cytokines and chemokines.  
Impaired recognition and phagocytosis and extracellular killing mechanisms by effector 
cells in haemato-oncology patients allow inhaled spores to survive and germinate to 
produce hyphae that can become angioinvasive (13). 
The adaptive immune response has been extensively investigated in the murine model, as 
described in Section 1.4.3.  Immune response is difficult to investigate in the human 
haemato-oncology setting, due to the presence of other co-morbidities, neutropenic 
episodes and corticosteroid treatment.  This is reflected in the paucity of publications 
profiling immune response to IPA in this setting.  The tissue lining the respiratory tract is 
fragile and easily damaged by excessive or inappropriate inflammation.  Immune response 
to pathogens must be regulated to rapidly clear infection, whilst not exposing the tissue to 
chronic inflammation.  The immune response to IPA in the lung has not been directly 
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investigated in vivo in immunocompromised humans.  However, an evaluation of the local 
and systemic inflammatory response associated with pulmonary complications in 
immunocompromised patients did include 16 cases of fungal pneumonia attributed to 
Aspergillus species (238).  Patients with haematological malignancies treated with 
chemotherapy, HSCT recipients and patients who had received SOT were demonstrated to 
generate cytokine responses to pneumonia.  Increased BAL levels of TNF-α, IL-6, IL-8 and IL-
10 and serum TNF-α and IL-6 were found in immunocompromised patients when compared 
to healthy controls.   Within the immunocompromised population, significantly higher BAL 
fluid levels of IL-6 and IL-8 were found in patients with pulmonary infiltrates of an 
infectious aetiology than in those with non-infectious complications.  The authors observed 
a trend towards a more intense inflammatory response in those with bacterial infections, 
as opposed to fungal or viral.  Chai et al (239) studied serum IL-6, IL‐8, IL‐10, IFN‐γ, and CRP 
trends in the setting of immunocompromised patients with IA, over the first 4 weeks of 
therapy and found that circulating IL‐6 and CRP levels were high at the start of therapy and 
generally decreased with antifungal treatment.  Persistence of elevated IL-6 and CRP levels 
after 1 week of therapy was associated with an increased likelihood of treatment failure 
and death (P = 0.02, for both IL‐6 and CRP).  However, it is likely that these patients were 
receiving multiple antibiotics/antiviral treatment, making interpretation very difficult.   The 
generation of cytokine responses by immunocompromised patients has also been 
demonstrated in Pneumocystis jirovecii infection (240), in which higher BAL fluid level of IL-
6 was found in immunocompromised patients with P. jirovecii infection than in non-
infected immunocompromised or immunocompetent controls.  IL-17, IL-10 and TNF-α 
levels were no different between the groups.  Though very limited in number, these reports 
suggest that patients with haematological malignancy, receiving cytotoxic chemotherapy, 
still mount an immune response to respiratory pathogens in the lung.  Innate lung defences 
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have also been shown to be highly inducible in mice receiving myeloablative chemotherapy 
when infected with Streptococcus pneumoniae (241, 242) and A. fumigatus conidia (243).  
Innate defence did not depend on recruited neutrophils or resident alveolar macrophages.  
Instead results support a hypothesis that the principal means of protection is a localised 
innate response by lung epithelium.    
Western blotting and ELISA are traditional techniques for cytokine analysis.  However, both 
are limited by their ability to report only a single antigen at a time, requiring up to 100µl of 
sample for analysis of each required antigen.  Multiplexed bead arrays are a very efficient 
alternative to these traditional methods (244, 245), quantifying multiple cytokines at once, 
in a single 50µl sample, in a relatively short time.  This multiplexing technique is more 
suited to studies in which clinical sample volumes are limited.  
Two commonly used multiplex bead arrays are the BD Biosciences CBA kit (San Diego, CA) 
and the Luminex system.  Both use immobilised antibodies on spherical beads to catch 
soluble antigens from a sample in suspension.  Fluorescence systems are used to detect 
binding of a secondary antibody to the soluble antigen.  Whilst the Luminex system must 
be run on a specific Luminex machine, the BD CBA assay will run on any flow cytometer.   
Limited sample volume, together with local flow cytometer availability, made the BD 
Biosciences CBA kit the most suitable option for use in this study. 
This section first describes a series of experiments in which fluorescence-activated cell 
sorting (FACS) analysis was used to quantify 5 human chemokines and 7 cytokines involved 
in the differentiation of/secreted by each Th1/Th2/Th17 cell type in clinical samples from 
cases of proven IPA and patients with haematological malignancy at high risk of IA.  These 
results were analysed to determine whether a respiratory cytokine profile could be used as 
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a tool in the early diagnosis of respiratory infection, reflecting initial response to infection.  
Finally, respiratory sample results are compared to circulating cytokine and chemokine 
levels detected in serial serum samples over the course of antifungal therapy in two 
haemato-oncology patients. 
 
5.2.2 Results 
5.2.2.1 Cytokine and chemokine concentration in BAL fluids from ‘gold standard’ 
proven IPA cohort and haemato-oncology Study cohort 
This study was a retrospective evaluation of inflammatory cytokine profiling for IPA 
diagnosis, with no impact on patient management.  The ‘gold standard’ proven IPA cohort 
of 11 BAL fluids came from 10 patients, obtained at routine diagnostic work-up at the 
Innsbruck University Hospital between January 2008 and November 2012 [Section 2.1.2].  
The Study cohort of patients were a subset of those recruited in an observational study of 
IPA diagnosis in the Division of Haemato-Oncology, St Bartholomew’s Hospital [Section 
2.1.1], based on the availability of BAL samples and full clinical data.  20 BAL fluid samples 
from adults at high risk of IFD following intensive chemotherapy or allogeneic stem cell 
transplantation were included in this study.  Sample numbers correspond to those 
investigated in Chapter 4.  Corresponding biomarker test results for Aspergillus are taken 
from Chapter 4, defining BAL fluids as combination biomarker positive or negative. 
The CBA Human Th1/Th2/Th17 Cytokine Kit and Human Chemokine Kit (BD Biosciences, 
USA) were selected, in order to quantify 5 human chemokines (IL-8, CCL5 (RANTES), CXCL9 
(MIG), CCL2 (MCP-1) and CXCL10 (IP-10)) and 7 cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ 
and TNF) in BAL fluid.  Testing was performed on the BD FACS Canto II [Section 2.7.2].  
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Assay standards were prepared for the Th1/Th2/Th17 cytokine kit [Section 2.7.2.2] and the 
chemokine kit [Section 2.7.2.3] and used to generate a standard curve covering a range 
from 20 to 5000pg/ml and 10 to 2500pg/ml, respectively.  Clinical samples were tested 
[Section 2.7.2.4] and data files exported for analysis using FCAP Array software, to calculate 
cytokine and chemokine concentrations (pg/ml) in each clinical sample [Section 2.9.3].   
LFD+PCR combination test positive vs negative:  The mean concentration of each cytokine 
and chemokine (pg/ml) is shown in Table 14, for BAL fluid from LFD+PCR dual test (DT) 
positive and negative samples [biomarker test results from chapter 4, sections 4.2.2.1 and 
4.2.2.3].  All variables were non-normally distributed.  Median concentrations of each 
cytokine and chemokine are shown for DT+ and DT- samples, together with the 
concentration range.  The Mann-Whitney U Test was conducted to compare cytokine and 
chemokine distributions between patients that were DT+ and DT-, with 2-tailed P values 
(Table 14), to determine whether there was a significant difference in the median 
concentration of any cytokines and chemokines between the two populations. 
Concentrations of IL-2, IL-4, IL-10, TNF-α, INF-γ and IL-17A were <100pg/ml in both DT+ and 
DT- patients.    There was no significant difference in the median concentration of these 
analytes between the DT+ and DT- populations.  Concentration of INF-γ is calculated to be 
significantly different in distribution between the 2 populations (P = 0.018).  However, 
there are only 5 non-zero values, all in the DT+ population, all below the lowest assay 
standard concentration (<20pg/ml). 
The concentration of CCL5 was low in both populations, <100pg/ml in all 16 DT+ samples 
and in 13/15 DT- patients, with no significant difference in median concentration between 
the 2 populations. 
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Table 14.  Mean cytokine and chemokine concentrations detected in BAL fluid samples from the gold standard proven IPA (N=11) and study cohorts (N=20).  
Sample IL-8 CCL5 (RANTES) MIG (CXCL9) CCL2 (MCP-1) IP-10 (CXCL10) IL-2 IL-4 IL-6 IL-10 TNF INF-g IL-17A
Proven 1 33721.6 50.2 1209.3 4079.7 412.9 0.0 0.0 838.1 0.0 1.7 0.0 12.3 Positive
Proven 2 6495.9 0.0 951.0 1153.7 0.0 0.0 0.2 2275.0 9.9 81.2 0.0 2.0 Positive
Proven 3 26928.1 3.6 500.7 2830.5 12.2 0.0 0.0 312.8 0.0 0.3 0.0 1.5 Positive
Proven 4 18178.3 3.2 3214.5 687.2 0.0 0.0 0.0 181.5 2.1 9.7 0.2 0.5 Positive
Proven 5 6667.1 74.8 3133.3 10574.2 4052.8 0.0 0.1 347.3 1.0 16.1 3.4 6.4 Positive
Proven 6 1006.7 0.2 77.4 1860.7 76.4 0.0 0.1 108.8 0.0 0.0 0.0 4.5 Positive
Proven 7 2715.4 5.3 1.7 9.8 3.6 0.0 0.0 0.0 0.1 1.3 0.1 15.7 Positive
Proven 8 4520.2 0.0 0.0 2.2 0.0 0.0 0.0 0.4 0.2 58.5 0.0 5.5 Positive
Proven 9 900.9 1.3 0.4 4.8 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 Positive
Proven 10 11834.2 5.7 171.2 2872.5 329.6 0.0 0.1 1723.6 1.0 0.1 0.0 0.0 Positive
Proven 11 25237.1 8.9 111.5 1361.4 19.3 0.0 0.0 957.7 0.5 6.8 0.0 2.3 Positive
Study 1 2411.6 18.2 163.7 558.3 817.5 0.0 0.0 267.5 1.3 1.3 0.0 63.2 Positive
Study 2 3213.0 4.9 80.2 6192.5 865.5 6.1 5.4 4067.6 9.9 5.3 4.2 error Positive
Study 3 1297.5 25.5 131.7 222.9 173.7 0.0 0.8 41.5 0.0 1.5 0.0 0.0 Positive
Study 4 2595.5 19.3 17912.6 710.7 3489.2 error error error error error error error Positive
Study 5 401.0 2.5 103.4 90.3 162.1 1.1 1.0 95.6 0.6 0.0 1.8 0.0 Positive
Study 7 32.7 0.0 10.1 43.5 5.8 1.8 0.0 2.0 0.0 1.7 0.0 0.0 Negative
Study 8 7391.9 1324.6 5965.2 10242.6 4237.8 0.0 2.6 286.0 3.9 1.6 0.0 0.0 Negative
Study 9 1274.0 32.8 1141.3 746.3 1398.5 0.0 0.8 83.1 0.0 0.7 0.0 0.0 Negative
Study 10 250.8 8.1 17.3 208.2 23.2 0.0 0.0 20.5 1.3 1.3 0.0 0.0 Negative
Study 12 3308.3 15.2 381.5 95.3 381.7 0.0 0.0 13.9 0.6 1.2 0.0 0.0 Negative
Study 13 1411.0 121.2 13361.5 121.3 1842.1 2.3 2.1 71.0 0.7 2.8 0.0 11.3 Negative
Study 15 100.2 4.6 5.9 35.0 11.9 0.0 1.8 20.1 0.0 1.9 0.0 0.0 Negative
Study 16 718.2 5.6 36.5 7227.2 83.1 0.0 1.2 266.3 1.3 1.6 0.0 18.2 Negative
Study 17 34.2 0.0 1.5 23.2 2.2 0.0 0.0 3.1 0.0 0.6 0.0 0.0 Negative
Study 18 1184.1 2.2 6.2 3200.0 59.4 0.0 0.9 854.5 0.7 3.0 0.0 84.1 Negative
Study 19 68.1 16.8 69.7 36.6 27.1 0.0 1.1 18.3 0.0 0.0 0.0 18.2 Negative
Study 20 129.2 4.5 64.0 122.8 98.7 0.7 0.0 5.8 0.0 0.0 0.0 13.1 Negative
Study 23 71.3 1.7 2.9 62.5 4.7 0.8 1.1 8.3 1.4 0.6 0.0 17.2 Negative
Study 24 3700.1 47.2 22.5 516.7 62.1 0.0 1.0 400.6 0.0 1.1 0.0 10.8 Negative
Study 25 24.6 1.6 6.1 26.3 11.8 0.0 0.0 0.0 0.0 1.9 0.0 0.0 Negative
DT+ MEDIAN 3866.6 5.1 147.7 932.2 119.2 0.0 0.0 267.5 0.5 1.5 0.0 2.1
DT+ RANGE 401.0-33721.6 0.0-74.8 0.0-17912.6 2.2-10574.2 0.0-4052.8 0.0-6.1 0.0-5.4 0.0-4067.6 0.0-9.9 0.0-81.2 0.0-4.2 0.0-63.2
DT- MEDIAN 250.8 5.6 22.5 121.3 59.4 0.0 0.9 20.1 0.0 1.3 0.0 0.0
DT- RANGE 24.6-7391.9 0.0-1324.6 1.5-13361.5 23.2-10242.6 2.2-4237.8 0.0-2.3 0.0-2.6 0.0-854.5 0.0-3.9 0.0-3.0 0.0-0.0 0.0-84.1
DT +/- P value 0.001 0.737 0.161 0.244 0.921 0.458 0.166 0.068 0.357 0.480 0.018 0.946
Mean concentration (pg/ml)
LFD+qPCR result Table 14.  Dual 
LFD+qPCR 
biomarker test 
results are shown.  
Cytokine and 
chemokine 
distributions 
between patients 
that were DT+ and 
DT-, with 2-tailed P 
values calculated. 
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The concentrations of IL-8, CXCL9, CCL2, CXCL10 and IL-6 were very variable within the 2 
populations, with a concentration range of 2-4 logs.  A highly significant difference was 
calculated between the median IL-8 concentration of DT+ (median= 3866.6pg/ml) and DT- 
samples (median = 250.8pg/ml) with a P value of 0.001 (Figure 33).   
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Figure 33.  Box plot showing IL-8 concentrations detected in dual test positive (DT+) and negative (DT-) BAL 
fluids. 
The upper hinge of the boxes represents the 75th percentile. The middle horizontal line of the boxes represents 
the median value. The lower hinge of the boxes represents the 25th percentile. 
 
Exclusion of patients that do not meet EORTC/MSG inclusion criteria:  In a separate 
analysis, samples were excluded from patients not meeting the EORTC/MSG 2008 (51) host 
factor inclusion criteria.  Only immunocompromised patients with cancer, hematopoietic 
stem cell transplant recipients, solid-organ transplant recipients, patients with hereditary 
immunodeficiencies, connective tissue disorders, and receiving immunosuppressive agents 
(such as corticosteroids or T cell immunosuppressants) were included in this analysis.  With 
this exclusion, proven 1-4 and 9-10 were removed from analysis.  The difference between 
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the median IL-8 concentration of DT+ patients meeting EORTC/MSG host criteria and DT- 
samples remains significant, with a P value of 0.016 (Figure 34). 
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Figure 34.  Box plot showing IL-8 concentrations detected in dual test positive (DT+) and negative (DT-) BAL 
fluids, with the exclusion of patients not meeting EORTC/MSG host factor inclusion criteria. 
The upper hinge of the boxes represents the 75th percentile. The middle horizontal line of the boxes represents 
the median value. The lower hinge of the boxes represents the 25th percentile. 
 
5.2.2.2 Cytokine and chemokine concentration in serum samples from the 
haemato-oncology Study cohort 
The Study episodes included in this chapter had EDTA blood and serum samples collected 
twice weekly for the duration of their time in the study [section 2.1.1.4.3].  However, 
previous investigations, including the combination biomarker testing described in chapter 
4, exhausted the supply of the majority of these samples.  Consequently, only Study 
samples 5 and 10 had serum samples available for evaluation of inflammatory cytokine 
profiling for IPA diagnosis.  Five serum samples from Study 5 (from seven days prior to 
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starting antifungal treatment to 13 days after starting antifungal treatment) and four serum 
samples from Study 10 (from three days prior to starting antifungal treatment to seven 
days after starting antifungal treatment) were included in this study.  The serum samples 
were analysed using the CBA Human Th1/Th2/Th17 Cytokine Kit and Human Chemokine Kit 
(BD Biosciences, USA) as described in section 5.2.2.1. 
Circulating serum levels of IL-8, CCL5, MIG (CXCL9), CCL2 and IP-10 (CXCL10) from seven 
days prior to starting antifungal treatment to 13 days after starting antifungal treatment 
are shown for haemato-oncology Study sample 5 (Figure 35).  The cytokine levels for the 
BAL fluid sample, collected 4 days after commencing antifungal treatment, are shown for 
comparison.  Results show that IL-8 concentration is 10-fold higher in BAL fluid than in 
serum, with serum levels remaining stable over the testing period.  CCL5 level is high in 
serum and remains elevated throughout the study period (400-580pg/ml).  Circulating 
serum concentrations of MIG (CXCL9), CCL2 and IP-10 (CXCL10) increase from seven days 
prior to antifungal start, until they all peak at seven days after antifungal treatment start, 
then all decline with time.  
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Figure 35.  Bar graph showing circulating serum levels of IL-8, CCL5, MIG (CXCL9), CCL2 and IP-10 (CXCL10) in 
Study sample 5, from 7 days prior to starting antifungal treatment to 13 days after starting antifungal 
treatment.    
Levels in BAL fluid, sampled four days after starting antifungal treatment, are shown for comparison.  
 
Circulating serum levels of IL-2, IL-4, IL-6, IL-10, TNFα and INF-γ from seven days prior to 
starting antifungal treatment to 13 days after starting antifungal treatment are shown for 
haemato-oncology Study sample 5 (Figure 36).  IL-17A detection was not included in this 
test.  Results show that IL-6 concentration is elevated in circulating serum and remains 
elevated 13 days after the start of antifungal treatment.  
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Figure 36.  Bar graph showing circulating serum levels of IL-2, IL-4, IL-6, IL-10, TNF and INF-γ in Study sample 
5, from 7 days prior to starting antifungal treatment to 13 days after starting antifungal treatment.    
Levels in BAL fluid, sampled four days after starting antifungal treatment, are shown for comparison. 
 
Circulating serum levels of IL-8, CCL5, MIG (CXCL9), CCL2 and IP-10 (CXCL10) from three 
days prior to starting antifungal treatment to seven days after starting antifungal treatment 
are shown for haemato-oncology Study sample 10 (Figure 37).  The cytokine levels for the 
BAL fluid sample, collected 3 days after commencing antifungal treatment, are shown for 
comparison.  Results show circulating serum concentrations of IL-8 and CCL2 increase from 
3 days prior to antifungal start, until they all peak at 3 days after antifungal treatment start, 
then both decline.  CXCL9 and CXCL10 concentrations remain low in serum throughout the 
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testing period.  CCL5 concentration increases in serum throughout the testing period. 
 
Figure 37.  Bar graph showing circulating serum levels of IL-8, CCL5, MIG (CXCL9), CCL2 and IP-10 (CXCL10) in 
Study sample 10, from 3 days prior to starting antifungal treatment to 7 days after starting antifungal 
treatment.   
Levels in BAL fluid, sampled 3 days after starting antifungal treatment, are shown for comparison. 
 
Circulating serum levels of IL-2, IL-4, IL-6, IL-10, TNFα, INF-γ and IL-17A from 3 days prior to 
starting antifungal treatment to 7 days after starting antifungal treatment are shown for 
haemato-oncology Study sample 10 (Figure 38).  Results show that IL-6 concentration is 
elevated in circulating serum and remains elevated 7 days after the start of antifungal 
treatment.  IL-6 concentration is approximately 40-fold higher in circulating serum than BAL 
fluid at 3 days after antifungal treatment start. 
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Figure 38.  Bar graph showing circulating serum levels of IL-2, IL-4, IL-6, IL-10, TNF and INF-γ in Study sample 
10, from 3 days prior to starting antifungal treatment to 7 days after starting antifungal treatment 
Levels in BAL fluid, sampled 3 days after starting antifungal treatment, are shown for comparison. 
 
5.2.3 Discussion 
IA is primarily a pulmonary pathology in the haemato-oncology setting.  The main aim of 
this series of investigations was to determine whether a respiratory cytokine profile could 
be used as a tool in the early diagnosis of IPA, reflecting initial response to infection. 
This study identified that INF-γ levels were very low in all tested BAL fluids, undetectable in 
84% of samples.  Low INF-γ levels have previously been observed in BAL fluids from 
patients with IPA (239) and may be the result of immune suppressive treatments (246) 
received by these patients.  However, a limitation of this study is the absence of healthy 
control samples.  Therefore, it is not possible to know for certain that the assay is efficiently 
detecting INF-γ. 
The median IL-8 concentration in the BAL fluid of DT+ patients was 3866.6pg/ml and was 
significantly higher than the median concentration in the BAL fluid of patients with 
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suspected non-Aspergillus infection (DT-) (P=0.001).  Data was also analysed with the 
exclusion of patients not meeting EORTC/MSG host inclusion criteria.  The 5 excluded 
samples were from cases of histologically proven IPA, from patients whose underlying 
disease did not leave them profoundly immunocompromised and who were not receiving 
immune suppressive agents.  With the exclusion of these patients, IL-8 concentration 
remained significantly higher in the DT+ patients (P=0.016).  
The high levels of IL-8 detected in the BAL fluid are likely to reflect a localised immune 
response in the lung.  This finding is consistent with results obtained in vitro (247), in which 
human respiratory epithelial cells produced IL-8 when stimulated with proteases released 
by A. fumigatus or by fungal filaments.  Neutrophils stimulated with A. fumigatus antigens 
also produce IL-8, via TLR2 and TLR4 (248).  However, it is unlikely that neutrophils and 
monocytes are the main source of IL-8 during febrile episodes and neutropenia (249). 
IL-6 concentration is higher in the DT+ (median = 267.5pg/ml) than the DT- (median = 
20.1pg/ml) BAL fluids, though the difference in the median values is not statistically 
significant.  The inflammatory response detected in these Study samples, characterised by 
high BAL fluid levels of IL-6 and IL-8, are in agreement with a previous report (238), 
however the IL-8 concentrations detected in this study using cytokine bead array chemistry 
are considerably higher than those reported previously (using ELISA detection). 
Although the results of this study indicate a higher concentration of IL-8 in the BAL fluid of 
suspected Aspergillus versus non-Aspergillus infection, the data set is small.  None of the 
inflammatory mediators evaluated was specific enough to clearly distinguish between 
suspected Aspergillus and non-Aspergillus infections. 
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The availability of corresponding serum samples was very limited in the haemato-oncology 
Study cohort.  Serial serum samples from two Study episodes were identified and the 
inflammatory cytokine profiles were evaluated.  The main difference between local (lung) 
and systemic (serum) inflammatory response was in detected CCL5 concentration, which 
was higher in serial serum samples than in BAL fluid.  CCL5 is chemotactic for T-cells and is 
required for T cell infiltration and activation in the adaptive immune response.  IL-6 levels 
were also high in serial serum samples, as reported in previous studies (238, 239).  
However, this data set is too small to draw any conclusions about systemic inflammatory 
response in the Study cohort.  Analysis of routine laboratory screening results shows that 
coagulase negative Staphylococci was cultured from the blood of 18 of the 25 haemato-
oncology Study episodes on at least one occasion during the study period.  Enterococcus 
(including E. faecium), Enterobacter, Escherichia coli, Klebsiella pneumoniae and 
Corynebacterium were also reported as isolated from the blood of DT- Study patients 
during the study period.   
The isolation of many pathogens from blood cultures, together with the multiple 
antibiotics/antiviral treatment that the patients receive, and the absence of defined 
outcome (fever is often resolved without a clear indication of the pathogen responsible) 
make it very difficult to investigate immune response to IPA in the haemato-oncology 
setting.  Although their underlying disease and its treatment lead to periods of prolonged 
immunosuppression, leaving them with insufficient neutrophils and macrophages to 
protect the lungs, the results of this study support previous reports that patients with 
haematological malignancy, receiving cytotoxic chemotherapy, still mount an immune 
response to respiratory pathogens in the lung.  The analysis of this mechanism may identify 
new prognostic markers and/or therapeutic targets. 
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5.3 PROXIMITY LIGATION ASSAY FOR THE SENSITIVE, SPECIFIC AND EARLY 
DIAGNOSIS OF INVASIVE FUNGAL DISEASE 
5.3.1 Background 
IPA occurs predominantly in immunocompromised patients, with an attributed mortality 
rate as high as 90% (250).  During IPA pathogenesis, conidia adhere to the pulmonary 
epithelial cells that line the alveoli and are internalised.  In immunocompromised hosts 
these conidia germinate to form hyphae, which exit the pulmonary epithelial cells and 
penetrate endothelial cells to access the blood vessel lumen.  The bloodstream carries 
hyphal fragments to distal sites where they adhere to and penetrate the luminal surface of 
endothelial cells and invade deep organs  (251).  Therefore, rapid recognition and early, 
appropriate treatment are vital whilst fungal burden is still relatively low and localised to 
the lungs. 
qPCR holds significant promise for the sensitive and specific identification of Aspergillus in 
clinical samples.  However, as already discussed, there are significant issues with the 
practical application of this technology.  Although I have identified major flaws in current 
qPCR methods and introduced a new qPCR assay, optimised and validated according to 
best practice as per the MIQE guidelines [Chapter 3, (117)], there remains the fact that the 
presence of a DNA sequence does not prove active infection.  Pathogen DNA detection is 
uninformative with respect to whether the fungus is actively growing and so one cannot 
unequivocally associate its presence with infection.   
The Aspergillus LFD uses a MAb (JF5) that is highly specific for an epitope expressed only by 
actively growing hyphae (119).  This assay provides a rapid and reliable assessment of the 
presence of actively growing Aspergillus.  However, the main drawback of any pure 
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antibody-based strategy is the relative lack of sensitivity compared with nucleic acid-based 
assays such as qPCR. 
Data presented in chapter 4 has demonstrated a very high level of agreement between 
qPCR and LFD detection in BAL fluid of high risk Haematology patients.  Whilst positive 
qPCR results were always supported by positive LFD in this small study population, the 
relative performance parameters of the technologies indicate that PCR positivity would 
pre-date LFD positivity in an early testing/screening approach (126).  With a high risk of 
assay contamination from Aspergillus spores that are ubiquitous in the environment, and 
DNA detection not proving active infection, an unsupported qPCR positive result could be 
false positive for IA. 
As a consequence there is a need for an assay that combines the specificity of hyphal-
specific antibody detection with the sensitivity of qPCR.  The proximity ligation assay (PLA), 
invented by Fredriksson et al (252) could in theory be used to achieve this, using two 
antibodies to detect adjacent epitopes on the same protein [Section 2.8], in this case 
proteins expressed exclusively at the growing tips of Aspergillus hyphae.  PLA is a 
quantitative assay, allowing quantification of fungal burden in clinical samples.  Compared 
to traditional ELISA it is more sensitive (10- to 100-fold), its dynamic range is broader (4 
logs vs 2.5 logs), its workflow is simpler (no wash steps), its time to result is faster (2.5 vs 5 
hours) and it only requires a few microlitres of clinical sample.  Together with enrichment 
methods already discussed, this provides the potential to increase further the sensitivity of 
this assay. PLA detection of actively growing Aspergillus would provide a ground-breaking 
new approach to early detection of IA. 
This section describes the development of a new PLA application for the early and reliable 
detection of IA in high risk patients, using the JF5 MAb and a polyclonal serum raised 
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against the same Aspergillus-specific N-linked glycoprotein antigen that is secreted 
constitutively at the hyphal apex in actively growing organisms.  
 
5.3.2 Results 
5.3.2.1 IL-6 expression in a Control Assay  
In order to gain familiarity with the work flow for TaqMan Protein Assays, a control assay 
was performed using antibodies and assay conditions that had been optimised at Life 
Technologies, to demonstrate the performance of PLA technology.    
A ready-biotinylated polyclonal antibody (pAb) to human IL-6 and a purified recombinant 
protein target were used in a positive control assay, as described in section 2.8.1.  The pAb 
was split into two pools and used to prepare assay probe A and assay probe B [Section 
2.8.1.1].  Assay probe solution was prepared [Section 2.8.1.2] and a dilution plate was 
prepared from recombinant protein target [Section 2.8.1.3].  Assay probe solution and 
recombinant protein dilutions were combined in a binding plate [Section 2.8.1.4] reaction.  
Following binding of the oligo probes to their protein targets, a ligation reaction was 
performed to seal the gap to generate a molecule that was amplified and detected by qPCR 
[Section 2.8.1.5].  Data from the TaqMan protein expression experiment was analysed 
using a threshold setting of 0.2 with automatic baseline.  The Cq data was exported for 
comparative analysis and used to generate a standard curve of 5-fold serial dilutions from 
2,000 to 0.128pg/mL.  The result at 0pg/mL represents the no protein control (NPC).   A 
dynamic range of 0.128-2000pg/mL was demonstrated (Figure 39), with linearity over 4 
logs in this assay.  
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Figure 39.  Detection of IL-6 recombinant protein dilutions 0.128-2000pg/mL, by pAb probes in a PLA control 
assay.   
The result at 0pg/mL represents the no protein control (NPC). 
 
5.3.2.2 Aspergillus PLA  
5.3.2.2.1 Antibody selection 
Life Technologies recommend the simplest way to perform PLA is to use a single pAb and 
split it into two pools to prepare 3’ and 5’ probes.  pAbs must be immunogen affinity 
purified prior to use, to remove non-specific antibodies, as their presence diminishes the 
sensitivity and specificity of the assay (253). The performance of unpurified or protein A 
purified pAbs have not been well characterised.  
MAbs have been shown to perform well in PLAs (254, 255).  Life Technologies advise that a 
single MAb is not suitable for generating a pair of assay probes because it binds to a single 
epitope and therefore cannot form the required proximity binding pair.  However, the JF5 
MAb developed by Dr Christopher Thornton (119) binds an Aspergillus-specific 
mannoprotein antigen by recognising multiple repeat epitopes on the same antigen (Figure 
  
190 
 
40).  Therefore, I reasoned that this single MAb could be used to generate both PLA probes.  
Dr Thornton provided JF5 MAb and antiserum (pAb) raised in rabbits against purified A. 
fumigatus mannoprotein antigen [Section 2.8.2.1].  
 
 
Figure 40.  Structure of the Aspergillus-specific mannoprotein antigen recognised by MAb JF5.   
α1,3 and α1,6 linked high mannose glycoprotein.  Structural detail kindly provided by Dr Christopher Thornton 
(Exeter, UK). 
 
5.3.2.2.2 Probe development – Part 1 
The crude pAb antiserum and the JF5 MAb were biotinylated using the APEX antibody 
labelling kit [Section 2.8.2.4].  The biotinylated antibodies were extensively dialysed against 
PBS, to remove any free, unbound biotin.  A forced proximity test was performed for each 
antibody to determine whether or not the biotinylated antibody was suitable for making 
proximity probes [Section 2.8.2.5].  The results of the first forced proximity tests are shown 
in Figure 41.  The ΔCq value was calculated for each biotinylated antibody: Average Cq 
(negative control) – Average Cq (Forced Proximity Probe).  ΔCq≥8.5 was required for the 
antibody to pass the Forced Proximity Probe Test. 
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Figure 41A shows the results of the pAb assay.  ΔCq is <8.5, therefore the pAb fails the test.    
Figure 41B shows the results of the MAb assay.  ΔCq is <8.5, therefore the MAb also fails 
the test.  This could have been caused by the presence of free biotin in the preparation, if 
dialysis was insufficient, or by under-biotinlyation of the antibodies.  A third explanation for 
failing the forced proximity test is that the antibody concentration was lower than 
expected, as the Apex kit indicates that recovery is typically between 40-80%.    
 
 
Figure 41.  Forced proximity test amplification curve for a) pAb forced proximity probe (left trace) and 
negative control (right trace) and b) MAb forced proximity probe (left trace) and negative control (right 
trace). 
 
B 
A 
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5.3.2.2.3 TaqMan Protein Assay – TPA I protocol – Part 1 
Despite failing the forced proximity test, the decision was made to use the biotinylated pAb 
pool and MAb to make an initial set of proximity probes.  The purpose was to test whether 
or not the probes could generate a signal even with sub-optimal probe labelling.  These 
probes were used together with the TaqMan Protein Assays Open Kit [Section 2.8.2.6] in 
the first attempt at Aspergillus PLA. 
The 3’ and 5’ pAb probes were incubated with 10-fold serial dilutions of a crude 
preparation of purified target glycoprotein [Section 2.8.2.3] or with buffer (Negative 
control) in the binding step, followed by a ligation reaction to seal the gap to generate a 
molecule that was amplified and detected by qPCR [Section 2.8.2.6].  Increasing Cqs were 
seen with serial 10-fold dilutions of purified glycoprotein antigen (A to D), with a 70-fold 
difference between the highest dilutions (D) and the antigen-negative sample (Negative C) 
(Figure 42).  Results successfully demonstrate the ability of the PLA to detect its target 
antigen. 
 
Figure 42.  Detection of Aspergillus-specific N-linked glycoprotein antigen by TPA I in serial 10-fold dilutions 
of purified glycoprotein antigen (A to D), and antigen-negative sample (Negative C). 
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In a second PLA, combinations of 3’ (A) and 5’ (B) probes were incubated with a 1:1000 
dilution of purified glycoprotein antigen or with buffer (Negative control).   The results for 
pAb A/pAb B (Figure 43A), MAb A/pAb B (Figure 43B) and pAb A/MAb B (Figure 43C) are 
shown.  In all cases, the ΔCq was <2.5 between an antigen positive and negative sample.  
This is a very small difference, but demonstrates a successful PLA run. 
 
 
 
Figure 43.  Bar graph representation of PLA result for probes A) pAb A/pAb B, B) MAb A/pAb B and C) pAb 
A/MAb B PLA. 
Cq (y axis) is shown for a 1:1000 dilution of purified glycoprotein antigen and negative control (buffer). 
C 
A 
B 
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5.3.2.2.4 Probe development – Part 2 
The crude pAb antiserum and the JF5 MAb were biotinylated using the APEX antibody 
labelling kit. 
The biotinylation step was repeated in the pAb serum and MAb, using the APEX antibody 
biotinylation kit, but with the addition of a dialysis step prior to biotinylation as well as 
after, in order to remove any contaminants that may interfere with the biotinylation 
process.  Results for the pAb serum are shown in Figure 44.  ΔCq is 11, meaning that the 
antibody pool passes the test and is suitable for making proximity probes. 
 
Figure 44.  Repeat forced proximity test amplification curve for pAb forced proximity probe (left trace) and 
negative control (right trace). 
 
The pAb biotinylation process was also performed using an alternative kit; Thermo EZ link 
Biotinylation kit [Section 2.8.2.4], as recommended in the TaqMan Protein Assays 
Chemistry Guide.    The results of the forced proximity test were disappointing, as shown in 
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Figure 45, with a ΔCq of only 3.5.  Therefore, this biotinylated Ab pool failed the forced 
proximity test. 
 
Figure 45.  Forced proximity test amplification curve for pAb forced proximity probe (left trace) and negative 
control (right trace). 
 
The decision was made to continue using the APEX biotinylation kit and proceed to prepare 
a biotinylated stock of the JF5 MAb. 
 
5.3.2.2.5 TaqMan Protein Assay – TPA I protocol – Part 2 
Once they had passed the forced proximity test, the biotinylated stocks of pAb and MAb 
were used to prepare new 3’ (A) and 5’ (B) proximity probes [Section 2.8.1.1]. 
Combinations of 3’ and 5’ probes were incubated with neat, 1:100 and 1:200 dilutions of a 
crude Aspergillus culture filtrate (CF) preparation [Section 2.8.2.2] or with buffer (negative 
control).   The results for pAb A/pAb B (Figure 46A), MAb A/pAb B (Figure 46B) and pAb 
A/MAb B (Figure 46C) are shown.  In all cases, the ΔCq was <2.  This is a very small 
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difference, but demonstrates that PLA works in principle.  However, further optimisation is 
needed. 
 
 
 
Figure 46.  Bar graph representation of PLA result for probes A) pAb A/pAb B, B) MAb A/pAb B and C) pAb 
A/MAb B PLA.   
Cq (y axis) is shown for dilutions of Aspergillus culture filtrate (CF) preparation and negative control (buffer). 
 
5.3.2.2.6 TaqMan Protein Assay – TPA II protocol  
A simplified work flow and modified reagents (designated TPA II) were provided by Life 
Technologies [Section 2.8.2.7].  The main difference between the original TPA I and the 
new TPA II protocols is the move from a 3 step process, consisting of i) the binding reaction, 
A 
B 
C 
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ii) ligation and iii) PCR amplification, to a 2 step process in which ligation and PCR mixes are 
combined and take place in one step, on-board the thermocycler.  Using the TPA II 
protocol, combinations of 3’ and 5’ probes were incubated with crude Aspergillus culture 
filtrate preparation or with buffer (Negative control).   The results for pAb A/MAb B (Figure 
47A) and MAb A/MAb B (Figure 47B) are shown.  In both cases, the ΔCq was 5.  Results 
demonstrate a higher ΔCq and a greater sensitivity compared to the TPA I protocol. 
 
 
Figure 47.  Bar graph representation of PLA result for probes A) pAb A/MAb B and B) MAb A/MAb B. 
Cq (y axis) is shown for dilutions of Aspergillus culture filtrate (CF) preparation and negative control (buffer). 
A 
B 
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5.3.2.2.7 Further probe development 
The MAb and pAb stocks were purified using the Thermo Scientific Nab protein A Plus spin 
kit [Section 2.8.2.8].  This kit purifies IgG antibody from other antibody classes that may be 
present.  This purification step is used to remove non-specific antibodies that would 
otherwise be biotinylated along with the target antibodies in the next stage.  The results of 
the forced proximity test for the protein A purified antibodies are shown for the MAb 
(Figure 48A) and pAb (Figure 48B).  ΔCq is >8.5.  Therefore, both antibodies pass the forced 
proximity test. 
 
 
Figure 48.  Forced proximity test amplification curve for protein A purified A) MAb and B) pAb.   
Forced proximity probe (left trace) and negative control (right trace). 
A 
B 
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5.3.2.2.8 TaqMan Protein Assay – TPA II protocol – Part 2 
Once they had passed the forced proximity test, the protein A purified and biotinylated 
stock of MAb was used to prepare new 3’ (A) and 5’ (B) proximity probes [Section 2.8.1.1]. 
These probes were incubated with crude Aspergillus culture filtrate preparation or with 
buffer (negative control).   The results are shown in Figure 49.  ΔCq was 4.40.   
 
Figure 49.  Bar graph representation of PLA result for probes MAb A/MAb B.   
Cq (y axis) is shown for dilutions of Aspergillus culture filtrate (CF) preparation and negative control (buffer). 
 
5.3.3 Discussion 
Molecular tools such as qPCR and ELISA are providing sensitive and specific detection of 
nucleic acids and proteins, respectively.  This is enabling the earlier diagnosis and 
treatment of human diseases.  These tools are being combined in innovative ways, as 
exemplified by the PLA, to push the limits of biomarker detection.  PLA has previously been 
used to directly quantify proteins in biological samples such as plasma and serum (252, 
253).  To date, only a single publication has explored the use of PLA for microbial pathogen 
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detection (255), demonstrating proof of principle for MAb detection of porcine parvovirus 
and a bacterium.   
This section describes three firsts: 
1. the first ever application of PLA to the detection of fungal protein.  The key 
criterion that will determine the success of PLA diagnostic assay for IA is the 
availability of PLA-compatible antibodies that target Aspergillus-specific proteins, 
ideally proteins that are secreted only during the active growth of the fungus.  To 
this end, a MAb and pAb antiserum preparation raised against an Aspergillus-
specific N-linked glycoprotein antigen (119), have been demonstrated to be 
capable of detecting antigen present in culture filtrate.  Firstly, Life Technologies’ 
commercially available TPA I open kit was used, together with a non-optimised 
antibody preparation for the target glycoprotein to show the feasibility of using 
PLA as a diagnostic assay.  Results demonstrate the successful biotinylation and 
oligonucleotide attachment of the MAb and pAb, the ability of the PLA to detect its 
target antigen and an observed difference between the Cq of an Aspergillus 
antigen-positive and an antigen-negative sample.  Unlike standard qPCR, the 
negative control in a PLA generates a Cq due to ligation of PLA probes being 
brought into proximity by chance.  This background can be minimised through 
further optimisation of the assay parameters.   
Access was given to Life Technologies’ new, improved TPA II open kit (not 
commercially available).  This has increased the ΔCq and the sensitivity of the 
assay.  However, Cq of the negative control remains <30.  Further assay 
optimisation is needed to decrease background signal, by reducing non-specific 
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ligations.  Altering the antibody to oligonucleotide ratio in the preparation of assay 
probes may achieve this by minimising free oligonucleotide.   
2. This section describes the first PLA detection of a target protein with probes that 
are not an immunogen affinity purified pAb.  The expectation is that further pAb 
purification will result in even better assay performance in terms of it sensitivity 
and dynamic range.  An additional antibody purification step, in the form of protein 
A purification, was performed in this study, but did not result in a marked 
improvement in assay performance.  In some respects, this could seem counter-
intuitive.  However, because the assay is very sensitive, antibody concentration and 
handling are very important and can have an impact on assay performance.  If one 
considers that with each step, the antibody can be ‘lost’ or denatured, then it is 
possible for performance to decrease with these additional steps.  
3. This section also demonstrates the first use of a single MAb for generating a pair of 
assay probes, binding multiple repeat epitopes on the same antigen. This 
significantly improves the potential of this assay, since it removes the requirement 
for two compatible antibodies, which had been thought an essential prerequisite 
for a successful PLA. 
The results presented in this thesis section demonstrate the proof-of-concept for a PLA-
based non-invasive diagnostic test that allows early detection of actively growing 
Aspergillus infection.  However, several factors require improvement and optimisation in 
order to evaluate create an assay of suitable a standard for evaluation with clinical 
samples.  This work should include the optimisation of both the antibody-oligonucleotide 
ratio in the probe preparation step and the probe concentration in the PLA assay.  These 
steps will minimise free oligonucleotides in the PLA and minimise background signal 
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(increase Cq of the negative control).  Optimisation of binding incubation and ligation 
incubation times may further improve assay performance.  Optimisation of antibody 
preparation and purification steps may improve the sensitivity and dynamic range of the 
assay, however any additional steps need careful evaluation to ensure that the potential 
gain is not outweighed by the risk of antibody denaturation with each additional antibody 
handling step.  The sensitivity and dynamic range of the assay will need to be established 
using purified target protein as well as Aspergillus supernatants and assay specificity will 
need to be established by testing supernatants from related and unrelated fungal species.  
It would then be necessary to evaluate assay performance using appropriate biological 
samples such as blood and BAL fluid, spiked with known number of Aspergillus targets.  
Normalisation against chromosomal DNA present in the sample should permit translation 
of qPCR quantification cycles into a quantitative PLA assay that determines proliferating 
fungal load within a patient sample.  It is important to consider that blood and BAL samples 
could inhibit the PCR assay and may require additional purification.  Building on the proof-
of-concept demonstrated in this chapter, further optimisation and validation steps could 
result in a unique assay that allows more sensitive, specific and earlier detection of IA and 
so will translate immediately into more targeted clinical decision-making, helping reduce 
the mortality rate for high-risk individuals.  It will also open the way for the development of 
additional assays that will assist with early and appropriate initiation of systemic 
antimicrobial therapy, leading to improved clinical outcomes, patient satisfaction and 
reduced associated costs.  In the future, the combined testing of DNA and protein targets 
from the same sample on the same analytical platform (i.e. qPCR) may further improve the 
sensitivity and specificity of disease diagnosis.  Finally, further technical improvements that 
make possible the multiplexing of PLAs will enable the detection of multiple infectious 
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organisms (i.e. different fungal species) in a single test, which ultimately may have the 
greatest positive impact on the health of at-risk patients. 
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CHAPTER 6 
 
GENERAL DISCUSSION 
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Molecular diagnostics has had a huge impact on our ability to detect diseases and 
pathogens early, speedily and with great certainty.  Unfortunately its contribution to more 
accurate and early diagnosis of fungal diseases has been somewhat peripheral, mainly due 
to the many limitations inherent in the techniques used and discussed throughout this 
thesis.  The rising incidence of IFD, especially IA, remains an important cause of morbidity 
and mortality in the haemato-oncology setting  (77, 256), where it is primarily a pulmonary 
pathology, with inhaled Aspergillus conidia reaching the lungs and germinating to produce 
invasive hyphae (207).  The lack of definitive diagnostic criteria has a significant impact on 
survival in these patients (257), since it precludes early and targeted initiation of systemic 
antifungal therapy. 
Culture from a normally sterile site is rarely feasible ante-mortem as patients are too 
unwell to undergo invasive procedures and viable fungi are extremely rare, as evidenced by 
poor blood culture results (129).  Therefore, antifungal prophylaxis and empirical therapy 
have become commonplace in the haemato-oncology setting (54).  This approach to 
patient management is likely to lead to treatment of patients who do not have IFD, 
exposing them to unnecessary drug toxicities and potential complication in the 
management of their underlying disease.  By contrast, a diagnostic-driven approach 
combines imaging techniques and biomarker detection to direct antifungal therapy to 
those with evidence of IFD, withholding therapy in patients with negative diagnostic 
biomarker results.  The success of this approach relies heavily on the early availability of 
imaging and biomarker detection assays.  Respiratory specimens such as BAL fluid can be 
tested for biomarkers of infection, but the utility of a combination biomarker detection 
approach in BAL fluid for the early diagnosis of IPA has not been extensively studied.  
Although the introduction of new non-invasive tests, combined with more effective and 
better-tolerated antifungal agents, has resulted in lower mortality rates associated with 
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IPA, this disease continues to have substantial attributable mortality combined with a 
major impact on hospital resource use (258). 
 
6.1 Findings 
Nucleic acid-based tests, such as qPCR, are readily adaptable for use in the fungal 
diagnostic laboratory.  However, the EORTC/MSG has not yet recommended the use of 
qPCR in the diagnosis of IA (51), mainly because of the absence of standardised protocols 
(187).  Together with the inadequate reliability of amplification from blood and serum, this 
has led to attempts to reach a consensus for qPCR diagnosis.  This was pioneered by 
EAPCRI, which aims to provide optimal standardised protocols for diagnostic Aspergillus 
PCR (114).  Thus far its members have focused on blood samples and asserted that the 
efficiency of Aspergillus PCR is limited by the DNA extraction procedure and not by the PCR 
amplification.  However, in this thesis it is shown that analysis of their own data 
demonstrates that PCR assays are in fact highly variable, with different PCR efficiencies 
resulting in significantly different sensitivities.   
Increasing acceptance of the MIQE guidelines is a development that may further improve 
the reliability of qPCR-based assays for IA (167), by offering a strategy for reproducibility 
and quality control to improve practices in qPCR experiments.  This thesis describes the 
development of the first qPCR assay targeting Aspergillus species designed, optimised and 
validated in strict compliance with the MIQE guidelines.  This thesis also describes the 
evaluation of this new qPCR assay, alongside the existing EORTC/MSG-endorsed GM ELISA 
and the new Aspergillus LFD, for diagnosis of IPA.  A new finding demonstrated in this 
thesis is that a dual Aspergillus LFD and qPCR testing approach applied to BAL fluid is a very 
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sensitive and highly specific aid in IPA diagnosis.  A combination biomarker approach could 
be incorporated into a diagnostic-driven approach to patient management to direct 
antifungal treatment to patients with evidence of invasive fungal disease.  These results 
support the use of LFD/qPCR testing as a clinical tool to aid in IPA diagnosis, in the absence 
of histological proof. 
Clinical studies have relied on the EORTC/MSG classification of IFD to attribute a 
possible/probable likelihood of IFD in the absence of definitive proof.  Instead, this thesis 
details an investigation into the use of a triple biomarker strategy (qPCR, LFD, GM) on BAL 
fluid and defines the performance characteristics of the assays in a gold standard cohort of 
proven cases of IPA and a cohort of patients with no EORTC/MSG risk factors nor evidence 
of IPA.  The application of the triple testing in a study cohort shows near perfect agreement 
between qPCR and the LFD in BAL fluid, but disappointing assay performance with 
blood/serum in BAL positive cases. Importantly, while microscopy and culture are not 
informative in the face of mould-active anti-fungal therapy, biomarkers remain positive in 
BAL fluid.  Using the LFD/qPCR biomarker data as a reference standard, the EORTC/MSG 
criteria have a sensitivity of less than 40%, in keeping with previous post-mortem 
comparisons.  This highlights that the EORTC/MSG criteria should be used with caution 
when evaluating new diagnostic approaches for IFD and when used in clinical algorithms to 
define management of patients in unproven cases.   
To date, there is a single report in the peer-reviewed literature in which the use of a triple 
biomarker strategy (PCR, LFD, GM) on BAL fluid has been evaluated (259).  The PCR assay 
used in the study was a nested, two-step PCR (260), with traditional end-point detection 
achieved by separating products using agarose gel electrophoresis, with ethidium bromide 
staining.  Therefore, quantification is not possible.  The report is very recent (March 2014) 
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and although it included 78 BAL fluids, only three (4%) samples were from cases of 
histologically proven IPA.  The other 96% were unproven and classified by EORTC/MSG 
likelihood.  Assay sensitivity was calculated using an imperfect reference standard of 
EORTC/MSG proven/probable cases.   
Biomarker detection in blood has failed to transform IFD management in haemato-
oncology.  There are conflicting reports about the clinical utility of serum-positive GM 
results in the diagnosis of IA.  Although early reports indicated both high sensitivity and 
specificity, more recent studies have reported a lower sensitivity of between 40 and 50%, 
particularly in the setting of mould-active antifungal drugs and in the absence of serial 
sampling (261).  The findings of this thesis indicate the insensitivity of combination 
biomarker detection in blood compared to respiratory sampling.  Furthermore, this thesis 
presents data that confirm previously published concerns over the repeatability of GM in 
serum (215, 216), whilst also demonstrating that BAL GM results appear stable (229). 
In the final results chapter of this thesis, three small-scale investigations are described, 
introducing novel approaches to IPA diagnosis.  Findings are reported from a series of 
experiments evaluating the potential of EBC as a clinical sample for non-invasive diagnosis 
of IPA.  The findings of this thesis indicate that biomarker detection results in EBC do not 
correlate well with results in BAL fluid samples.  Although Aspergillus DNA was detected in 
the EBC of two patients with corresponding positive BAL fluid, detection was at the lower 
limits of assay accuracy and sample volume limitations prevented confirmation testing or 
attempts to optimise sample handling.  From this small data set it is fair to conclude that 
EBC is currently unsuitable for clinically relevant detection of Aspergillus biomarkers in the 
respiratory tract.  However, changes to sampling technique (262) or appropriate 
fractionation of EBC (263) may lead to improved results.  Therefore, the translation of the 
  
209 
 
potential of EBC into practical diagnostic use may be possible with a greater understanding 
of the technical problems and subsequent optimisation of sample handling and processing 
steps. 
This thesis also reports findings from an evaluation of the inflammatory cytokine profile 
associated with IPA biomarker positive BAL fluid.  The findings reported are from a small 
sample population and do not identify any inflammatory markers that can distinguish 
between suspected Aspergillus and non-Aspergillus infections.  The findings do, however, 
agree with previous reports that patients with haematological malignancy, undergoing 
cytotoxic therapy, still mount an immune response to respiratory pathogens in the lung 
(238-240). 
In a final investigation into novel approaches to IPA diagnosis, this thesis details the first 
ever application of a PLA test to the detection of an Aspergillus diagnostic antigen.  The 
findings presented in this thesis show that pAbs and a mAb raised against the JF5 
mannoprotein (119) can be used to develop a PLA test to detect actively growing 
Aspergillus species.  Further optimisation and normalisation against chromosomal DNA will 
allow the translation of Cq values into a quantitative assay to determine the proliferating 
fungal load in a clinical sample. 
 
6.2 Future Directions 
The findings presented in this thesis support the use of a dual LFD/qPCR biomarker 
detection approach in BAL fluid, to direct antifungal treatment for IPA in the absence of 
direct examination or culture of pulmonary tissue.   
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The empirical strategy of administering antifungal therapy in the setting of persistent or 
relapsing neutropenic fever despite antibiotics for 3-7 days, with no alternative 
microbiological aetiology identified, remains the standard approach to patient 
management in many centres, although there may be variations to the formal definition of 
empirical management.  The widespread use of early CT scanning of the chest to help in the 
management of IFD is handicapped by the not insignificant limitation that it cannot identify 
the pathogen.  However, with the emergence of new technologies, more informative 
biomarkers and a wider choice of antifungal drugs, a more rational approach may be to 
devise a diagnostic-driven management strategy, with the aim of withholding antifungal 
treatment in those who have biomarker negative results.  Drives for this include the 
documented overtreatment of patients and the impact on hospital resource use.  Indeed, 
the findings reported in this thesis are the basis for a new Public Health England (PHE)-led 
service, offering my Aspergillus qPCR together with LFD and GM combination testing at the 
Royal London Hospital as a diagnostic service that can be requested for BAL and blood 
samples within Barts Health NHS Trust, as well as from outside.  Within Barts Health NHS 
Trust, the Haemato-Oncology department is changing the patient management algorithm, 
based on the results of this thesis, to incorporate my Aspergillus qPCR, LFD and GM 
combination testing, in order to move from the current CT/GM strategy to a diagnostic-
driven approach incorporating the triple testing.  In a setting where rapid CT scanning is 
available (within 24 hours of request), with direct bronchoscopy for timely BAL fluid 
sampling, it is possible to envisage a scenario in which antifungal treatment is withheld in a 
stable patient whilst awaiting biomarker test results.  There are, however, some important 
caveats to such an approach.  Firstly, if a patient is not stable, antifungal treatment will not 
be withheld whilst awaiting biomarker test results.  Secondly, negative biomarker results 
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do not rule out a non-Aspergillus IFD.  Therefore, if an IFD is still suspected further 
investigations are required.   
Although the data presented in this thesis indicate the insensitivity of combination 
biomarker detection in blood compared to respiratory sampling, attempts were not made 
to optimise the DNA extraction method prior to qPCR analysis.  For the purpose of direct 
comparison between respiratory and systemic sampling, an automated DNA extraction 
platform was used to extract total DNA from 200µl of EDTA whole blood or BAL fluid.  
EAPCRI have published protocols for DNA extraction from serum (131) and whole blood 
(132), recommending extraction from ≥3 ml EDTA blood specimens.  In order to fully 
evaluate the use of blood samples it will be necessary to compare blood fractions and 
optimise the extraction protocol.   In addition, the manufacturer-recommended protocol 
for LFD testing of serum samples has undergone revision since the generation of the data 
presented in this thesis.  An evaluation of serum testing will be necessary using the revised 
protocol.  Full evaluation of combination biomarker detection in blood samples will be 
incorporated into the forthcoming study at Barts Health NHS Trust.  A combination of 
marker detection applied to blood may serve as a useful screening tool to further improve 
the identification of patients at high risk of developing IFD.  A positive result may enable 
the start of early targeted antifungal therapy, while expensive and potentially toxic 
antifungal drugs can be withheld with persistently negative results.  An alternate diagnostic 
strategy is to reserve testing for situations in which clinical and radiological data are 
suggestive of IA; in this scenario, marker detection applied to BAL, serum, and other tissues 
and fluids, may enable a definitive diagnosis of IA to be secured.  It is possible to envisage a 
situation in which LFD testing is performed as a near-patient assay in the bronchoscopy 
suite, allowing an immediate decision on antifungal drug usage, with qPCR results within 24 
hours for a definitive diagnosis.  Although this approach does not facilitate early antifungal 
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therapy, as it relies on CT-guided bronchoscopy in patients who are suspected of having 
IFD, a more definitive diagnosis would enable the administration of specific antifungal 
therapy and would be of considerable benefit for future diagnostic and therapeutic 
research.  As the need for rapid molecular diagnostics becomes more prominent, the 
requirement for tests to translate into diagnostics for point-of-care testing becomes more 
important.  Enormous technological improvements have demonstrated that qPCR is an 
adaptable molecular tool and complex molecular analysis is no longer confined to the 
laboratory.  With the availability of compact, handheld PCR devices (www.ahrambio.com, 
www.quantumdx.com) (264) and microfluidic chips to integrate DNA extraction and qPCR 
on a single platform (265), 40 qPCR cycles can now be completed in as little as ten minutes.  
Prototype devices can complete 30 cycles and record fluorescent output in 17 seconds.  
There is the real potential for qPCR assays to provide point-of-care diagnostics, with results 
generated in real-time to directly influence decisions in patient management.  If this 
technology was incorporated into PLA development, there is the potential to detect 
actively growing pathogens in a matter of minutes.  
 
6.3 Conclusions 
In the immunocompromised setting of haemato-oncology, the diagnostic challenges of IFD 
remain a major clinical problem, resulting in the widespread use of antifungal drugs for 
prophylaxis and empirical treatment.  The incidence of IA is rising, but its early diagnosis 
remains challenging.  There is an urgent need to improve existing diagnostic tools and 
develop new technologies.  An improved awareness of this problem has accelerated the 
pursuit of robust, rapid and reliable diagnostic tests.  Each approach has its own limitations 
and it is likely that a combination of methods will be necessary to achieve optimal 
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performance for IA diagnosis.  A combination biomarker approach could be incorporated 
into a diagnostic-driven approach to patient management, combining biomarker detection 
and imaging techniques to direct antifungal treatment to patients with evidence of IFD.  
The impact that these new tests have in the clinical setting will greatly depend on 
education and cooperation across departments and specialties, to ensure awareness of the 
tests available, turnaround time and practical limitations.  A multi-disciplinary approach to 
the management of these high risk patients will require microbiologists, haematology 
consultants, registrars, radiologists, respiratory physicians and pharmacists to work 
together, ensuring that the appropriate diagnostic tests are requested and the results of 
these tests are acted upon.  The data presented in this thesis, together with the study and 
procedural changes that it has set in motion, take this field forward.  Progress will require a 
paradigm shift in thinking, suggesting that agreement between a combination of biomarker 
assays, detecting different markers of Aspergillus in BAL fluid, together with the clinical 
picture, is sufficient to make a clinical diagnosis of IPA and guide patient management. 
One last thought…….. 
 
“A paradigm shift is a distinctly new way of thinking about old problems…… the problem is 
that you can’t embrace the new paradigm unless you let go of the old.”  
(New Age Confusion, David A Lewis) 
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Appendix 1 
 
Antimicrobial Protocol of Barts Health Haemato-oncology Unit 
 
Prophylaxis for high-risk patients (AML, ALL, Auto/Allo,) 
 Start on Day 1 of chemotherapy, stop when neutrophil count > 0.5 x 109/l 
 Ciprofloxacin 750 mg bd 
 Fluconazole 400 mg od 
 Aciclovir 200 mg qds 
 
1st line antimicrobials 
 Stop ciprofloxacin prophylaxis 
 Piptazobactam (Tazocin) 4.5 g tds 
 Tobramycin 7 mg/kg od (use ideal body weight) 
 Tobramycin to be stopped if BC negative for Gram negative rod after 48 hours 
 Trough levels at 24 hours and daily thereafter (aiming for < 1 mg/l) 
 If patient defervesces, stop antibiotics after five days  
 Dosing intervals in renal impairment should be adjusted.  
 
Creatinine 
clearance 
Dosage 
interval 
> 60ml/min 24 hours 
40 to 60 ml/min 36 hours 
20 to 40ml/min 48 hours 
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Adjust antibacterials according to BC sensitivities when they are made available, 
particularly of importance in continuing fever 
Appendix 1 continued 
 
2nd line antimicrobials (ongoing fever after 48 hours) 
 Imipenem 500 mg qds 
 Vancomycin 1 g bd 
 Trough levels before 3rd dose (aiming for through level <10 mg/l) 
 Adjust Vancomycin dosing according to levels and Renal function  
 
3rd line antimicrobials (ongoing fever after another 48 hours) 
 Add in amphotericin 1 mg/kg daily 
 Ambisome to be used only if uncontrollable infusional reactions, creatinine > 170 
 
 Decision to start amphotericin / ambisome to be made by attending consultant 
 Can be considered at 48 hours 
 
Management of ‘β-lactam allergy’ 
 Remember that most patients (approx 70%) who report this are not allergic 
 Low rate of cross-sensitivity with cephalosporins 
 Do not give β-lactams if prior Type I reaction (anaphylaxis) 
 Consider trial of β-lactams if uncertain history or skin rash only with antihistamine 
prophylaxis 
 
1st line antimicrobials with β-lactam allergy 
 Ceftazidime 2g tds 
 Tobramycin 7 mg/kg od  
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1. To be stopped if BC negative for Gram negative rod after 48 hours 
2. Trough levels at 24 hours and daily thereafter (aiming for < 1 mg/l) 
Appendix 1 continued 
 
2nd line antimicrobials with β-lactam allergy (ongoing fever after 48 hours) 
 Ceftazidime  2g tds 
 Tobramycin 7 mg/kg od  
1. To be stopped if BC negative for Gram negative rod after 48 hours 
2. Trough levels at 24 hours and daily thereafter (aiming for < 1 mg/l) 
 Vancomycin 1 g bd 
1. Trough levels before 3rd dose (or second dose in renal impairment) (aiming 
for through level <10 mg/l) 
2. Teicoplanin if significant renal impairment 
 
3rd line antimicrobials with β-lactam allergy (ongoing fever after another 48 hours) 
 Add in amphotericin 1 mg/kg daily 
 Ambisome to be used only if uncontrollable infusional reactions, creatinine > 170 
 
 Decision to start amphotericin / ambisome to be made by attending consultant 
 Can be considered at 48 hours 
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Appendix 2 
 
EORTC/MSG Criteria for the Diagnosis of Invasive Fungal Infection 
 
CATEGORY 
 
DESCRIPTION 
PROVEN Histo/cytopathological demonstration of fungal hyphae or yeast cells in 
tissue sample with associated tissue damage (microscopically or radiological) 
Positive culture from usually sterile tissue with clinical or radiological sign of 
infection  
Positive blood culture for candida accompanied by temporally related clinical 
signs/symptoms 
 
PROBABLE ≥ 1 Host Factor AND 
≥ 1 Microbiological criterion AND 
1 Major or 2 Minor Clinical criteria from abnormal site consistent with 
infection 
 
POSSIBLE ≥ 1 Host Factor AND 
1 Microbiological OR 
1 Major or 2 Minor Clinical criteria from abnormal site consistent with 
infection 
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Appendix 2 continued 
 
TYPE OF CRITERIA  
 
CRITERIA 
HOST FACTORS Neutropenia (<0.5 for >10 days) 
Fever for >96 hours despite broad spectrum antibiotic 
therapy in high-risk patients 
Temperature > 38˚C or < 36˚C WITH  
i) >10 days neutropenia in previous 60 days 
ii) Recent/current immunosuppressive therapy in 
last 30 days 
iii) Proven/probable IFI during previous episode of 
neutropenia 
iv) Coexistence of symptomatic AIDS 
> 3 weeks of corticosteroids in last 60 days 
Signs/symptoms of GVHD (particularly grade≥2 or chronic 
extensive disease) 
MICROBIOLOGICAL Positive culture for fungus on sputum /BAL /sinus aspirate 
Positive cytology/microscopy for fungus on sputum /BAL 
/sinus aspirate 
Positive Aspergillus Antigen on BAL /CSF />2 blood samples 
Positive blood culture for candida 
Positive cytology /microscopy for fungal elements in sterile 
body fluid samples 
2 positive urine cultures for yeasts or candida casts in 
absence of catheter 
 
CLINICAL  
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LRTI: Major 
 
New CT signs: halo; air-crescent; cavitating consolidation (in 
absence of other organisms) 
LRTI: Minor Symptoms of LRTI: cough, chest pain, haemoptysis, dyspnoea 
Pleural rub 
Pleural effusion 
Any new infiltrate not fulfilling major criteria 
SINONASAL INFECTION: 
Major 
 
Minor 
 
Radiological evidence of invasive infection in sinuses 
 
URT symptoms, nose ulceration, periorbital swelling, maxillary 
tenderness, necrosis or perforation of hard palate 
CNS INFECTION 
Major 
Minor 
 
Radiological evidence suggesting CNS infection 
Focal neurological symptoms/signs 
Cognitive change 
Abnormalities in CSF biochemistry and cell count 
DISSEMINATED FUNGAL 
INFECTION 
Unexplained papular /nodular skin lesions 
Intraocular evidence of chorioretinitis or endophthalmitis  
CHRONIC DISSEMINATED 
CANDIDIASIS 
Radiological demonstration of small target-like abscesses and 
↑ALP 
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Appendix 3 
Estimation of efficiency of PCR assays from DNA standard amplification plot 
A. 
 
Figure.A1: Amplification plot of standard A. fumigatus DNA dilution series from Sanguinetti 
et al (179). 
Estimated Cq value from the above plot:  
log concentration (x) 6 5 4 3 2 1 
Cq (y) 22 26 29 32 34.5 37 
 
The equation for the slope of the regression line is calculated using the following formula:  
 
where x and y are the sample means AVERAGE (known_x’s) and AVERAGE (known_y’s) and 
the derived slope is -2.957 
Using the formula(167)  
PCR efficiency = 10 -1/slope -1 
= 10-1/-2.957 -1 
= 118 % 
Therefore, the estimated efficiency of the assay is 118%. 
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Appendix 3 continued 
B.   Estimation of efficiency of PCR assays from DNA standard curve 
 
   
Figure.A2: Standard curve of A. fumigatus DNA dilution series from White et al (183). 
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